THE LANCET
Public Health

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Akl J, Lee S, Ju JH, et al. Estimating the burden of vitiligo: a systematic review and modelling study. *Lancet Public Health* 2024; published online March 26. https://doi.org/10.1016/S2468-2667(24)00026-4.

Supplementary Appendix

Supplementary Text. Estimation of the global, regional and country-specific prevalence of vitiligo

A Bayesian hierarchical linear mixed model was employed to estimate the prevalence of vitiligo on a global, regional, and country-specific scale. In this Bayesian hierarchical framework, prevalence estimates were influenced by data within the same country, when available, as well as by data from other countries. The outcome variable, representing the prevalence of vitiligo, was log-transformed, facilitating the use of a linear model and modelling the skewness of the data. Prevalence was estimated from these models and back-transformed to the original prevalence scale. Countries were categorized based on the Global Burden of Disease (GBD) classification, organized into hierarchical groups comprising 189 countries nested within 21 regions, and these regions further nested within 7 super-regions.

The model includes a 4-level hierarchy, random effects, denoted as:

- 35 countries are denoted c and indexed by ***i***;
- 12 regions are denoted r and indexed by ***j***;
- 7 super-region are denoted s and indexed by ***k***;
- 1 global random intercept

Our regression is as follows, with p_h equal to the prevalence measure reported by each study or calculated using the number of prevalent cases and the denominator provided (the prevalence reported by each study) and p_{ijk} equals to the pooled prevalence estimated by the model for *i* th country, *j* th region and *k* th super-region:

$$y_h = log_e(p_h),\ y_h \sim Normal(\mu, \sigma 2)$$

$$\text{And } p_{ijk} = log_e(\beta_{0ijk} + \beta' X_{ijk})$$

$$\text{Where: } \beta_{0ijk} = \gamma_{000} + u_{00k} + u_{0jk} + u_{ijk}$$

With: γ_{000} being the overall intercept; u_{00k} the random intercept for super-region k ($k = 1 \ldots . s$); u_{0jk} the random intercept for region j($j = 1 \ldots . r$) within super-region k; and u_{ijk} the random intercept for country i ($i = 1 \ldots . c$) within region j and super-region k. X_i are the regression coefficients for the three covariates age strata (children, adults, overall); type of diagnosis (physician, self-reported) and type of prevalence (lifetime, point or period prevalence) for each country. The subscript *i* refers to the countries included in the study: i = 1….21). The subscript *h* refers to the prevalence of study h (h=1, ..84).

In total, three covariates were considered, each modeled as categorical variables and treated as fixed effects. These were "age strata" (children, adults and overall population); "diagnostic method" (physician/dermatologist vs self-reported) and "type of prevalence measure" (point/period prevalence vs lifetime prevalence).

$$p_{ijk} = \log_e(\beta_{0ijk} + \beta_{1ijk}\, age\ strata + \beta_{2ijk}\, diagnostic\ method + \beta_{3ijk}\, prevalence\ measure)$$

The statistical model employed for estimating the prevalence of vitiligo utilized Bayesian inference and sampled from the posterior distribution of parameters through the Hamiltonian Markov Chain Monte Carlo method. Four chains, each comprising 2000 iterations with a burn-in period of 1000, were employed for model execution. We applied the N(0, 10) prior solely to the intercept to ensure flexibility in our prevalence estimates, allowing data to predominantly shape the model while accommodating varied baseline prevalence across the countries and regions. Posterior predictions were subsequently generated for each country and age strata combination, presenting prevalence estimates alongside 95% credible intervals. In instances where countries lacked data, the model leveraged geographical groupings to estimate vitiligo prevalence, with higher-level estimates being pivotal in the absence of country-specific data, while accounting for fixed effects in the model. To determine the number of individuals affected by vitiligo per country, the country-specific prevalence estimate (with 95% credible intervals) was multiplied by the corresponding population size based on the United Nations population structure. The overall model fit was evaluated by assessing i) measures relative to effective sample size and autocorrelation and ii) the trace plot.

Supplementary Figure S1. Trace plots and variance for covariates in the Bayesian hierarchical linear mixed model

The plots display the trace of each parameter according to iterations in a Bayesian hierarchical linear mixed model. The parameters corresponding to fixed effects are shown in blue color, indicating the relationships of prevalence among children, adults, and the overall age group. Similarly, the prevalence of self-reported vitiligo appears higher than that of physician-diagnosed vitiligo, and lifetime prevalence is higher than point prevalence. The orange color represents the parameters for random effects, illustrating the variability of country, region, and super-region across the categories. The variance exhibited is greater for the region than for the country, and even more so for the super-region. The level of heterogeneity in the input data for these parameters also follows a similar trend.



Supplementary Figure S2. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram



Supplementary Figure S3. Lifetime physician- or dermatologist-diagnosed prevalence of vitiligo for adults

This forest plot provides the prevalence estimates of vitiligo for each world region. The extrapolated regions are central Asia, eastern Europe, high-income southern Latin America, Andean Latin America, Caribbean, central Latin America, Oceania, central sub-Saharan Africa, and southern sub-Saharan Africa. The error bar indicates 95% credible intervals for each region.



Supplementary Figure S4. Lifetime physician- or dermatologist-diagnosed prevalence of vitiligo for children

This forest plot provides the prevalence estimates of vitiligo for each world region. The extrapolated regions are central Asia, eastern Europe, high-income southern Latin America, Andean Latin America, Caribbean, central Latin America, Oceania, central sub-Saharan Africa, and southern sub-Saharan Africa. The error bar indicates 95% credible intervals for each region.

Table S1. Countries and regions within the designated analytical areas. The table presents a comprehensive breakdown of the geographical categories and structure employed within the statistical model.

Region	Countries
Central Europe, eastern Europe, and central Asia	
Asia, central	Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, Uzbekistan
Europe, central	Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, TFYR Macedonia
Europe, eastern	Belarus, Estonia, Latvia, Lithuania, Moldova, Russia, Ukraine
High income	
Asia Pacific, high income	Brunei Darussalam, Japan, Republic of Korea, Singapore
Australasia	Australia, New Zealand
Europe, western	Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom
Latin America, southern	Argentina, Chile, Uruguay
North America, high income	Canada, United States of America
Latin America and Caribbean	
Caribbean	Antigua and Barbuda, Bahamas, Barbados, Belize, Cuba, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Puerto Rico, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Virgin Island (US)
Latin America, Andean	Bolivia, Ecuador, Peru
Latin America, central	Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Venezuela (Bolivarian Republic of)
Latin America, tropical	Brazil, Paraguay
North Africa and Middle East	
North Africa and the Middle East	Afghanistan, Algeria, Bahrain, Egypt, Iran (Islamic Republic of), Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territory, Oman, Qatar, Saudi Arabia, Sudan, Syrian Arab Republic, Sudan, Tunisia, Turkey, United Arab Emirates, Yemen
South Asia	
Asia, south	Bangladesh, Bhutan, India, Nepal, Pakistan
South East Asia, east Asia, and Oceania	
Asia, east	China, Dem. People's Republic of Korea, Taiwan
Asia, South East	Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, Maldives, Mauritius, Myanmar, Philippines, Seychelles, Sri Lanka, Thailand, Timor-Leste, Vietnam
Oceania	Fiji, Guam, Kiribati, Marshall Islands, Micronesia (Fed. States of), Papua New Guinea, Samoa, Solomon Islands, Tonga, Vanuatu
Sub-Saharan Africa	
Sub-Saharan Africa, central	Angola, Central African Republic, Congo, Democratic Republic of the Congo, Equatorial Guinea, Gabon
Sub-Saharan Africa, eastern	Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, Somalia, South Sudan, Uganda, United Republic of Tanzania, Zambia
Sub-Saharan Africa, southern	Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe
Sub-Saharan Africa, western	Benin, Burkina Faso, Côte d'Ivoire, Cameroon, Cape Verde, Chad, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, São Tomé and Príncipe, Senegal, Sierra Leone, Togo

Institute for Health Metrics and Evaluation (IHME). GBD Results. Seattle, WA: IHME, University of Washington, 2020. Available from https://vizhub.healthdata.org/gbd-results/

Table S2. Characteristics of studies reporting on incidence of vitiligo

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
United States	North America, high income	Dunlap	2017	2000–2012	Cohort	51337	51337	White	Physician	Incidence	Low	Dunlap R, Wu S, Wilmer E, Cho E, Li W, Lajevardi N, et al. Pigmentation Traits, Sun Exposure, and Risk of Incident Vitiligo in Women. Journal of Investigative Dermatology. 2017;137(6):1234–1239.
South Korea	Asia Pacific, high income	Lee	2020	2009–2012	Cohort	22991641	11396444	NR	Physician	Incidence	Low	Lee YB, Lee JH, Lee SY, Yu DS, Han KD, Park YG. Association between vitiligo and smoking: A nationwide population-based study in Korea. Scientific Reports. 2020;10(1):6231.
South Korea	Asia Pacific, high income	Lee	2021	2005–2008	Cohort	15980754	7579432	NR	Physician	Incidence	Low	Lee YB, Kim HS. Height and Risk of Vitiligo: A Nationwide Cohort Study. Journal of Clininal Medicine. 2021;10(17):3958.
United Kingdom	Europe, western	Subramanian	2021	2006–2016	Cohort	4414357	2329575	White (British, Irish, other white, 3811730) South Asian (Bangladeshi, Pakistani, Indian, Sri Lankan, British Asian or other South Asian, 233432) Afro-Caribbean (black African, black Caribbean, black British or other black people, 161534) Mixed race or other minority ethnic groups (including Chinese, Vietnamese and other South East Asian, 207661)	Physician	Incidence, Prevalence	Low	Subramanian A, Adderley NJ, Gkoutos GV, Gokhale KM, Nirantharakumar K, Krishna MT. Ethnicity-based differences in the incident risk of allergic diseases and autoimmune disorders: A UK-based retrospective cohort study of 4·4 million participants. Clinical and Experimental Allergy. 2021;51(1):144–7.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
United States	North America, high income	Gandhi	2021	2013–2017	Cohort	NR	NR	NR	Physician	Incidence, Prevalence	High	Gandhi K, Ray M, Borra S, Sruti I, Xu L, Pandya A. Prevalence and incidence of vitiligo in the United States: A real-world analysis. 2021.
South Korea	Asia Pacific, high income	Lee	2022	2006–2015	Cohort	51014947	NR	NR	Physician	Incidence	Low	Lee YB, Kim S, Kim HS. The Incidence, Prevalence, and Mortality of Vitiligo in Korea: A Nationwide Population-Based Cohort Study. Journal of Cutaneous Medicine and Surgery. 2023;27(2):166–167.
South Korea	Asia Pacific, high income	Lim	2022	2010–2018	Cohort	115683	50749	NR	Physician	Incidence	Low	Lim JH, Lew BL, Sim WY, Kwon SH. Incidence of childhood-onset vitiligo and increased risk of atopic dermatitis, autoimmune diseases, and psoriasis: A nationwide population-based study. Journal of the American Academy of Dermatology. 2022;87(5):1196–1198.
United Kingdom	Europe, western	Conrad	2023	2000–2019	Cohort	978872	625879	African or Caribbean (17257) Asian (46621) Mixed or other (45363) White (824573) Missing (45058)	Physician	Incidence	Low	Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878–1890.
South Korea	Asia Pacific, high income	Kang	2023	2003–2019	Cohort	1035504	579972	NR	Physician	Incidence, Prevalence	Low	Kang H, Lee S. Prevalence and incidence of vitiligo and associated comorbidities: a nationwide population-based study in Korea. Clinical and Experimental Dermatology. 2023;48(5):484–9.
United States	North America, high income	Mastacouris	2023	2015–2019	Cohort	2980778	1697610	White (2002447) Black (333794)	Physician	Incidence, Prevalence	Low	Mastacouris N, Strunk A, Garg A. Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
								Asian (36886) Hispanic/Latino (40086) Other/multiracial (177964)				JAMA Dermatology. 2023 Jul 19;e232162.
United States	North America, high income	Ray	2023	2013–2017	Cohort	140901558	NR	NR	Physician	Incidence, Prevalence	Low	Ray M, Gandhi K, Maughn K, Pandya AG. Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims. JID Innovations. 2023;3(4):100199.

Table S3. Characteristics of studies reporting on prevalence of vitiligo

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
India	Asia, south	Mehta	1973	1971–1972	Cross-sectional	9065	NR	NR	Physician	Prevalence	Moderate	Mehta NR. Epidemiological study of vitiligo in Surat area, South Gujarat. Indian Journal of Medical Research. 1973; 61(1):145–54.
Denmark	Europe, western	Howitz	1977	1971–1972	Cross-sectional	47033	23261	NR	Physician	Prevalence	Low	Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Archives of dermatology. 1977;113(1):47–52.
United States	North America, high income	Johnson	1978	1971–1974	Cross-sectional	193976447	99825388	White (169584263) All other (24342184)	Physician	Prevalence	Low	Johnson MT, Roberts J. Skin conditions and related need for medical care among persons 1–74 years. United States, 1971–1974. Vital and Health Statistics - Series 11. 1978;(212):i-v, 1–72
Australia	Australasia	Quirk	1979	NR	Cross-sectional	1037	NR	NR	Self	Prevalence	High	Quirk CJ. Skin disease in the Busselton population survey. The Medical journal of Australia. 1979; 1(12):569–70.
Sweden	Europe, western	Larsson	1980	1975–1976	Cross-sectional	8298	4040	Caucasian (Majority)	Physician	Prevalence	Low	Larsson PA, Liden S. Prevalence of skin diseases among adolescents 12–16 years of age. Acta Dermato-venereologica. 1980;60(5):415–23.
Denmark	Europe, western	Weismann	1980	1976	Cross-sectional	584	409	NR	Physician	Prevalence	Moderate	Weismann K, Krakauer R, Wanscher B. Prevalence of skin diseases in old age. Acta Dermato-Venereologica. 1980;60(4);352–3.
Brazil	Latin America, tropical	Bechelli	1981	1974–1975	Cross-sectional	9955	5220	NR	Physician	Prevalence	Low	Bechelli LM, Haddad N, Pimenta WP, Pagnano PM, Melchior JrE, Fregnan RC, et al. Epidemiological survey of skin diseases in schoolchildren living in the Purus Valley (Acre State, Amazonia,

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												Brazil). Dermatologica. 1981;163(1):78–93.
India,	Asia, south	Bhalla	1984	1982–1983	Cross-sectional	5166	NR	NR	Physician	Prevalence	Moderate	Bhalla K. Pattern of skin diseases in a semi-urban community of Delhi. Indian Journal of Dermatology, Venereology and Leprology. 1984;50:213–214
India	Asia, south	Das	1985	1978	Cross-sectional	15685	8130	NR	Physician	Prevalence	Moderate	Das SK, Majumder PP, Chakrabotry R, Majumdar TK, HaldarB, Rao DC. Studies on vitiligo I. Epidemiological profile in Calcutta, India. Genetic epidemiology. 1985;2(1):71–8.
India	Asia, south	Nanda	1989	1986	Cross-sectional	900	447	NR	Physician	Prevalence	Moderate	Nanda A, Kaur S, Bhakoo ON, Dhall K. Survey of cutaneous lesions in Indian newborns. Pediatric dermatology. 1989;6(1):39–42.
Tanzania	Sub-Saharan Africa, eastern	Gibbs	1996	1994	Cross-sectional	1114	NR	NR	Physician	Prevalence	Moderate	Gibbs SAM. Skin disease and socioeconomic conditions in rural Africa: Tanzania. International journal of dermatology. 1996;35(9):633–9.
India	Asia, south	Bhatia	1997	1988–1989	Cross-sectional	666	329	NR	Physician	Prevalence	Moderate	Bhatia V. Extent and pattern of paediatric dermatoses in rural areas of central India. Indian Journal of Dermatology, Venereology and Leprology. 1997;63(1):22–25.
Romania	Europe, central	Popescu	1999	1995	Cross-sectional	1114	513	White Romanian (1074) Gipsy (11) Mixed (12) Others (1)	Physician	Prevalence	Low	Popescu R, Popescu CM, Williams HC, Forsea D. The prevalence of skin conditions in Romanian school children. British journal of dermatology. 1999;140(5):891–6.
Sri Lanka	Asia, South East	Perera	2000	1997	Cross-sectional	1806	899	NR	Physician	Prevalence	Moderate	Perera A, Atukorale DN, Sivayogan S, Ariyaratne VS, Karunaratne LA. Prevalence of skin diseases in

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												suburban Sri Lanka. Ceylon Medical Journal. 2000;45(3):123–8.
China	Asia, east	Fung	2000	1996–1997	Cross-sectional	1006	NR	NR	Physician	Prevalence	Low	Fung WK, Lo KK. Prevalence of skin disease among school children and adolescents in a Student Health Service Center in Hong Kong. Pediatric dermatology. 2000;17(6):440–6.
Iran	North Africa and the Middle East	Massarrat	2002	1997–1999	Cross-sectional	61137	NR	NR	Physician	Prevalence	Moderate	Massarrat MS, Tahaghoghi-Mehrizi S. Iranian national health survey: a brief report. Archives of Iranian Medicine. 2002;5(2):73–9.
United States	North America, high income	Prahalad	2002	NR	Case-control	110 / 45	89 / 41	Caucasian (107 / 43)	Self	Prevalence	Moderate	Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2002;46(7):1851–6.
Egypt	North Africa and the Middle East	Abdel-Hafez	2003	1994–1996	Cross-sectional	8008	4128	NR	Physician	Prevalence	Low	Abdel-Hafez K, Abdel-Aty MA, Hofny ER. Prevalence of skin diseases in rural areas of Assiut Governorate, Upper Egypt. International journal of dermatology. 2003;42(11):887–92
India	Asia, south	Dogra	2003	2001	Cross-sectional	12586	6236	NR	Physician	Prevalence	Moderate	Dogra S, Kumar B. Epidemiology of skin diseases in school children: a study from northern India. Pediatric dermatology. 2003;20(6):470–3.
France	Western Europe	Wolkenstein	2003	2002	Cross-sectional	18137	8815	NR	Self	Prevalence	Low	Wolkenstein P, Grob JJ, Bastuji-Garin S, Ruszczynski S, Roujeau JC, Revuz J. French people and skin diseases: results of a survey

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												using a representative sample. Archives of dermatology. 2003;139(12): 1614–9.
Italy	Western Europe	Naldi	2004	2003	Cross-sectional	3660	1999	NR	Self	Prevalence	Moderate	Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology. 2004;208(1):38–42.
Turkey	North Africa and the Middle East	A. Almila Tuncel	2005	NR	Cross-sectional	682	0	NR	Physician	Prevalence	Moderate	Tuncel AA, Erbagci Z. Prevalence of skin diseases among male adolescent and post-adolescent boarding school students in Turkey. The Journal of Dermatology. 2005;32(7):557–64.
Iraq	North Africa and the Middle East	Al-Rubiay	2005	NR	Cross-sectional	6666	3438	NR	Self	Prevalence	Low	Al-Rubiay KK, Al-Rubiay LK. Dermatoepidemiology: a household survey among two urban areas in Basrah City, Iraq. Internet Journal of Dermatology. 2005;4(2):1–6.
Mali	Sub-Saharan Africa, western	O. Faye	2005	2001	Cross-sectional	1729	NR	NR	Physician	Prevalence	Moderate	Faye O, N'diaye HT, Keita S, Traore AK, Hay RJ, Mahe A. High prevalence of non-leprotic hypochromic patches among children in a rural area of Mali, West Africa. Leprosy review. 2005;76(2):144–6.
Saudi Arabia	North Africa and the Middle East	Al-Saeed	2006	2003	Cross-sectional	2239	2239	NR	Physician	Prevalence	Moderate	Al-Saeed WY, Al-Dawood KM, Bukhari IA, Bahnassy AA. Prevalence and pattern of skin disorders among female schoolchildren in Eastern Saudi Arabia. Saudi Medical Journal. 2006;27(2):227–34.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
Italy	Western Europe	Ingordo	2007	2001–2004	Cross-sectional	34740	0	NR	Physician	Prevalence	Low	Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. The 'EpiEnlist' project: a dermo-epidemiologic study on a representative sample of young Italian males. Prevalence of selected pigmentary lesions. Journal of the European Academy of Dermatology and Venereology. 2007;21(8):1091–6.
Mozambique	Sub-Saharan Africa, eastern	Chhaganlal	2007	NR	Cross-sectional	1066	539	African	Self	Prevalence	Moderate	Chhaganlal K, van Jaarsveld I, Hoffmann K, Ramos MI, Krober M, de Hoop D. Cutaneous disorders in the "bairro Inhamudima" of Beira, Mozambique. International Journal of Dermatology. 2007;46 Suppl 2:35–8.
United States	North America, high income	El-Essawi	2007	NR	Cross-sectional	421	217	Arab American	Self	Prevalence	Low	El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. Journal of the American Academy of Dermatology. 2007;56(6):933–8.
China	Asia, east	Lu	2007	2002–2003	Cross-sectional	42833	20817	NR	Physician	Prevalence	Low	Lu T, Gao T, Wang A, Jin Y, Li Q, Li C. Vitiligo prevalence study in Shaanxi province, China. International journal of dermatology. 2007;46(1):47–51.
Romania	Europe, central	Birlea	2008	2001–2006	Cross-sectional	1673	NR	White	Physician	Prevalence	Low	Birlea SA, Fain PR, Spritz RA. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Archives of dermatology. 2008;144(3):310–6.
Taiwan (Province of China)	Asia, east	Chen	2008	2005	Cross-sectional	3273	1614	NR	Physician	Prevalence	Low	Chen GY, Cheng YW, Wang CY, Hsu TJ, Hsu MML, Yang PT, Chen WC. Prevalence of skin diseases

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												among schoolchildren in Magong, Penghu, Taiwan: a community-based clinical survey. Journal of the Formosan Medical Association. 2008;107(1):21–9.
Nepal	Asia, south	Walker	2008	NR	Cross-sectional	878	471	NR	Physician	Prevalence	Moderate	Walker SL, Shah M, Hubbard VG, Pradhan HM, Ghimire M. Skin disease is common in rural Nepal: results of a point prevalence study. British Journal of Dermatology. 2008;158(2):334–8.
Italy	Western Europe	Naldi	2009	1997	Cross-sectional	3660	1999	NR	Self	Prevalence	Low	Naldi L, Parazzini F, Gallus S, GISED CS. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. Acta Dermato-Venereologica. 2009;89(2):122–5.
Tanzania	Sub-Saharan Africa, eastern	Komba	2010	NR	Cross-sectional	420	207	NR	Physician	Prevalence	Low	Komba EV, Mgonda YM. The spectrum of dermatological disorders among primary school children in Dar es Salaam. BMC Public Health. 2010;10:765.
Germany	Western Europe	M. Augustin	2011	2004–2009	Cross-sectional	90880	42409	NR	Physician	Prevalence	Low	Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schafer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. British Journal of Dermatology. 2011;165(4):865–73.
Turkey	North Africa and the Middle East	Serdaroğlu	2012	NR	Cross-sectional	8959	4216	NR	Physician	Prevalence	High	Serdaroğlu S, Parlak AH, Engin B, Bahçetepe N, Keskin S, Antonova M, et al. The Prevalence of Psoriasis and Vitiligo in a Rural Area in Turkey. Journal of the Turkish Academy of Dermatology. 2012;6(1):0–0.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
India	Asia, south	Vora	2012	2006–2010	Cross-sectional	26177	10929	NR	Self	Prevalence	Moderate	Vora R, Bodiwala N, Patel S. Prevalence of various dermatoses in school children of Anand district. National Journal of Community Medicine. 2012;3(01):100–3.
Egypt	North Africa and the Middle East	Yamamah	2012	2008–2009	Cross-sectional	2194	1071	NR	Physician	Prevalence	Low	Yamamah GA, Emam HM, Abdelhamid MF, Elsaie ML, Shehata H, Farid T, et al. Epidemiologic study of dermatologic disorders among children in South Sinai, Egypt. International journal of dermatology. 2012;51(10):1180–5.
Cameroon	Sub-Saharan Africa, western	Bissek	2012	2010	Cross-sectional	400	200	NR	Physician	Prevalence	Low	Bissek ACZK, Tabah EN, Kouotou E, Sini V, Yepnjio FN, Nditanchou R, et al. The spectrum of skin diseases in a rural setting in Cameroon (sub-Saharan Africa). BMC dermatology. 2012;12:7.
Egypt	North Africa and the Middle East	El-Khateeb	2013	2011–2012	Cross-sectional	6162	3402	NR	Physician	Prevalence	Moderate	El-Khateeb EA, Lotfi RA, Abd Elaziz KM, El-Shiekh SE. Prevalences of skin diseases among primary schoolchildren in D amietta, E gypt. International journal of dermatology. 2014;53(5):609–16.
Ghana	Sub-Saharan Africa, western	Hogewoning	2013	2004, 2007	Cross-sectional	1394	734	NR	Physician	Prevalence	Low	Hogewoning A, Amoah A, Bavinck JNB, Boakye D, Yazdanbakhsh M, Adegnika A, et al. Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. International journal of dermatology. 2013;52(5):589–600.
Gabon	Sub-Saharan Africa, central	Hogewoning	2013	2005	Cross-sectional	454	227	NR	Physician	Prevalence	Low	Hogewoning A, Amoah A, Bavinck JNB, Boakye D, Yazdanbakhsh M, Adegnika A, et al. Skin diseases among schoolchildren in Ghana,

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												Gabon, and Rwanda. International journal of dermatology. 2013;52(5):589–600.
Rwanda	Sub-Saharan Africa, eastern	Hogewoning	2013	2007	Cross-sectional	2528	1296	NR	Physician	Prevalence	Low	Hogewoning A, Amoah A, Bavinck JNB, Boakye D, Yazdanbakhsh M, Adegnika A, et al. Skin diseases among schoolchildren in Ghana, Gabon, and Rwanda. International journal of dermatology. 2013;52(5):589–600.
China	Asia, east	Wang	2013	NR	Cross-sectional	19974	9487	NR	Physician	Prevalence	Low	Wang X, Du J, Wang T, Zhou C, Shen Y, Ding X, et al. Prevalence and clinical profile of vitiligo in China: a community-based study in six cities. Acta dermato-venereologica. 2013;93(1):62–65.
Iran	North Africa and the Middle East	Afkhami-Ardekani	2014	2011	Cross-sectional	1100	609	NR	Physician	Prevalence	Moderate	Afkhami-Ardekani M, Ghadiri-Anari A, Ebrahimzadeh-Ardakani M, Zaji N. Prevalence of vitiligo among type 2 diabetic patients in an Iranian population. International Journal of Dermatology. 2014;53(8):956–8.
Nigeria	Sub-Saharan Africa, western	Henshaw	2014	NR	Cross-sectional	1447	828	NR	Physician	Prevalence	Low	Henshaw EB, Olasode OA, Ogedegbe EE, Etuk I. Dermatologic conditions in teenage adolescents in Nigeria. Adolescent health, medicine and therapeutics. 2014;5:79–87.
Finland	Western Europe	Sinikumpu S-P	2014	2012–2013	Cross-sectional	1930	1036	NR	Physician	Prevalence	Low	Sinikumpu SP, Huilaja L, Jokelainen J, Koiranen M, Auvinen J, Hagg PM, et al. High prevalence of skin diseases and need for treatment in a middle-aged population. A Northern Finland birth cohort 1966 study. PloS one. 2014;9(6):e99533.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
India	Asia, south	Reddy	2014	NR	Cross-sectional	22037	NR	NR	Self	Prevalence	Low	Reddy J. A survey on the prevalence of vitiligo in Bangalore city, India. International Journal of Pharma Medicine and Biological Sciences. 2014;3(1):34–45.
Taiwan (Province of China)	Asia, east	Chen	2015	1997–2011	Cohort	23143071	NR	NR	Physician	Prevalence	Moderate	Chen YT, Chen YJ, Hwang CY, Lin MW, Chen TJ, Chen CC, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. Journal of the European Academy of Dermatology and Venereology. 2015;29(7):1362–9.
South Korea	Asia Pacific, high income	Lee	2015	2009–2011	Cohort	50593516	NR	NR	Physician	Prevalence	Low	Lee H, Lee MH, Lee DY, Kang HY, Kim KH, Choi GS, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei medical journal. 2015;56(3):719–25.
Poland	Europe, central	Cybulski	2015	2015	Cross-sectional	200	NR	NR	Physician	Prevalence	Low	Cybulski M, Krajewska-Kulak E. Skin diseases among elderly inhabitants of Bialystok, Poland. Clinical Interventions in Aging. 2015;10:1937–43.
Turkey	North Africa and the Middle East	Uludağ	2016	2013	Cross-sectional	1957	NR	NR	Physician	Prevalence	Low	Uludağ A, Kılıc SO, Isık S, Haydar Ertekin Y, Tekin M, Cevizci S, et al. Prevalence of skin disorders in primary and secondary school age children in Canakkale, Turkey: a community-based survey. Postepy Dermatol Alergol. 2016;33(3):176–81.
Brazil	Latin America, tropical	Castro	2018	2017	Cross-sectional	17004	NR	NR	Physician	Prevalence	Moderate	Cesar Silva de Castro C, Miot HA. Prevalence of vitiligo in Brazil-A population survey. Pigment Cell & Melanoma Research. 2018;31(3):448–50.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
France	Western Europe	Richard	2018	2016	Cross-sectional	20012	10252	NR	Physician	Prevalence	Low	Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V, et al. Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the ≪OBJECTIFS PEAU≫ study. Journal of the European Academy of Dermatology and Venereology. 2018;32(11):1967–71.
Cote d'Ivoire	Sub-Saharan Africa, western	Yotsu	2018	2015–2016	Cross-sectional	4339	1930	NR	Physician	Prevalence	Moderate	Yotsu RR, Kouadio K, Vagamon B, N'guessan K, Akpa AJ, Yao A, et al. Skin disease prevalence study in schoolchildren in rural Coˆte d'Ivoire: Implications for integration of neglected skin diseases (skin NTDs). PLoS Neglected Tropical Diseases. 2018;12(5):e0006489.
South Korea	Asia Pacific, high income	Lee	2018	2007–2016	Cohort	142580	NR	NR	Physician	Prevalence	Moderate	Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. Journal of the European Academy of Dermatology and Venereology. 2018;32(10):1784–1790.
United States	North America, high income	Haber	2018	2014–2017	Cross-sectional	4242400	NR	NR	Physician	Prevalence	High	Haber J, Strunk A, Garg A. Prevalence Estimates for Vitiligo among Children and Adolescents in the United States: A Gender and Age Adjusted Population Analysis. Pediatric Dermatology. 2018;35:715.
Saudi Arabia	North Africa and	Rahamathulla	2019	2016	Cross-sectional	499	348	NR	Self	Prevalence	Low	Rahamathulla MP. Prevalence of skin disorders and associated socio-economic factors among primary

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
	the Middle East											school children in the Eastern region of Saudi Arabia. Journal of the Pakistan Medical Association. 2019;69(8):1175–80.
South Korea	Asia Pacific, high income	Hahn	2019	NR	Cohort	1113656	555470	NR	Physician	Prevalence	Moderate	Hahn HJ, Kwak SG, Kim DK, Kim JY. A nationwide, population-based cohort study on potential autoimmune Association of Meniere Disease to Atopy and Vitiligo. Scientific Reports. 2019;9(1): 4406.
Brazil	Latin America, tropical	Tolentino	2019	2016	Cross-sectional	60413	29602	NR	Physician	Prevalence	Moderate	Tolentino Junior DS, de Oliveira CM, de Assis EM. Population-based study of 24 autoimmune diseases carried out in a Brazilian microregion. Journal of Epidemiology and Global Health. 2019;9(4):243–51.
Germany	Western Europe	Zander	2019	NR	Cross-sectional	121783	NR	NR	Physician	Prevalence	High	Zander N, Petersen J, Schaefer I, Kirsten N, Augustin M. Prevalence and dermatological Comorbidity of Vitiligo in Germany-a dual population-based Approach. Journal der Deutschen Dermatologischen Gesellschaft. 2019;17:205–6
China	Asia, east	Shen	2020	2017–2018	Cross-sectional	28364	13185	NR	Physician	Prevalence	Low	Shen M, Xiao Y, Su J, Zhao S, Li J, Tao J, Kang X, Wu B, Shan S, Wang X, Chen X. Prevalence and patient-reported outcomes of noncommunicable skin diseases among college students in China. Journal of the American Academy of Dermatology International. 2020;1(1):23–30.
India	Asia, south	Singhal	2020	2017	Cross-sectional	2214	1193	NR	Physician	Prevalence	Low	Singhal RR, Talati KN, Gandhi BP, Shinde MK, Nair PA, Phatak AG.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												Prevalence and Pattern of Skin Diseases in Tribal Villages of Gujarat: A Teledermatology Approach. Indian Journal of Community Medicine. 2020;45(2):199–203.
Finland	Western Europe	Sinikumpu	2020	2018–2019	Cross-sectional	552	346	White	Physician	Prevalence	Low	Sinikumpu SP, Jokelainen J, Haarala AK, Keränen MH, Keinänen-Kiukaanniemi S, Huilaja L. The High Prevalence of Skin Diseases in Adults Aged 70 and Older. Journal of the American Geriatrics Society. 2020;68(11):2565–71.
Taiwan (Province of China)	Asia, east	Chen	2020	2000–2013	Cohort	989,753	NR	NR	Physician	Prevalence	Low	Chen CY, Wang WM, Chung CH, Tsao CH, Chien WC, Hung CT. Increased risk of psychiatric disorders in adult patients with vitiligo: A nationwide, population-based cohort study in Taiwan. The Journal of Dermatology. 2020;47(5):470–5.
United States	North America, high income	Conic	2020	2019	Cross-sectional	8314220	4022450	Caucacian (4434260) African American (1028080) Others (2853040)	Physician	Prevalence	Low	Conic RZ, Tamashunas NL, Damiani G, Fabbrocini G, Cantelli M; Young Dermatologists Italian Network; Bergfeld WF. Comorbidities in pediatric alopecia areata. Journal of the European Academy of Dermatology and Venereology. 2020;34(12):2898–901.
India	Asia, south	Nijhawan	2020	2019	Cross-sectional	576	358	NR	Physician	Prevalence	Moderate	Nijhawan M, Bagri M, Nijhawan S, Bishnoi S, Agarwal S, Nijhawan S. Pattern of common skin diseases among school going children in Semi-Urban Area of Jaipur: A cross-sectional study. Indian

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
												Journal of Paediatric Dermatology. 2020;21(4):275–8.
Japan	Asia Pacific, high income	Tanaka	2020	2010–2019	Cross-sectional	3626	1,823	NR	Physician	Prevalence	Low	Tanaka A, Niimi N, Takahashi M, Takahashi H, Nagata K, Nishiyama N, et al. Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan. The Journal of Dermatology. 2022;49(12):1284–90.
Singapore	Asia Pacific, high income	Yew	2020	2016–2018	Cross-sectional	1510	848	East Asian (Chinese, 1189) South Asian (Malaysian, Indian, 280) Others (41)	Self	Prevalence	Low	Yew YW, Kuan AHY, Ge L, Yap CW, Heng BH. Psychosocial impact of skin diseases: A population-based study. PLoS One. 2020;15(12):e0244765.
Germany	Western Europe	Nicole Mohr	2021	2004–2014	Cohort	121783	52951	NR	Physician	Prevalence	Low	Mohr N, Petersen J, Kirsten N, Augustin M. Epidemiology of Vitiligo - A Dual Population-Based Approach. Clinical Epidemiology. 2021;13:373–82.
Germany	Western Europe	Nicole Mohr	2021	2010	Cohort	1619678	1001539	NR	Physician	Prevalence	Low	Mohr N, Petersen J, Kirsten N, Augustin M. Epidemiology of Vitiligo - A Dual Population-Based Approach. Clinical Epidemiology. 2021;13:373–82.
China	Asia, east	Tang	2021	2009–2010	Cross-sectional	9114	4288	NR	Physician	Prevalence	Low	Tang L, Li F, Xu F, Yan S, Zhou J, Li J, et al. Prevalence of vitiligo and associated comorbidities in adults in Shanghai, China: a community-based, cross-sectional survey. Annals of Palliative Medicine. 2021;10(7):8103–11.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
United Kingdom	Europe, western	Subramanian	2021	2006–2016	Cohort	4414357	2329575	White (British, Irish, other white, 3811730) South Asian (Bangladeshi, Pakistani, Indian, Sri Lankan, British Asian or other South Asian, 233432) Afro-Caribbean (black African, black Caribbean, black British or other black people, 161534) Mixed race or other minority ethnic groups (including Chinese, Vietnamese and other South East Asian, 207661)	Physician	Incidence, Prevalence	Low	Subramanian A, Adderley NJ, Gkoutos GV, Gokhale KM, Nirantharakumar K, Krishna MT. Ethnicity-based differences in the incident risk of allergic diseases and autoimmune disorders: A UK-based retrospective cohort study of 4·4 million participants. Clinical and Experimental Allergy. 2021;51(1):144–7.
India	Asia, south	Palanivel	2021	2018	Cross-sectional	850	520	NR	Physician	Prevalence	Low	Palanivel N, Govardhanan VM, Moorthi SS, Maalik Babu ANM, Kannan SM. A Cross Sectional Survey for Dermatoses in Children and Adolescents Residing in Orphanages in Urban Tirunelveli, Tamil Nadu, India. Indian Journal of Dermatology. 2021;66(4):352–9.
Sweden, Germany, Netherlands, Italy, Portugal	Western Europe	Svensson	2018	2008–2011	Cross-sectional	12377	6671	NR	Physician	Prevalence	Low	Svensson A, Ofenloch RF, Bruze M, Naldi L, Cazzaniga S, Elsner P, et al. Prevalence of skin disease in a population-based sample of adults from five European countries. British Journal of Dermatology. 2018;178(5):1111–8.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
United States	North America, high income	Gandhi	2021	2013–2017	Cohort	NR	NR	NR	Physician	Incidence, Prevalence	High	Gandhi K, Ray M, Borra S, Sruti I, Xu L, Pandya A. Prevalence and incidence of vitiligo in the United States: A real-world analysis. 2021.
United States	North America, high income	Gandhi	2022	2019–2020	Cross-sectional	40888	23170	White (30428) African American (5253) Hispanic (4225) Asian (1481) Multiracial (1181) American Indian&Alaska Native (367) Native Hawaiian(85) Others (2086)	Physician, Self	Prevalence	Low	Gandhi K, Ezzedine K, Anastassopoulos KP, Patel R, Sikirica V, Daniel SR, et al. Prevalence of Vitiligo Among Adults in the United States. JAMA Dermatology. 2022;158(1):43–50.
France, Germany, Italy, Spain, United Kingdom, United States, Japan	Western Europe North America, high income Asia Pacific, high income	Bibeau	2022	2019	Cross-sectional	35694	19882	NR	Physician, Self	Prevalence	Low	Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. Journal of the European Academy of Dermatology and Venereology. 2022;36(10):1831–44.
Europe, United States, Japan	North America, high income Asia Pacific, high income	Harris	2020	NR	Cross-sectional	35694	NR	NR	Physician, Self	Prevalence	High	Harris JE, Ezzedine K, Bibeau K, Jones H, Na L, Pandya A. Global survey investigating the prevalence of vitiligo and vitiligo signs among adults in Europe, Japan, and the United States. Journal of the American Academy of Dermatology. 2020;83(6):AB198
Egypt	North Africa and	Khater	2022	NR	Cross-sectional	185	101	North African (Egypt)	Physician	Prevalence	Low	Khater MH, Abbas RA, Elshobaky OA, Khashaba SA. Prevalence of Hypopigmentary Disorders in

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
	the Middle East											Primary School Children in Zagazig City, Sharkia Governorate, Egypt. Journal of Cosmetic Dermatology. 2022;21(3):1208–15.
United States	North America, high income	Alchirazi	2022	NR	Cross-sectional	70383890	NR	NR	Physician	Prevalence	High	Alchirazi KA, Eltelbany A, Mohammed A, Almomani A, Hamid O, Abu-Shawer O, et al. S1044 Prevalence of Vitiligo Among IBD and Celiac Disease Patients: Results From a Population-Based Study. The American Journal of Gastroenterology. 2022;117(10S):pe757–8.
South Korea	Asia Pacific, high income	Kang	2023	2003–2019	Cohort	1035504	579972	NR	Physician	Incidence, Prevalence	Low	Kang H, Lee S. Prevalence and incidence of vitiligo and associated comorbidities: a nationwide population-based study in Korea. Clinical and Experimental Dermatology. 2023;48(5):484–9.
United States	North America, high income	Mastacouris	2023	2015–2019	Cohort	2980778	1697610	White (2002447) African American (333794) Asian (36886) Hispanic/Latino (40086) Other/multiracial (177964)	Physician	Incidence, Prevalence	Low	Mastacouris N, Strunk A, Garg A. Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US. JAMA Dermatology. 2023 Jul 19;e232162.
United States	North America, high income	Ahmed	2023	NR	Cohort	284004	171008	White (155761) African American (51616) Hispanic (49336) Others (27291)	Physician	Prevalence	Moderate	Ahmed F, Moseley I, Ragi SD, Ouellette S, Rao B. Vitiligo in underrepresented communities: An All of Us database analysis. Journal of the American Academy of Dermatology. 2023;88(4):945–8.
United States	North America,	Patel	2023	2019–2020	Cross-sectional	9118	3059	White (6810) African American (1105)	Physician, Self	Prevalence	Low	Patel R, Pandya AG, Sikirica V, Gandhi K, Daniel SR, Anastassopoulos KP, et al.

Country	Region	Author	Year	Study time	Study design	Total population	Female population	Ethnicity	Diagnostic criteria	Study outcome	Risk of bias	Reference
	high income							Asian (474) Multiracial(367) American Indian&Alaska Native (33) Native Hawaiian (15) Others (314)				Prevalence of Vitiligo among Children and Adolescents in the United States. Dermatology. 2023;239(2):227–34.
United States	North America, high income	Moseley	2023	2002–2014	Cohort	63692	63692	White (62126) African American(883) Others(683)	Physician	Prevalence	Moderate	Moseley IH, Thompson JM, George EA, Ragi SD, Kang JH, Reginato AM, et al. Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women. Archives of Dermatological Research. 2023;315(4):807–13.
United States	North America, high income	Ray	2023	2013–2017	Cohort	140901558	NR	NR	Physician	Incidence, Prevalence	Low	Ray M, Gandhi K, Maughn K, Pandya AG. Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims. JID Innovations. 2023;3(4):100199.

Table S4. Studies reporting on the prevalence of vitiligo in overall population

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Mehta	1973	1971–1972	India	Physician	9065	Overall	LP	1·52 (1·28–1·80)[2,3]	NR	NR
Howitz	1977	1971–1972	Denmark	Physician	47,033	Overall	LP	0·38 (0·33–0·44)[1,3]	0·40 (0·33–0·49)[1,3]	0·36 (0·29–0·44)[1,3]
Johnson	1978	1971–1974	United States	Physician	193,976,447	Overall	LP	0·49 (0·49–0·49)[2,3]	0·62 (0·62–0·62)[2,3]	0·36 (0·36–0·36)[2,3]
Bhalla	1984	1982–1983	India	Physician	4,133	Overall	LP	0·29 (0·15–0·51)[1,3]	NR	NR
Das	1985	1978	India	Physician	15,685	Overall	LP	0·46 (0·41–0·51)[1]	0·46 (0·38–0·53)[1]	0·46 (0·39–0·54)[1]
Gibbs	1996	1994	Tanzania	Physician	1,114	Overall	LP	0·27 (0·00–0·57)[1,3]	NR	NR
Perera	2000	1997	Sri Lanka	Physician	1,806	Overall	LP	1·22 (0·77–1·84)[1,3]	NR	NR
Massarrat	2002	1997–1999	Iran	Self	61,137	Overall	LP	0·60[1,4]	NR	NR
Prahalad	2002	NR	United States	Physician	496	Overall	LP	0·40 (0·05–1·45)[1,3]	NR	NR
Abdel-Hafez	2003	1994–1996	Egypt	Physician	8,008	Overall	LP	1·22 (0·99–1·49)[1,3]	NR	NR
Wolkenstein	2003	2002	France	Self	18,137	Overall	PP	0·28[1,4]	NR	NR
A. Almila Tuncel	2005	NR	Turkey	Physician	682	Overall	LP	0·29 (0·04–1·06)[1,3]	0·29 (0·04–1·06)[1,3]	NR
Al-Rubiay	2005	NR	Iraq	Self	6,666	Overall	LP	0·51 (0·51–0·71)[2,3]	NR	NR
Al-Saeed	2006	2003	Saudi Arabia	Physician	2,239	Overall	LP	0·36 (0·15–0·70)[1,3]	NR	0·36 (0·15–0·70)[1,3]
Chhaganlal	2007	NR	Mozambique	Self	1,066	Overall	LP	0·09 (0·00–0·52)[1,3]	NR	NR
El-Essawi	2007	NR	United States	Self	401	Overall	LP	2·00 (0·87–3·89)[1,3]	NR	NR

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Lu	2007	2002–2003	China	Physician	42,833	Overall	PP	0·09 (0·07–0·13)[1]	0·08 (0·05–0·13)[1,3]	0·10 (0·07–0·16)[1,3]
Birlea	2008	2001–2006	Romania	Physician	3,694	Overall	LP	1·38 (1·03–1·81)[2,3]	NR	NR
Walker	2008	NR	Nepal	Physician	878	Overall	PP	0·91 (0·39–1·79)[1,3]	NR	NR
M. Augustin	2011	2004–2009	Germany	Physician	90,880	Overall	LP	0·52 (0·48–0·57)[1]	0·47 (0·40–0·54)[1,3]	0·58 (0·51–0·65)[1,3]
Serdaroğlu	2012	NR	Turkey	Physician	8,502	Overall	LP	0·46 (0·33–0·63)[1,3]	NR	NR
Bissek	2012	2010	Cameroon	Physician	400	Overall	LP	0·50 (0·06–1·79)[2,3]	NR	NR
Wang	2013	NR	China	Physician	17,345	Overall	LP	0·70 (0·59–0·84)[1]	0·50 (0·37–0·65)[1]	0·95 (0·76–1·19)[1]
Afkhami-Ardekani	2014	2011	Iran	Physician	1,100	Overall	LP	1·82 (1·11–2·79)[2,3]	1·81 (0·91–3·21)[2,3]	1·83 (0·84–3·45)[2,3]
Reddy	2014	NR	India	Self	22,037	Overall	LP	0·73 (0·62–0·85)[2,3]	NR	NR
Chen	2015	1997–2011	Taiwan (Province of China)	Physician	23,143,071	Overall	LP	0·06[1,4]	NR	NR
Lee****	2015	2009–2011	South Korea	Physician	50,593,516	Overall	LP	0·12 (0·12–0·12)[1,3]	0·07[1,4]	0·05[1,4]
Castro	2018	2017	Brazil	Physician	17,004	Overall	LP	0·57 (0·46–0·68)[1]	0·52 (0·39–0·66)[1]	0·63 (0·46–0·83)[1]
Richard	2018	2016	France	Physician	20,012	Overall	LP	0·46 (0·38–0·57)[1,5]	0·48 (0·36–0·63)[1,5]	0·45 (0·34–0·61)[1,5]
Lee	2018	2007–2016	South Korea	Physician	142,580	Overall	LP	0·33 (0·30–0·37)[1,3]	NR	NR
Hahn****	2019	NR	South Korea	Physician	1,113,656	Overall	LP	0·11 (0·11–0·12)[1,3]	NR	NR
Tolentino	2019	2016	Brazil	Physician	60,413	Overall	LP	0·13 (0·11–0·16)[1]	0·15	0·12

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
									(0·11–0·20)[1]	(0·08–0·17)[1]
Zander	2019	NR	Germany	Physician	121,783	Overall	LP	0·17[4]	0·18[4]	0·14[4]
Singhal	2020	2017	India	Physician	2,214	Overall	LP	0·63 (0·35–1·06)[2,3]	NR	NR
Chen	2020	2000–2013	Taiwan (Province of China)	Physician	989,753	Overall	LP	0·17 (0·17–0·18)[2,3]	NR	NR
Nicole Mohr	2021	2004–2014	Germany	Physician	121,783	Overall	LP	0·77 (0·72–0·82)[2,3]	0·67 (0·60–0·74)[2,3]	0·84 (0·78–0·91)[2,3]
Nicole Mohr	2021	2004–2014	Germany	Physician	1,619,678	Overall	LP	0·17 (0·16–0·17)[2,3]	0·18 (0·18–0·19)[2,3]	0·14 (0·13–0·15)[2,3]
Subramanian	2021	2006–2016	United Kingdom	Physician	4,414,357	Overall	LP	0·18 (0·18–0·19)[2,3]	NR	NR
Gandhi	2021	2013–2017	United States	Physician	NR	Overall	PP	0·076[1,4]	NR	NR
Alchirazi	2022	NR	United States	Physician	70,383,890	Overall	LP	0·07 (0·07–0·07)[2,3]	NR	NR
Kang****	2023	2003–2019	South Korea	Physician	51,849,861	Overall	LP	0·33 (0·33–0·33)[2,3]	0·37 (0·37–0·37)[2,3]	0·29 (0·29–0·30)[2,3]
Mastacouris	2023	2015–2019	United States	Physician	1,057,534	Overall	LP	0·16 (0·15–0·17)[1,5]	0·16 (0·15–0·17)[1,5]	0·16 (0·15–0·17)[1,5]
Ahmed	2023	NR	United States	Physician	284,004	Overall	LP	0·33 (0·31–0·35)[1]	0·33 (0·31–0·36)[1]	0·33 (0·29–0·36)[1]
Ray	2023	2013–2017	United States	Physician	140,998,102	Overall	PP	0·08 (0·08–0·08)[1,3]	NR	NR

* Diagnostic methods: Physician = Dermatologists or Physicians; Self = Self–reported diagnosis.

** Prevalence measure: PP = Point prevalence; LP = Lifetime prevalence.

*** Notes: 1 Value reported from the study; 2 Rate checked and confirmed; 3 Confidence Interval (CI) estimated and added by the authors as it was not present in the original study; 4 It was not possible to calculate the confidence interval due to lack of raw data; 5 Age and/or sex adjusted. NR= Not Reported.

**** Data from these 3 studies were directly extracted from the South Korean National Health Information database for use as a single dataset in the statistical modelling.

Table S5. Studies reporting on the prevalence of vitiligo in adults

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Howitz	1977	1971–1972	Denmark	Physician	32,209	Adult	LP	0·50 (0·43–0·58)[2,3]	0·52 (0·42–0·65)[2,3]	0·48 (0·38–0·60)[2,3]
Quirk	1979	NR	Australia	Self	1,037	Adult	LP	1·2 (0·60–2·01)[1,3]	NR	NR
Weismann	1980	1976	Denmark	Physician	584	Adult	LP	1·2 (0·48–2·45)[1,3]	NR	NR
Das	1985	1978	India	Physician	8,066	Adult	LP	0·46 (0·32–0·63)[2,3]	0·49 (0·29–0·79)[2,3]	0·43 (0·27–0·67)[2,3]
Naldi	2004	2003	Italy	Self	3,660	Adult	LP	0·7[1,4]	NR	NR
Lu	2007	2002–2003	China	Physician	29,350	Adult	PP	0·12 (0·09–0·17)[2,3]	NR	NR
M. Augustin	2011	2004–2009	Germany	Physician	89,765	Adult	LP	0·53 (0·48–0·58)[2,3]	NR	NR
Wang	2013	NR	China	Physician	14,678	Adult	LP	0·78 (0·65–0·94)[2,3]	0·51 (0·37–0·69)[2,3]	1·13 (0·89–1·42)[2,3]
Sinikumpu S-P	2014	2012–2013	Finland	Physician	1,930	Adult	LP	1·66 (1·14–2·33)[2,3]	2·12 (1·34–3·20)[2,3]	1·12 (0·54–2·05)[2,3]
Cybulski	2015	2015	Poland	Physician	200	Adult	LP	1·50 (0·31–4·32)[2,3]	NR	NR
Shen	2020	2017–2018	China	Physician	28,364	Adult	LP	0·23 (0·17–0·28)[1]	0·16 (0·09–0·23)	0·29 (0·20–0·38)
Sinikumpu	2020	2018–2019	Finland	Physician	552	Adult	LP	1·99 (1·00–3·54)[1,3]	1·45 (0·47–3·34)[2,3]	2·91 (1·08–6·23)[2,3]
Yew	2020	2016–2018	Singapore	Self	1,510	Adult	LP	0·46 (0·19–0·95)[2,3]	0·47 (0·13–1·20)[2,3]	0·45 (0·09–1·32)[2,3]
Tang	2021	2009–2010	China	Physician	9,114	Adult	LP	0·91 (0·73–1·13)[1]	0·81 (0·58–1·10)[1]	1·03 (0·75–1·38)[1]
Svensson	2018	2008–2011	Netherlands	Physician	12,377	Adult	LP	2·2 (1·5–3·1)[1,5]	NR	NR

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Svensson	2018	2008–2011	Germany	Physician	12,377	Adult	LP	1·5 (1·2–1·9)[1,5]	NR	NR
Svensson	2018	2008–2011	Sweden	Physician	12,377	Adult	LP	1·1 (0·7–1·7)[1,5]	NR	NR
Svensson	2018	2008–2011	Italy	Physician	12,377	Adult	LP	0·4 (0·2–0·8)[1,5]	NR	NR
Svensson	2018	2008–2011	Portugal	Physician	12,377	Adult	LP	0·3 (0·1–0·7)[1,5]	NR	NR
Gandhi	2022	2019–2020	United States	Physician	40,888	Adult	PP	0·76 (0·68–0·84)[1]	NR	NR
Gandhi	2022	2019–2020	United States	Self	40,888	Adult	PP	1·38 (1·26–1·49)[1]	NR	NR
Bibeau	2022	2019	France	Physician	3,678	Adult	LP	0·8 (0·5–1·1)[1]	NR	NR
Bibeau	2022	2019	Germany	Physician	6,590	Adult	LP	0·5 (0·3–0·6)[1]	NR	NR
Bibeau	2022	2019	Italy	Physician	2,025	Adult	LP	1·5 (1·0–2·0)[1]	NR	NR
Bibeau	2022	2019	Spain	Physician	3,794	Adult	LP	0·8 (0·5–1·1)[1]	NR	NR
Bibeau	2022	2019	United Kingdom	Physician	2,698	Adult	LP	1·1 (0·7–1·5)[1]	NR	NR
Bibeau	2022	2019	United States	Physician	8,517	Adult	LP	0·6 (0·4–0·7)[1]	NR	NR
Bibeau	2022	2019	Japan	Physician	8,392	Adult	LP	0·6 (0·1–0·4)[1]	NR	NR
Bibeau	2022	2019	France	Self	3,678	Adult	LP	0·95 (0·66–1·32)[2,3]	NR	NR
Bibeau	2022	2019	Germany	Self	6,590	Adult	LP	0·85 (0·64–1·10)[2,3]	NR	NR
Bibeau	2022	2019	Italy	Self	2,025	Adult	LP	2·87 (2·14–3·63)[2,3]	NR	NR
Bibeau	2022	2019	Spain	Self	3,794	Adult	LP	1·24 (0·91–1·64)[2,3]	NR	NR

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Bibeau	2022	2019	United Kingdom	Self	2,698	Adult	LP	1·59 (1·16–2·14)[2,3]	NR	NR
Bibeau	2022	2019	United States	Self	8,517	Adult	LP	0·94 (0·75–1·17)[2,3]	NR	NR
Bibeau	2022	2019	Japan	Self	8,392	Adult	LP	0·41 (0·28–0·57)[2,3]	NR	NR
Harris	2020	NR	United States	Self	35,694	Adult	LP	1·4[1,4]	NR	NR
Harris	2020	NR	Japan	Self	35,694	Adult	LP	0·5[1,4]	NR	NR
Mastacouris	2023	2015–2019	United States	Physician	831,228	Adult	LP	0·18 (0·17–0·19)[1,5]	NR	NR
Moseley	2023	2002–2014	United States	Physician	63,692	Adult	LP	0·62 (0·56–0·69)[2,3]	NR	NR
Ray	2023	2013–2017	United States	Physician	108,927,783	Adult	PP	0·08 (0·08–0·08)[1,3]	NR	NR

* Diagnostic methods: Physician = Dermatologists or Physicians; Self = Self–reported diagnosis.

** Prevalence measure: PP = Point prevalence; LP = Lifetime prevalence.

*** Notes: 1 Value reported from the study; 2 Rate checked and confirmed; 3 Confidence Interval (CI) estimated and added by the authors as it was not present in the original study; 4 It was not possible to calculate the confidence interval due to lack of raw data; 5 Age and/or sex adjusted. NR= Not Reported.

Table S6. Studies reporting on the prevalence of vitiligo in children

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Howitz	1977	1971–1972	Denmark	Physician	14,824	Children	LP	0·12 (0·07–0·19)[2,3]	0·14 (0·07–0·23)[2,3]	0·10 (0·05–0·21)[2,3]
Larsson	1980	1975–1976	Sweden	Physician	8,298	Children	LP	0·374 (0·25–0·53)[1,3]	0·32 (0·17–0·55)[1,3]	0·42 (0·25–0·67)[1,3]
Bechelli	1981	1974–1975	Brazil	Physician	9,955	Children	LP	0·04 (0·01–0·10)[1,3]	NR	NR
Das	1985	1978	India	Physician	7,619	Children	LP	0·46 (0·32–0·64)[2,3]	0·43 (0·26–0·66)[2,3]	0·51 (0·28–0·84)[2,3]
Nanda	1989	1986	India	Physician	310	Children	LP	0·32 (0·01–1·78)[2,3]	NR	NR
Bhatia	1997	1988–1989	India	Physician	666	Children	LP	0·60 (0·16–1·53)[1,3]	0·91 (0·19–2·64)	0·30 (0·01–1·64)[1,3]
Popescu	1999	1995	Romania	Physician	1,114	Children	PP	0·27 (0·06–0·78)[1,3]	NR	NR
Fung	2000	1996–1997	China	Physician	1,006	Children	LP	0·10 (0·00–0·55)[2,3]	NR	NR
Dogra	2003	2001	India	Physician	12,586	Children	PP	2·16 (1·91–2·43)[1,3]	2·87 (2·47–3·32)[2,3]	1·46 (1·18–1·79)[2,3]
O. Faye	2005	2001	Mali	Physician	1,729	Children	PP	0·23 (0·06–0·59)[2,3]	NR	NR
Ingordo	2007	2001–2004	Italy	Physician	34,740	Children	LP	0·17 (0·13–0·22)[1]	0·17 (0·13–0·22)[1,3]	NR
Lu	2007	2002–2003	China	Physician	13,483	Children	PP	0·03 (0·01–0·08)[2,3]	NR	NR
Chen	2008	2005	Taiwan (Province of China)	Physician	3,273	Children	PP	0·09 (0·00–0·19)[1]	0·06 (0·00–0·34)[1,3]	0·12 (0·01–0·43)[1,3]
Naldi	2009	1997	Italy	Physician	3,179	Children	LP	0·66 (0·41–1·01)[1,3]	NR	NR
Komba	2010	NR	Tanzania	Physician	420	Children	PP	0·71 (0·15–2·07)[1,3]	0·00 (0·00–1·77)[1,3]	1·41 (0·29–4·06)[1,3]

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
M. Augustin	2011	2004–2009	Germany	Physician	1,115	Children	LP	0·36 (0·10–0·92)[2,3]	NR	NR
Vora	2012	2006–2010	India	Self	26,177	Children	LP	0·21 (0·16–0·28)[1,3]	0·21 (0·13–0·32)[1,3]	0·21(0·13–0·32)[1,3]
Yamamah	2012	2008–2009	Egypt	Physician	2,194	Children	LP	0·18 (0·05–0·47)[1,3]	NR	NR
El-Khateeb	2013	2011–2012	Egypt	Physician	6,162	Children	LP	0·06 (0·02–0·17)[1,3]	NR	NR
Hogewoning	2013	2004, 2007	Ghana	Physician	1,857	Children	PP	0·05 (0·00–0·30)[2,3]	NR	NR
Hogewoning	2013	2005	Gabon	Physician	454	Children	PP	0·00 (0·00–0·81)[1,3]	NR	NR
Hogewoning	2013	2007	Rwanda	Physician	2,528	Children	PP	0·00 (0·00–0·15)[1,3]	NR	NR
Wang	2013	NR	China	Physician	2,667	Children	LP	0·26 (0·11–0·54)[2,3]	0·40 (0·13–0·92)[2,3]	0·14 (0·02–0·51)[2,3]
Henshaw	2014	NR	Nigeria	Physician	1,447	Children	LP	0·07 (0·00–0·38)[2,3]	NR	NR
Reddy	2014	NR	India	Self	22,037	Children	LP	0·15[1,4]	NR	NR
Uludağ	2016	2013	Turkey	Physician	1,957	Children	LP	0·31 (0·11–0·67)[1,3]	NR	NR
Yotsu	2018	2015–2016	Cote d'Ivoire	Physician	4,483	Children	LP	0·22 (0·11–0·41)	NR	NR
Haber	2018	2014–2017	United States	Physician	4,242,400	Children	LP	0·0401 (0·0382–0·0421)[1,5]	0·0402 (0·0375–0·0430)[1,5]	0·0400 (0·0373–0·0429)[1,5]
Rahamathulla	2019	2016	Saudi Arabia	Self	499	Children	LP	1·00 (0·33–2·32)[1,3]	NR	NR
Conic	2020	2019	United States	Physician	8,314,220	Children	LP	0·04 (0·04–0·04)[2,3]	NR	NR
Nijhawan	2020	2019	India	Physician	576	Children	LP	0·87 (0·28–2·01)[2,3]	0·84 (0·17–2·43)[2,3]	0·92 (0·11–3·27)[2,3]
Tanaka	2020	2010–2019	Japan	Physician	3,626	Children	LP	0·14 (0·04–0·32)[2,3]	NR	NR

Author	Year	Study time	Country	Diagnostic method	Population size	Population	Type of rate	Prevalence % (95% confidence interval)	Prevalence % (95% confidence interval) - Female	Prevalence % (95% confidence interval) - Male
Palanivel	2021	2018	India	Physician	850	Children	PP	0·35 (0·07–1·03)[2,3]	0·19 (0·00–1·07)[2,3]	0·61 (0·07–2·17)[2,3]
Khater	2022	NR	Egypt	Physician	185	Children	LP	1·62 (0·34–4·67)[2,3]	NR	NR
Mastacouris	2023	2015–2019	United States	Physician	226,306	Children	LP	0·10 (0·09–0·12)[1,5]	NR	NR
Patel	2023	2019–2020	United States	Physician	9,118	Children	PP	0·69 (0·41–0·97)[1]	NR	NR
Patel	2023	2019–2020	United States	Self	9,118	Children	PP	1·52 (1·11–1·93)[1]	NR	NR
Ray	2023	2013–2017	United States	Physician	32,070,319	Children	PP	0·06 (0·06–0·06)[1,3]	NR	NR

* Diagnostic methods: Physician = Dermatologists or Physicians; Self = Self–reported diagnosis.

** Prevalence measure: PP = Point prevalence; LP = Lifetime prevalence.

*** Notes: 1 Value reported from the study; 2 Rate checked and confirmed; 3 The confidence interval estimated and added by the authors as it was not present in the original study; 4 It was not possible to calculate the confidence interval due to lack of raw data; 5 Age and/or sex adjusted. NR= Not Reported.

Table S7. Quality assessment of studies reporting on the incidence and prevalence of vitiligo using the Appraisal tool for Cross-Sectional Studies (AXIS) tool

Year	Author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
1973	Mehta	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No	**moderate**
1977	Howitz	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	**low**
1978	Johnson	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	**low**
1979	Quirk	Unclear	No	No	Yes	Unclear	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	**high**
1980	Larsson	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	**low**
1980	Weismann	Yes	Yes	Yes	Yes	No	No	No	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
1981	Bechelli	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**low**
1984	Bhalla	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Unclear	No	No	No	Yes	Yes	Yes	No	No	No	**moderate**
1985	Das	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No	**moderate**
1989	Nanda	Yes	Yes	Yes	Yes	Unclear	Unclear	No	Yes	No	No	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	**moderate**
1996	Gibbs	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
1997	Bhatia	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Unclear	Unclear	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
1999	Popescu	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	**low**
2000	Perera	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No	**moderate**
2000	Fung	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2002	Massarrat	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Unclear	Yes	No	No	Unclear	Unclear	Yes	Yes	No	No	**moderate**
2002	Prahalad	Yes	Yes	No	Yes	Yes	Unclear	No	Yes	Yes	Yes	Unclear	Unclear	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
2003	Abdel-Hafez	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2003	Dogra	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
2003	Wolkenstein	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	No	**low**
2004	Naldi	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	No	No	No	No	No	**moderate**

Year	Author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
2005	A. Almila Tuncel	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
2005	Al-Rubiay	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**low**
2005	O. Faye	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Unclear	Yes	Unclear	Yes	Unclear	Unclear	Yes	Yes	Yes	Yes	No	No	**moderate**
2006	Al-Saeed	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Unclear	**moderate**
2007	Ingordo	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2007	Chhaganlal	Yes	Yes	Yes	Yes	Unclear	Unclear	No	Yes	Yes	No	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	**moderate**
2007	El-Essawi	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2007	Lu	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2008	Birlea	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2008	Chen	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**low**
2008	Walker	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Unclear	Yes	Yes	Yes	No	Yes	**moderate**
2009	Naldi	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2010	Komba	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2011	M. Augustin	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**low**
2012	Serdaroğlu	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	No	Yes	No	No	No	No	No	No	No	No	**high**
2012	Vora	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Unclear	No	No	**moderate**
2012	Yamamah	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	**low**
2012	Bissek	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	**low**
2013	El-Khateeb	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	No	No	**moderate**
2013	Hogewoning	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2013	Wang	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**

Year	Author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
2014	Afkhami-Ardekani	Yes	Yes	Yes	Unclear	Yes	Unclear	No	Yes	Yes	Yes	Unclear	Yes	No	No	Yes	Yes	Yes	No	No	Unclear	**moderate**
2014	Henshaw	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	No	No	Yes	**low**
2014	Sinikumpu	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	Yes	**low**
2014	Reddy	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2015	Chen	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**moderate**
2015	Lee	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	**low**
2015	Cybulski	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2016	Uludağ	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	**low**
2017	Dunlap	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	**low**
2018	Castro	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	No	No	No	**moderate**
2018	Richard	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2018	Yotsu	Yes	Yes	No	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	Yes	No	No	Yes	Yes	Yes	**moderate**
2018	Lee	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Unclear	Unclear	Unclear	**moderate**
2018	Haber	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	**high**
2019	Rahamathulla	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	Yes	Yes	**low**
2019	Hahn	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	**moderate**
2019	Tolentino	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Unclear	Unclear	Unclear	Unclear	**moderate**
2019	Zander	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**high**
2020	Shen	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2020	Singhal	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	**low**
2020	Sinikumpu	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**

Year	Author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
2020	Chen	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2020	Conic	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	**low**
2020	Lee	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2020	Nijhawan	Yes	Yes	Unclear	Yes	Unclear	Unclear	No	Yes	No	Yes	Unclear	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**moderate**
2020	Tanaka	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2020	Yew	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2021	Nicole Mohr	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2021	Tang	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2021	Lee	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	**low**
2021	Subramanian	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2021	Palanivel	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2018	Svensson	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2021	Gandhi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	No	**high**
2022	Gandhi	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	**low**
2022	Bibeau	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2020	Harris	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	**high**
2022	Khater	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2022	Lee	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2022	Lim	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2022	Alchirazi	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	No	Yes	Yes	No	No	No	No	**high**
2023	Conrad	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2023	Kang	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	**low**

Year	Author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13	Q14	Q15	Q16	Q17	Q18	Q19	Q20	Overall risk
2023	Mastacouris	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**low**
2023	Ahmed	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Unclear	Yes	Yes	No	No	No	Yes	Yes	Yes	No	No	No	**moderate**
2023	Patel	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	**low**
2023	Moseley	Yes	Yes	Yes	Yes	Unclear	Unclear	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	**moderate**
2023	Ray	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	**low**

AXIS: Appraisal tool of Cross-Sectional Studies:

Q1) Were the aims/objectives of the study clear?

Q2) Was the study design appropriate for the stated aim(s)?

Q3) Was the sample size justified?

Q4) Was the target/reference population clearly defined? (Is it clear who the research was about?)

Q5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?

Q6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation?

Q7) Were measures undertaken to address and categorise non-responders?

Q8) Were the risk factor and outcome variables measured appropriate to the aims of the study?

Q9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published previously?

Q10) Is it clear what was used to determined statistical significance and/or precision estimates? (eg, p values, CIs)

Q11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?

Q12) Were the basic data adequately described?

Q13) Does the response rate raise concerns about non-response bias?

Q14) If appropriate, was information about non-responders described?

Q15) Were the results internally consistent?

Q16) Were the results for the analyses described in the methods, presented?

Q17) Were the authors' discussions and conclusions justified by the results?

Q18) Were the limitations of the study discussed?

Q19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?

Q20) Was ethical approval or consent of participants attained?

Table S8. Lifetime physician- or dermatologist-diagnosed prevalence of vitiligo for overall population and number of people with vitiligo (in thousands) by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			0·43	0·25	0·86	11·93	7·06	23·99	Yes	Super-region	2790·9735
Azerbaijan			0·43	0·25	0·86	44·07	26·07	88·65	Yes	Super-region	10312·992
Georgia			0·43	0·25	0·86	16·06	9·5	32·3	Yes	Super-region	3757·98
Kazakhstan			0·43	0·25	0·86	82·02	48·53	165·01	Yes	Super-region	19196·4655
Kyrgyzstan			0·43	0·25	0·86	27·89	16·5	56·11	Yes	Super-region	6527·7435
Mongolia			0·43	0·25	0·86	14·3	8·46	28·78	Yes	Super-region	3347·7825
Tajikistan			0·43	0·25	0·86	41·66	24·65	83·81	Yes	Super-region	9750·064
Turkmenistan			0·43	0·25	0·86	27·1	16·03	54·51	Yes	Super-region	6341·855
Uzbekistan			0·43	0·25	0·86	145·62	86·17	292·95	Yes	Super-region	34081·449
	Central Asia		0·43	0·25	0·86				Yes	Super-region	
Albania			0·52	0·28	1·07	14·92	8·02	30·53	Yes	Region	2854·71
Bosnia and Herzegovina			0·52	0·28	1·07	17·1	9·19	34·99	Yes	Region	3270·943
Bulgaria			0·52	0·28	1·07	35·99	19·34	73·65	Yes	Region	6885·8675
Croatia			0·52	0·28	1·07	21·22	11·41	43·43	Yes	Region	4060·1355
Czech Republic			0·52	0·28	1·07	54·94	29·53	112·43	Yes	Region	10510·7505
Hungary			0·52	0·28	1·07	50·75	27·28	103·86	Yes	Region	9709·786
Macedonia, FYR			0·52	0·28	1·07	10·99	5·91	22·5	Yes	Region	2103·33
Montenegro			0·52	0·28	1·07	3·28	1·76	6·72	Yes	Region	627·8585
Poland			0·53	0·28	1·11	204·84	105·71	423·63			38307·7255

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			0·54	0·29	1·11	105·19	55·11	214·45			19328·56
Serbia			0·52	0·28	1·07	38·14	20·5	78·05	Yes	Region	7296·7685
Slovakia			0·52	0·28	1·07	28·47	15·3	58·27	Yes	Region	5447·622
Slovenia			0·52	0·28	1·07	11·08	5·95	22·67	Yes	Region	2119·4095
	Central Europe		0·52	0·28	1·07						
Belarus			0·43	0·25	0·86	40·93	24·22	82·33	Yes	Super-region	9578·1675
Estonia			0·43	0·25	0·86	5·68	3·36	11·42	Yes	Super-region	1328·701
Latvia			0·43	0·25	0·86	8·01	4·74	16·11	Yes	Super-region	1873·919
Lithuania			0·43	0·25	0·86	11·91	7·05	23·95	Yes	Super-region	2786·6505
Moldova			0·43	0·25	0·86	13·08	7·74	26·32	Yes	Super-region	3061·5065
Russian Federation			0·43	0·25	0·86	620	366·86	1247·25	Yes	Super-region	145102·755
Ukraine			0·43	0·25	0·86	186	110·06	374·18	Yes	Super-region	43531·422
	Eastern Europe		0·43	0·25	0·86				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	0·43	0·25	0·86						
Australia			0·35	0·18	0·71	91·18	46·88	184·34			25921·089
New Zealand			0·35	0·19	0·68	17·98	9·68	35·05	Yes	Region	5129·7275
	Australasia		0·35	0·19	0·68						
Brunei			0·30	0·19	0·46	1·34	0·84	2·06	Yes	Region	445·373
Japan			0·29	0·17	0·46	356·62	215·89	567·16			124612·5305
Singapore			0·29	0·17	0·48	17·4	10·17	28·75			5941·0605

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·31	0·19	0·49	159·83	98·48	254·51			51830·139
	High-income Asia Pacific		0·30	0·19	0·46						
Canada			0·28	0·19	0·43	108·74	70·85	165·14	Yes	Region	38155·012
Greenland			0·28	0·19	0·43	0·16	0·1	0·24	Yes	Region	56·243
United States			0·27	0·19	0·39	907·42	625	1310·55			336997·624
	High-income North America		0·28	0·19	0·43						
Argentina			0·34	0·23	0·49	152·93	104·27	221·22	Yes	Super-region	45276·78
Chile			0·34	0·23	0·49	65·84	44·89	95·24	Yes	Super-region	19493·1845
Uruguay			0·34	0·23	0·49	11·57	7·89	16·74	Yes	Super-region	3426·2595
	High-income Southern Latin America		0·34	0·23	0·49				Yes	Super-region	
Andorra			0·39	0·27	0·55	0·3	0·22	0·43	Yes	Region	79·034
Austria			0·39	0·27	0·55	34·39	24·49	48·85	Yes	Region	8922·082
Belgium			0·39	0·27	0·55	44·76	31·87	63·58	Yes	Region	11611·4195
Cyprus			0·39	0·27	0·55	4·8	3·42	6·81	Yes	Region	1244·188
Denmark			0·38	0·25	0·57	22·11	14·58	33·15			5854·2405
Finland			0·41	0·27	0·66	22·79	15·01	36·29			5535·992
France			0·38	0·25	0·57	247·25	163·42	370·1			64531·444
Germany			0·38	0·26	0·55	317·21	219·15	460·57			83408·5545
Greece			0·39	0·27	0·55	40·27	28·67	57·19	Yes	Region	10445·365

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			0·39	0·27	0·55	1·43	1·02	2·03	Yes	Region	370·335
Ireland			0·39	0·27	0·55	19·22	13·69	27·3	Yes	Region	4986·526
Israel			0·39	0·27	0·55	34·31	24·43	48·73	Yes	Region	8900·059
Italy			0·39	0·26	0·58	229·9	153·09	345·14			59240·3295
Luxembourg			0·39	0·27	0·55	2·46	1·75	3·5	Yes	Region	639·321
Malta			0·39	0·27	0·55	2·03	1·45	2·88	Yes	Region	526·748
Netherlands			0·40	0·26	0·64	70·43	45·78	112·02			17501·6955
Norway			0·39	0·27	0·55	20·83	14·83	29·58	Yes	Region	5403·021
Portugal			0·37	0·23	0·58	38·43	24·11	59·23			10290·103
Spain			0·39	0·26	0·60	184·49	122·4	283			47486·935
Sweden			0·40	0·26	0·62	41·7	27·56	64·93			10467·097
Switzerland			0·39	0·27	0·55	33·51	23·86	47·59	Yes	Region	8691·4065
United Kingdom			0·39	0·25	0·59	260·15	170·42	394·39			67281·0395
	Western Europe		0·39	0·27	0·55						
		High-income	0·34	0·23	0·49						
Bolivia			0·31	0·16	0·52	37·43	19·51	63·33	Yes	Super-region	12079·472
Ecuador			0·31	0·16	0·52	55·15	28·75	93·31	Yes	Super-region	17797·737
Peru			0·31	0·16	0·52	104·47	54·46	176·77	Yes	Super-region	33715·4715
	Andean Latin America		0·31	0·16	0·52				Yes	Super-region	
Antigua and Barbuda			0·31	0·16	0·52	0·29	0·15	0·49	Yes	Super-region	93·2195
Bahamas, The			0·31	0·16	0·52	1·26	0·66	2·14	Yes	Super-region	407·9055

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·31	0·16	0·52	0·87	0·45	1·47	Yes	Super-region	281·1995
Belize			0·31	0·16	0·52	1·24	0·65	2·1	Yes	Super-region	400·031
Bermuda			0·31	0·16	0·52	0·2	0·1	0·34	Yes	Super-region	64·185
Cuba			0·31	0·16	0·52	34·88	18·18	59·02	Yes	Super-region	11256·3725
Dominica			0·31	0·16	0·52	0·22	0·12	0·38	Yes	Super-region	72·4125
Dominican Republic			0·31	0·16	0·52	34·45	17·96	58·29	Yes	Super-region	11117·8735
Grenada			0·31	0·16	0·52	0·39	0·2	0·65	Yes	Super-region	124·61
Guyana			0·31	0·16	0·52	2·49	1·3	4·22	Yes	Super-region	804·567
Haiti			0·31	0·16	0·52	35·47	18·49	60·02	Yes	Super-region	11447·569
Jamaica			0·31	0·16	0·52	8·76	4·57	14·83	Yes	Super-region	2827·6945
Puerto Rico			0·31	0·16	0·52	10·09	5·26	17·07	Yes	Super-region	3256·0275
St. Lucia			0·31	0·16	0·52	0·56	0·29	0·94	Yes	Super-region	179·6515
St. Vincent and the Grenadines			0·31	0·16	0·52	0·32	0·17	0·55	Yes	Super-region	104·332
Suriname			0·31	0·16	0·52	1·9	0·99	3·21	Yes	Super-region	612·9845
Trinidad and Tobago			0·31	0·16	0·52	4·73	2·46	8	Yes	Super-region	1525·663
Virgin Islands (U.S.)			0·31	0·16	0·52	0·31	0·16	0·52	Yes	Super-region	100·091
	Caribbean		0·31	0·16	0·52				Yes	Super-region	
Colombia			0·31	0·16	0·52	159·63	83·21	270·1	Yes	Super-region	51516·562
Costa Rica			0·31	0·16	0·52	15·97	8·32	27·02	Yes	Super-region	5153·957
El Salvador			0·31	0·16	0·52	19·56	10·2	33·1	Yes	Super-region	6314·1675

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·31	0·16	0·52	54·56	28·44	92·32	Yes	Super-region	17608·4835
Honduras			0·31	0·16	0·52	31·85	16·6	53·89	Yes	Super-region	10278·3455
Mexico			0·31	0·16	0·52	392·61	204·65	664·31	Yes	Super-region	126705·138
Nicaragua			0·31	0·16	0·52	21·23	11·06	35·92	Yes	Super-region	6850·54
Panama			0·31	0·16	0·52	13·48	7·03	22·81	Yes	Super-region	4351·267
Venezuela, RB			0·31	0·16	0·52	87·38	45·55	147·85	Yes	Super-region	28199·8665
	Central Latin America		0·31	0·16	0·52				Yes	Super-region	
Brazil			0·25	0·13	0·46	530·49	268·08	983·94			214326·223
Paraguay			0·26	0·13	0·48	17·45	8·71	32·27	Yes	Region	6703·799
	Tropical Latin America		0·26	0·13	0·48						
		Latin America and Caribbean	0·31	0·16	0·52						
Afghanistan			0·47	0·31	0·72	187·23	123·82	289·68	Yes	Region	40099·462
Algeria			0·47	0·31	0·72	206·28	136·41	319·15	Yes	Region	44177·9685
Bahrain			0·47	0·31	0·72	6·83	4·52	10·57	Yes	Region	1463·2655
Egypt			0·47	0·30	0·76	517·21	330·83	829·45			109262·1775
Iran			0·49	0·31	0·80	428·97	270·12	699·73			87923·4325
Iraq			0·46	0·29	0·76	201·55	124·12	331·08			43533·5925
Jordan			0·47	0·31	0·72	52·05	34·42	80·54	Yes	Region	11148·2775
Kuwait			0·47	0·31	0·72	19·84	13·12	30·7	Yes	Region	4250·114
Lebanon			0·47	0·31	0·72	26·11	17·27	40·4	Yes	Region	5592·631

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			0·47	0·31	0·72	31·45	20·8	48·66	Yes	Region	6735·277
Morocco			0·47	0·31	0·72	173·12	114·49	267·85	Yes	Region	37076·5845
Oman			0·47	0·31	0·72	21·11	13·96	32·66	Yes	Region	4520·471
Palestine			0·47	0·31	0·72	23·97	15·85	37·08	Yes	Region	5133·392
Qatar			0·47	0·31	0·72	12·55	8·3	19·42	Yes	Region	2688·235
Saudi Arabia			0·48	0·30	0·78	172·24	107·73	280·24			35950·396
Sudan			0·47	0·31	0·72	213·18	140·98	329·83	Yes	Region	45657·2015
Syria			0·47	0·31	0·72	99·57	65·85	154·05	Yes	Region	21324·367
Tunisia			0·47	0·31	0·72	57·26	37·87	88·59	Yes	Region	12262·946
Turkey			0·46	0·29	0·73	390·28	244·87	615·28			84775·4035
United Arab Emirates			0·47	0·31	0·72	43·73	28·92	67·65	Yes	Region	9365·1445
Yemen, Rep.			0·47	0·31	0·72	154	101·84	238·26	Yes	Region	32981·6415
	North Africa and Middle East		0·47	0·31	0·72						
		North Africa and Middle East	0·40	0·25	0·67						
Bangladesh			0·52	0·33	0·82	875·13	553·57	1381·1	Yes	Region	169356·251
Bhutan			0·52	0·33	0·82	4·02	2·54	6·34	Yes	Region	777·4865
India			0·53	0·36	0·81	7521·42	5001·82	11355·07			1407563·842
Nepal			0·53	0·32	0·90	160·57	96·1	271·54			30034·9895
Pakistan			0·52	0·33	0·82	1195·74	756·38	1887·09	Yes	Region	231402·1165
	South Asia		0·52	0·33	0·82						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	0·42	0·26	0·76						
China			0·22	0·14	0·35	3190·49	2032·18	5019·73			1425893·465
North Korea			0·23	0·14	0·38	60·13	36·97	97·69	Yes	Region	25971·909
Taiwan (Province of China)			0·22	0·13	0·36	51·81	30·98	84·91			23859·912
	East Asia		0·23	0·14	0·38						
American Samoa			0·31	0·19	0·50	0·14	0·08	0·23	Yes	Super-region	45·035
Fiji			0·31	0·19	0·50	2·89	1·72	4·63	Yes	Super-region	924·6095
Guam			0·31	0·19	0·50	0·53	0·32	0·85	Yes	Super-region	170·534
Kiribati			0·31	0·19	0·50	0·4	0·24	0·65	Yes	Super-region	128·874
Marshall Islands			0·31	0·19	0·50	0·13	0·08	0·21	Yes	Super-region	42·05
Micronesia, Fed. Sts.			0·31	0·19	0·50	1·67	1	2·68	Yes	Super-region	534·606
Northern Mariana Islands			0·31	0·19	0·50	0·15	0·09	0·25	Yes	Super-region	49·4815
Papua New Guinea			0·31	0·19	0·50	31·15	18·55	49·82	Yes	Super-region	9949·437
Samoa			0·31	0·19	0·50	0·68	0·41	1·1	Yes	Super-region	218·764
Solomon Islands			0·31	0·19	0·50	2·22	1·32	3·54	Yes	Super-region	707·851
Tonga			0·31	0·19	0·50	0·33	0·2	0·53	Yes	Super-region	106·017
Vanuatu			0·31	0·19	0·50	1	0·59	1·6	Yes	Super-region	319·1365
	Oceania		0·31	0·19	0·50				Yes	Super-region	
Cambodia			0·38	0·19	0·86	62·22	31·05	142·73	Yes	Region	16589·0235
Indonesia			0·38	0·19	0·86	1026·68	512·46	2355·4	Yes	Region	273753·191

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			0·38	0·19	0·86	27·85	13·9	63·89	Yes	Region	7425·0575
Malaysia			0·38	0·19	0·86	125·92	62·85	288·87	Yes	Region	33573·8735
Maldives			0·38	0·19	0·86	1·96	0·98	4·49	Yes	Region	521·4575
Mauritius			0·38	0·19	0·86	4·87	2·43	11·18	Yes	Region	1298·9145
Myanmar			0·38	0·19	0·86	201·76	100·71	462·88	Yes	Region	53798·0845
Philippines			0·38	0·19	0·86	427·1	213·18	979·84	Yes	Region	113880·328
Seychelles			0·38	0·19	0·86	0·4	0·2	0·92	Yes	Region	106·4705
Sri Lanka			0·39	0·19	0·91	85·57	41·19	197·62			21773·4405
Thailand			0·38	0·19	0·86	268·53	134·04	616·06	Yes	Region	71601·103
Timor-Leste			0·38	0·19	0·86	4·95	2·47	11·37	Yes	Region	1320·942
Vietnam			0·38	0·19	0·86	365·54	182·46	838·63	Yes	Region	97468·0285
	Southest Asia		0·38	0·19	0·86						
		Southeast Asia, East Asia, and Oceania	0·31	0·19	0·50						
Angola			0·33	0·20	0·53	113·26	68·87	182·47	Yes	Super-region	34503·7735
Central African Republic			0·33	0·20	0·53	17·91	10·89	28·86	Yes	Super-region	5457·1545
Congo, Dem. Rep.			0·33	0·20	0·53	314·79	191·39	507·13	Yes	Super-region	95894·1185
Congo, Rep.			0·33	0·20	0·53	19·16	11·65	30·86	Yes	Super-region	5835·806
Equatorial Guinea			0·33	0·20	0·53	5·37	3·26	8·64	Yes	Super-region	1634·4655
Gabon			0·33	0·20	0·53	7·69	4·67	12·38	Yes	Super-region	2341·179

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·33	0·20	0·53				Yes	Super-region	
Burundi			0·31	0·17	0·55	39·03	21·62	68·78	Yes	Region	12551·213
Comoros			0·31	0·17	0·55	2·55	1·42	4·5	Yes	Region	821·6255
Djibouti			0·31	0·17	0·55	3·44	1·9	6·06	Yes	Region	1105·5575
Eritrea			0·31	0·17	0·55	11·26	6·24	19·84	Yes	Region	3620·312
Ethiopia			0·31	0·17	0·55	374	207·23	659·14	Yes	Region	120283·026
Kenya			0·31	0·17	0·55	164·81	91·32	290·47	Yes	Region	53005·614
Madagascar			0·31	0·17	0·55	89·91	49·82	158·46	Yes	Region	28915·6525
Malawi			0·31	0·17	0·55	61·84	34·27	108·99	Yes	Region	19889·742
Mozambique			0·29	0·15	0·54	93·84	47·58	174·51			32077·072
Rwanda			0·31	0·17	0·55	41·86	23·19	73·77	Yes	Region	13461·8875
Somalia			0·31	0·17	0·55	53·06	29·4	93·52	Yes	Region	17065·581
South Sudan			0·31	0·17	0·55	33·42	18·52	58·9	Yes	Region	10748·2725
Tanzania			0·33	0·18	0·60	207·19	111·44	383·65			63588·334
Uganda			0·31	0·17	0·55	142·58	79	251·27	Yes	Region	45853·778
Zambia			0·31	0·17	0·55	60·55	33·55	106·71	Yes	Region	19473·125
	Eastern sub-Saharan Africa		0·31	0·17	0·55						
Botswana			0·33	0·20	0·53	8·5	5·17	13·69	Yes	Super-region	2588·423
Lesotho			0·33	0·20	0·53	7·49	4·55	12·07	Yes	Super-region	2281·4545
Namibia			0·33	0·20	0·53	8·31	5·05	13·38	Yes	Super-region	2530·1505
South Africa			0·33	0·20	0·53	194·97	118·54	314·09	Yes	Super-region	59392·255

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·33	0·20	0·53	3·91	2·38	6·31	Yes	Super-region	1192·271
Zimbabwe			0·33	0·20	0·53	52·5	31·92	84·58	Yes	Super-region	15993·524
	Southern sub-Saharan Africa		0·33	0·20	0·53				Yes	Super-region	
Benin			0·31	0·17	0·53	39·72	22·33	68·61	Yes	Region	12996·895
Burkina Faso			0·31	0·17	0·53	67·54	37·97	116·68	Yes	Region	22100·6835
Cameroon			0·31	0·17	0·56	84·49	45·91	153·13			27198·628
Cape Verde			0·31	0·17	0·53	1·8	1·01	3·1	Yes	Region	587·925
Chad			0·31	0·17	0·53	52·51	29·52	90·7	Yes	Region	17179·74
Cote d'Ivoire			0·31	0·17	0·53	83·98	47·21	145·06	Yes	Region	27478·249
Gambia, The			0·31	0·17	0·53	8·07	4·54	13·94	Yes	Region	2639·9155
Ghana			0·30	0·16	0·55	98·51	52·89	180·7			32833·0315
Guinea			0·31	0·17	0·53	41·36	23·25	71·44	Yes	Region	13531·906
Guinea-Bissau			0·31	0·17	0·53	6·3	3·54	10·88	Yes	Region	2060·721
Liberia			0·31	0·17	0·53	15·87	8·92	27·42	Yes	Region	5193·4155
Mali			0·31	0·17	0·57	68·16	37·08	124·96			21904·983
Mauritania			0·31	0·17	0·53	14·1	7·93	24·36	Yes	Region	4614·974
Niger			0·31	0·17	0·53	77·18	43·39	133·32	Yes	Region	25252·722
Nigeria			0·29	0·15	0·53	624·47	328·99	1128·93			213401·3225
Senegal			0·31	0·17	0·53	51·58	28·99	89·1	Yes	Region	16876·72
Sierra Leone			0·31	0·17	0·53	25·74	14·47	44·45	Yes	Region	8420·641
São Tomé and Principe			0·31	0·17	0·53	0·68	0·38	1·18	Yes	Region	223·1075

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·31	0·17	0·53	26·42	14·85	45·64	Yes	Region	8644·829
	Western sub-Saharan Africa		0·31	0·17	0·53						
		Sub-Saharan Africa	0·33	0·20	0·53						
World			**0·36**	**0·24**	**0·54**	**28463·02**	**18936·12**	**42601·76**			**7909295·152**

Table S9. Lifetime physician- or dermatologist-diagnosed prevalence of vitiligo for adults and number of adults with vitiligo (in thousands) by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			0·80	0·46	1·66	16·96	9·66	35·19	Yes	Super-region	2121·798
Azerbaijan			0·80	0·46	1·66	59·29	33·77	123·02	Yes	Super-region	7417·088
Georgia			0·80	0·46	1·66	22·68	12·92	47·07	Yes	Super-region	2837·887
Kazakhstan			0·80	0·46	1·66	101·5	57·81	210·63	Yes	Super-region	12698·936
Kyrgyzstan			0·80	0·46	1·66	31·6	18	65·58	Yes	Super-region	3953·605
Mongolia			0·80	0·46	1·66	17·01	9·69	35·29	Yes	Super-region	2127·772
Tajikistan			0·80	0·46	1·66	45·21	25·75	93·82	Yes	Super-region	5656·627
Turkmenistan			0·80	0·46	1·66	32·45	18·48	67·33	Yes	Super-region	4059·3815
Uzbekistan			0·80	0·46	1·66	178·03	101·4	369·42	Yes	Super-region	22272·623
	Central Asia		0·80	0·46	1·66				Yes	Super-region	
Albania			0·98	0·51	2·08	22·3	11·68	47·44	Yes	Region	2280·3225
Bosnia and Herzegovina			0·98	0·51	2·08	26·23	13·74	55·82	Yes	Region	2682·8995
Bulgaria			0·98	0·51	2·08	56·03	29·35	119·21	Yes	Region	5729·8965
Croatia			0·98	0·51	2·08	32·94	17·26	70·09	Yes	Region	3368·753
Czech Republic			0·98	0·51	2·08	83·38	43·69	177·41	Yes	Region	8527·5865
Hungary			0·98	0·51	2·08	78·25	41	166·5	Yes	Region	8003·276
Macedonia, FYR			0·98	0·51	2·08	16·58	8·69	35·27	Yes	Region	1695·408
Montenegro			0·98	0·51	2·08	4·81	2·52	10·22	Yes	Region	491·441
Poland			1·00	0·50	2·19	313·35	157·34	686·8			31326·0285

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			1·02	0·51	2·17	158·9	80·28	339			15607·023
Serbia			0·98	0·51	2·08	59·09	30·96	125·74	Yes	Region	6043·7235
Slovakia			0·98	0·51	2·08	43·23	22·65	91·98	Yes	Region	4421·3775
Slovenia			0·98	0·51	2·08	17·01	8·91	36·19	Yes	Region	1739·3885
	Central Europe		0·98	0·51	2·08						
Belarus			0·80	0·46	1·66	61·36	34·95	127·33	Yes	Super-region	7676·7365
Estonia			0·80	0·46	1·66	8·54	4·87	17·73	Yes	Super-region	1068·9885
Latvia			0·80	0·46	1·66	12·19	6·95	25·3	Yes	Super-region	1525·5745
Lithuania			0·80	0·46	1·66	18·29	10·42	37·95	Yes	Super-region	2287·8675
Moldova			0·80	0·46	1·66	18·81	10·71	39·02	Yes	Super-region	2352·6915
Russian Federation			0·80	0·46	1·66	918·6	523·19	1906·19	Yes	Super-region	114924·9705
Ukraine			0·80	0·46	1·66	284·82	162·22	591·03	Yes	Super-region	35633·301
	Eastern Europe		0·80	0·46	1·66				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	0·80	0·46	1·66						
Australia			0·66	0·34	1·33	133·28	69·67	268·65			20254·151
New Zealand			0·66	0·36	1·26	26·03	14·15	49·9	Yes	Region	3970·489
	Australasia		0·66	0·36	1·26						
Brunei			0·56	0·35	0·86	1·83	1·15	2·82	Yes	Region	325·9675
Japan			0·54	0·33	0·85	570·96	349·41	905·71			106650·0435
Singapore			0·55	0·32	0·91	27·83	16·2	46·28			5080·6815

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·58	0·36	0·93	255·63	158·52	412·38			44313·0555
	High-income Asia Pacific		0·56	0·35	0·86						
Canada			0·53	0·34	0·82	164·95	104·98	253·89	Yes	Region	30940·394
Greenland			0·53	0·34	0·82	0·23	0·14	0·35	Yes	Region	42·3585
United States			0·50	0·34	0·75	1321·04	888·33	1960·54			262262·7025
	High-income North America		0·53	0·34	0·82						
Argentina			0·63	0·43	0·94	206·03	140·63	304·95	Yes	Super-region	32607·9345
Chile			0·63	0·43	0·94	95·91	65·46	141·96	Yes	Super-region	15179·711
Uruguay			0·63	0·43	0·94	16·53	11·28	24·46	Yes	Super-region	2615·569
	High-income Southern Latin America		0·63	0·43	0·94				Yes	Super-region	
Andorra			0·72	0·54	0·97	0·48	0·36	0·65	Yes	Region	66·2575
Austria			0·72	0·54	0·97	53·22	39·58	71·9	Yes	Region	7379·798
Belgium			0·72	0·54	0·97	66·94	49·78	90·44	Yes	Region	9282·645
Cyprus			0·72	0·54	0·97	7·27	5·41	9·82	Yes	Region	1007·896
Denmark			0·71	0·48	1·01	33·22	22·76	47·57			4702·388
Finland			0·77	0·53	1·19	34·64	23·79	53·47			4499·6195
France			0·72	0·49	1·03	365·27	250·72	525·13			50963·731
Germany			0·71	0·50	1·00	494·96	350·41	694·45			69572·764
Greece			0·72	0·54	0·97	62·39	46·4	84·29	Yes	Region	8651·1485

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			0·72	0·54	0·97	2·08	1·54	2·8	Yes	Region	287·771
Ireland			0·72	0·54	0·97	27·39	20·37	37	Yes	Region	3797·6205
Israel			0·72	0·54	0·97	43·05	32·02	58·17	Yes	Region	5969·9695
Italy			0·73	0·51	1·04	363·26	255·9	518·02			50037·0565
Luxembourg			0·72	0·54	0·97	3·73	2·78	5·04	Yes	Region	517·7405
Malta			0·72	0·54	0·97	3·21	2·39	4·33	Yes	Region	444·7195
Netherlands			0·75	0·51	1·15	106·85	72·82	163·64			14193·1635
Norway			0·72	0·54	0·97	30·97	23·03	41·85	Yes	Region	4295·17
Portugal			0·70	0·46	1·02	60·08	39·96	87·66			8599·991
Spain			0·73	0·50	1·06	285·54	195·22	417·33			39288·7635
Sweden			0·75	0·51	1·12	61·51	41·95	92·6			8252·4935
Switzerland			0·72	0·54	0·97	51·43	38·25	69·48	Yes	Region	7131·302
United Kingdom			0·72	0·50	1·05	384·18	263·47	555·08			53112·1275
	Western Europe		0·72	0·54	0·97						
		High-income	0·63	0·43	0·94						
Bolivia			0·58	0·30	1·03	44·11	22·46	78·26	Yes	Super-region	7609·281
Ecuador			0·58	0·30	1·03	70·8	36·05	125·63	Yes	Super-region	12214·1165
Peru			0·58	0·30	1·03	133·76	68·11	237·35	Yes	Super-region	23076·3785
	Andean Latin America		0·58	0·30	1·03				Yes	Super-region	
Antigua and Barbuda			0·58	0·30	1·03	0·42	0·21	0·74	Yes	Super-region	71·885
Bahamas, The			0·58	0·30	1·03	1·79	0·91	3·17	Yes	Super-region	308·109

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·58	0·30	1·03	1·29	0·66	2·29	Yes	Super-region	222·234
Belize			0·58	0·30	1·03	1·53	0·78	2·71	Yes	Super-region	263·7685
Bermuda			0·58	0·30	1·03	0·31	0·16	0·54	Yes	Super-region	52·631
Cuba			0·58	0·30	1·03	52·83	26·9	93·75	Yes	Super-region	9114·641
Dominica			0·58	0·30	1·03	0·32	0·16	0·56	Yes	Super-region	54·6945
Dominican Republic			0·58	0·30	1·03	43·43	22·11	77·06	Yes	Super-region	7491·8765
Grenada			0·58	0·30	1·03	0·52	0·26	0·92	Yes	Super-region	89·3115
Guyana			0·58	0·30	1·03	3·07	1·56	5·45	Yes	Super-region	529·606
Haiti			0·58	0·30	1·03	40·87	20·81	72·52	Yes	Super-region	7050·811
Jamaica			0·58	0·30	1·03	12·26	6·24	21·76	Yes	Super-region	2115·5395
Puerto Rico			0·58	0·30	1·03	15·67	7·98	27·8	Yes	Super-region	2702·7845
St. Lucia			0·58	0·30	1·03	0·81	0·41	1·43	Yes	Super-region	139·192
St. Vincent and the Grenadines			0·58	0·30	1·03	0·45	0·23	0·79	Yes	Super-region	76·847
Suriname			0·58	0·30	1·03	2·42	1·23	4·29	Yes	Super-region	417·5095
Trinidad and Tobago			0·58	0·30	1·03	6·8	3·46	12·06	Yes	Super-region	1172·4265
Virgin Islands (U.S.)			0·58	0·30	1·03	0·45	0·23	0·8	Yes	Super-region	77·4845
	Caribbean		0·58	0·30	1·03				Yes	Super-region	
Colombia			0·58	0·30	1·03	220·15	112·1	390·64	Yes	Super-region	37980·0935
Costa Rica			0·58	0·30	1·03	22·46	11·44	39·86	Yes	Super-region	3875·5675
El Salvador			0·58	0·30	1·03	25·2	12·83	44·71	Yes	Super-region	4346·715

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·58	0·30	1·03	61·9	31·52	109·84	Yes	Super-region	10678·836
Honduras			0·58	0·30	1·03	37·64	19·17	66·79	Yes	Super-region	6493·9485
Mexico			0·58	0·30	1·03	513·34	261·38	910·88	Yes	Super-region	88560·9005
Nicaragua			0·58	0·30	1·03	25·5	12·99	45·25	Yes	Super-region	4399·604
Panama			0·58	0·30	1·03	17·31	8·81	30·71	Yes	Super-region	2985·6415
Venezuela, RB			0·58	0·30	1·03	108·05	55·02	191·72	Yes	Super-region	18640·2835
	Central Latin America		0·58	0·30	1·03				Yes	Super-region	
Brazil			0·46	0·23	0·89	744·82	364·83	1428·72			160861·363
Paraguay			0·49	0·23	0·93	21·41	10·26	40·85	Yes	Region	4398·46
	Tropical Latin America		0·49	0·23	0·93						
		Latin America and Caribbean	0·58	0·30	1·03						
Afghanistan			0·87	0·52	1·49	172·96	103·79	294·23	Yes	Region	19801·576
Algeria			0·87	0·52	1·49	250·26	150·17	425·74	Yes	Region	28651·7635
Bahrain			0·87	0·52	1·49	9·74	5·85	16·58	Yes	Region	1115·543
Egypt			0·89	0·52	1·53	595·73	352·46	1031·04			67274·6775
Iran			0·91	0·52	1·62	579·53	330·69	1030·02			63497·966
Iraq			0·87	0·49	1·57	209·43	117·69	378·66			24181·98
Jordan			0·87	0·52	1·49	59·91	35·95	101·92	Yes	Region	6859·004
Kuwait			0·87	0·52	1·49	28·02	16·81	47·66	Yes	Region	3207·3735
Lebanon			0·87	0·52	1·49	32·72	19·63	55·66	Yes	Region	3746·015

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			0·87	0·52	1·49	38·46	23·08	65·43	Yes	Region	4403·6035
Morocco			0·87	0·52	1·49	220·97	132·59	375·9	Yes	Region	25297·7655
Oman			0·87	0·52	1·49	27·53	16·52	46·83	Yes	Region	3151·8155
Palestine			0·87	0·52	1·49	24·4	14·64	41·52	Yes	Region	2794·0265
Qatar			0·87	0·52	1·49	19·33	11·6	32·89	Yes	Region	2213·2485
Saudi Arabia			0·90	0·51	1·62	223·38	127·02	403·06			24924·363
Sudan			0·87	0·52	1·49	210·39	126·25	357·91	Yes	Region	24086·858
Syria			0·87	0·52	1·49	110·45	66·28	187·9	Yes	Region	12645·184
Tunisia			0·87	0·52	1·49	75·9	45·54	129·11	Yes	Region	8689·1405
Turkey			0·86	0·50	1·50	526·21	303·45	915·12			61102·1635
United Arab Emirates			0·87	0·52	1·49	67·83	40·7	115·4	Yes	Region	7765·9905
Yemen, Rep.			0·87	0·52	1·49	154·02	92·42	262·02	Yes	Region	17633·626
	North Africa and Middle East		0·87	0·52	1·49						
		North Africa and Middle East	0·76	0·45	1·40						
Bangladesh			0·97	0·58	1·63	1107·35	664·65	1872·57	Yes	Region	114555·2165
Bhutan			0·97	0·58	1·63	5·39	3·23	9·11	Yes	Region	557·492
India			1·00	0·63	1·62	9690·22	6087·81	15743·81			969400·0455
Nepal			1·00	0·57	1·79	192·94	109·06	344·52			19293·131
Pakistan			0·97	0·58	1·63	1265	759·27	2139·17	Yes	Region	130864·537
	South Asia		0·97	0·58	1·63						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	0·79	0·46	1·48						
China			0·42	0·26	0·66	4712·29	2980·25	7483·53			1125801·825
North Korea			0·43	0·26	0·72	86·76	51·92	143·61	Yes	Region	20031·794
Taiwan (Province of China)			0·41	0·24	0·68	81·98	47·91	137·19			20184·7595
	East Asia		0·43	0·26	0·72						
American Samoa			0·59	0·34	0·98	0·18	0·1	0·3	Yes	Super-region	30·364
Fiji			0·59	0·34	0·98	3·56	2·08	5·98	Yes	Super-region	608·597
Guam			0·59	0·34	0·98	0·69	0·4	1·15	Yes	Super-region	117·4305
Kiribati			0·59	0·34	0·98	0·44	0·26	0·74	Yes	Super-region	75·4165
Marshall Islands			0·59	0·34	0·98	0·15	0·09	0·25	Yes	Super-region	25·8365
Micronesia, Fed. Sts.			0·59	0·34	0·98	2·03	1·19	3·41	Yes	Super-region	347·2985
Northern Mariana Islands			0·59	0·34	0·98	0·22	0·13	0·36	Yes	Super-region	36·9235
Papua New Guinea			0·59	0·34	0·98	34·51	20·17	57·87	Yes	Super-region	5892·545
Samoa			0·59	0·34	0·98	0·72	0·42	1·21	Yes	Super-region	123·1865
Solomon Islands			0·59	0·34	0·98	2·26	1·32	3·78	Yes	Super-region	385·119
Tonga			0·59	0·34	0·98	0·37	0·21	0·61	Yes	Super-region	62·376
Vanuatu			0·59	0·34	0·98	1·02	0·59	1·71	Yes	Super-region	173·826
	Oceania		0·59	0·34	0·98				Yes	Super-region	
Cambodia			0·70	0·34	1·67	76	37·14	180·72	Yes	Region	10832·5515
Indonesia			0·70	0·34	1·67	1336·97	653·4	3179·24	Yes	Region	190565·6625

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			0·70	0·34	1·67	32·88	16·07	78·18	Yes	Region	4686·033
Malaysia			0·70	0·34	1·67	170·23	83·19	404·79	Yes	Region	24263·347
Maldives			0·70	0·34	1·67	2·73	1·34	6·5	Yes	Region	389·8085
Mauritius			0·70	0·34	1·67	7·2	3·52	17·13	Yes	Region	1026·905
Myanmar			0·70	0·34	1·67	264·31	129·17	628·5	Yes	Region	37672·9605
Philippines			0·70	0·34	1·67	508·22	248·38	1208·52	Yes	Region	72439·474
Seychelles			0·70	0·34	1·67	0·54	0·27	1·29	Yes	Region	77·539
Sri Lanka			0·74	0·35	1·80	115·08	54·31	281·85			15653·7185
Thailand			0·70	0·34	1·67	405·77	198·31	964·9	Yes	Region	57836·9715
Timor-Leste			0·70	0·34	1·67	5·32	2·6	12·66	Yes	Region	758·935
Vietnam			0·70	0·34	1·67	500·12	244·42	1189·26	Yes	Region	71284·906
	Southest Asia		0·70	0·34	1·67						
		Southeast Asia, East Asia, and Oceania	0·59	0·34	0·98						
Angola			0·61	0·35	1·04	102·37	58·48	173·98	Yes	Super-region	16670·7975
Central African Republic			0·61	0·35	1·04	14·81	8·46	25·17	Yes	Super-region	2411·966
Congo, Dem. Rep.			0·61	0·35	1·04	276·97	158·22	470·7	Yes	Super-region	45102·634
Congo, Rep.			0·61	0·35	1·04	18·73	10·7	31·82	Yes	Super-region	3049·498
Equatorial Guinea			0·61	0·35	1·04	5·6	3·2	9·52	Yes	Super-region	912·5695
Gabon			0·61	0·35	1·04	8·33	4·76	14·15	Yes	Super-region	1356·326

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·61	0·35	1·04				Yes	Super-region	
Burundi			0·58	0·31	1·09	34·29	18·09	64·29	Yes	Region	5896·029
Comoros			0·58	0·31	1·09	2·66	1·41	5	Yes	Region	458·1635
Djibouti			0·58	0·31	1·09	4·05	2·14	7·6	Yes	Region	696·7565
Eritrea			0·58	0·31	1·09	11·1	5·86	20·81	Yes	Region	1908·3375
Ethiopia			0·58	0·31	1·09	372·08	196·3	697·47	Yes	Region	63967·9975
Kenya			0·58	0·31	1·09	168·42	88·86	315·72	Yes	Region	28955·8805
Madagascar			0·58	0·31	1·09	90·88	47·95	170·35	Yes	Region	15623·913
Malawi			0·58	0·31	1·09	57·22	30·19	107·27	Yes	Region	9837·8915
Mozambique			0·55	0·27	1·07	87·07	42·45	170·47			15909·4165
Rwanda			0·58	0·31	1·09	42·46	22·4	79·6	Yes	Region	7300·3555
Somalia			0·58	0·31	1·09	45·68	24·1	85·63	Yes	Region	7853·412
South Sudan			0·58	0·31	1·09	29·83	15·74	55·91	Yes	Region	5127·76
Tanzania			0·61	0·32	1·19	192·05	99·81	376·33			31509·1305
Uganda			0·58	0·31	1·09	126·58	66·78	237·27	Yes	Region	21761·3175
Zambia			0·58	0·31	1·09	56·45	29·78	105·82	Yes	Region	9705·6205
	Eastern sub-Saharan Africa		0·58	0·31	1·09						
Botswana			0·61	0·35	1·04	9·75	5·57	16·58	Yes	Super-region	1588·2655
Lesotho			0·61	0·35	1·04	8·39	4·79	14·25	Yes	Super-region	1365·836
Namibia			0·61	0·35	1·04	9·03	5·16	15·34	Yes	Super-region	1469·692
South Africa			0·61	0·35	1·04	242·14	138·33	411·51	Yes	Super-region	39430·846

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·61	0·35	1·04	4·29	2·45	7·29	Yes	Super-region	698·9795
Zimbabwe			0·61	0·35	1·04	51·41	29·37	87·36	Yes	Super-region	8371·263
	Southern sub-Saharan Africa		0·61	0·35	1·04				Yes	Super-region	
Benin			0·57	0·31	1·04	37·85	20·31	69·07	Yes	Region	6620·7305
Burkina Faso			0·57	0·31	1·04	62·07	33·3	113·25	Yes	Region	10856·772
Cameroon			0·58	0·30	1·11	80·54	41·96	153·89			13859·6935
Cape Verde			0·57	0·31	1·04	2·29	1·23	4·17	Yes	Region	399·676
Chad			0·57	0·31	1·04	44·8	24·04	81·75	Yes	Region	7836·5965
Cote d'Ivoire			0·57	0·31	1·04	80·61	43·25	147·08	Yes	Region	14099·3615
Gambia, The			0·57	0·31	1·04	7·49	4·02	13·66	Yes	Region	1309·222
Ghana			0·56	0·29	1·09	104·07	53·4	203·03			18542·5115
Guinea			0·57	0·31	1·04	39·85	21·38	72·7	Yes	Region	6969·487
Guinea-Bissau			0·57	0·31	1·04	6·2	3·33	11·32	Yes	Region	1085·2905
Liberia			0·57	0·31	1·04	15·45	8·29	28·18	Yes	Region	2701·807
Mali			0·58	0·31	1·14	58·21	30·53	114·18			10000·52
Mauritania			0·57	0·31	1·04	13·51	7·25	24·64	Yes	Region	2362·506
Niger			0·57	0·31	1·04	64·02	34·35	116·8	Yes	Region	11197·111
Nigeria			0·55	0·28	1·06	584·58	295·86	1129·74			106790·1895
Senegal			0·57	0·31	1·04	49·79	26·72	90·85	Yes	Region	8709·111
Sierra Leone			0·57	0·31	1·04	25·96	13·93	47·36	Yes	Region	4540·172
São Tomé and Principe			0·57	0·31	1·04	0·67	0·36	1·23	Yes	Region	118·0285

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·57	0·31	1·04	26·36	14·14	48·09	Yes	Region	4609·918
	Western sub-Saharan Africa		0·57	0·31	1·04						
		Sub-Saharan Africa	0·61	0·35	1·04						
World			**0·67**	**0·43**	**1·07**	**37139·44**	**23880·07**	**58921·62**			**5516876·082**

Table S10. Lifetime physician- or dermatologist-diagnosed prevalence of vitiligo for children and number of children with vitiligo (in thousands) by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			0·29	0·17	0·59	1·93	1·12	3·95	Yes	Super-region	669·1755
Azerbaijan			0·29	0·17	0·59	8·37	4·83	17·11	Yes	Super-region	2895·904
Georgia			0·29	0·17	0·59	2·66	1·54	5·44	Yes	Super-region	920·093
Kazakhstan			0·29	0·17	0·59	18·79	10·84	38·39	Yes	Super-region	6497·5295
Kyrgyzstan			0·29	0·17	0·59	7·44	4·3	15·21	Yes	Super-region	2574·1385
Mongolia			0·29	0·17	0·59	3·53	2·04	7·21	Yes	Super-region	1220·0105
Tajikistan			0·29	0·17	0·59	11·84	6·83	24·19	Yes	Super-region	4093·437
Turkmenistan			0·29	0·17	0·59	6·6	3·81	13·49	Yes	Super-region	2282·4735
Uzbekistan			0·29	0·17	0·59	34·15	19·71	69·77	Yes	Super-region	11808·826
	Central Asia		0·29	0·17	0·59				Yes	Super-region	
Albania			0·35	0·18	0·75	2·03	1·04	4·33	Yes	Region	574·3875
Bosnia and Herzegovina			0·35	0·18	0·75	2·08	1·07	4·43	Yes	Region	588·0435
Bulgaria			0·35	0·18	0·75	4·09	2·1	8·71	Yes	Region	1155·971
Croatia			0·35	0·18	0·75	2·45	1·25	5·21	Yes	Region	691·3825
Czech Republic			0·35	0·18	0·75	7·01	3·6	14·94	Yes	Region	1983·164
Hungary			0·35	0·18	0·75	6·04	3·09	12·86	Yes	Region	1706·51
Macedonia, FYR			0·35	0·18	0·75	1·44	0·74	3·07	Yes	Region	407·922
Montenegro			0·35	0·18	0·75	0·48	0·25	1·03	Yes	Region	136·4175
Poland			0·36	0·18	0·78	25·26	12·6	54·33			6981·697

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			0·37	0·19	0·77	13·71	6·94	28·5			3721·537
Serbia			0·35	0·18	0·75	4·43	2·27	9·44	Yes	Region	1253·045
Slovakia			0·35	0·18	0·75	3·63	1·86	7·73	Yes	Region	1026·2445
Slovenia			0·35	0·18	0·75	1·34	0·69	2·86	Yes	Region	380·021
	Central Europe		0·35	0·18	0·75						
Belarus			0·29	0·17	0·59	5·5	3·17	11·23	Yes	Super-region	1901·431
Estonia			0·29	0·17	0·59	0·75	0·43	1·53	Yes	Super-region	259·7125
Latvia			0·29	0·17	0·59	1·01	0·58	2·06	Yes	Super-region	348·3445
Lithuania			0·29	0·17	0·59	1·44	0·83	2·95	Yes	Super-region	498·783
Moldova			0·29	0·17	0·59	2·05	1·18	4·19	Yes	Super-region	708·815
Russian Federation			0·29	0·17	0·59	87·26	50·36	178·31	Yes	Super-region	30177·785
Ukraine			0·29	0·17	0·59	22·84	13·18	46·67	Yes	Super-region	7898·121
	Eastern Europe		0·29	0·17	0·59				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	0·29	0·17	0·59						
Australia			0·24	0·12	0·48	13·49	6·86	27·34			5666·938
New Zealand			0·24	0·13	0·48	2·75	1·47	5·52	Yes	Region	1159·2385
	Australasia		0·24	0·13	0·48						
Brunei			0·20	0·13	0·32	0·24	0·15	0·38	Yes	Region	119·4055
Japan			0·19	0·12	0·32	34·79	20·75	56·97			17962·487
Singapore			0·20	0·11	0·34	1·7	0·97	2·91			860·379

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·21	0·13	0·33	15·69	9·56	25·16			7517·0835
	High-income Asia Pacific		0·20	0·13	0·32						
Canada			0·19	0·12	0·30	13·91	8·76	21·72	Yes	Region	7214·618
Greenland			0·19	0·12	0·30	0·03	0·02	0·04	Yes	Region	13·8845
United States			0·18	0·12	0·28	136·18	90·41	206·87			74734·922
	High-income North America		0·19	0·12	0·30						
Argentina			0·23	0·15	0·34	28·96	19·12	43·38	Yes	Super-region	12668·846
Chile			0·23	0·15	0·34	9·86	6·51	14·77	Yes	Super-region	4313·4735
Uruguay			0·23	0·15	0·34	1·85	1·22	2·78	Yes	Super-region	810·6905
	High-income Southern Latin America		0·23	0·15	0·34				Yes	Super-region	
Andorra			0·26	0·18	0·38	0·03	0·02	0·05	Yes	Region	12·7765
Austria			0·26	0·18	0·38	4·02	2·74	5·92	Yes	Region	1542·284
Belgium			0·26	0·18	0·38	6·08	4·14	8·93	Yes	Region	2328·7745
Cyprus			0·26	0·18	0·38	0·62	0·42	0·91	Yes	Region	236·292
Denmark			0·26	0·16	0·40	2·94	1·88	4·55			1151·8525
Finland			0·28	0·18	0·45	2·89	1·83	4·71			1036·3725
France			0·26	0·16	0·40	35·18	22·29	54·4			13567·713
Germany			0·26	0·17	0·39	35·61	23·64	53·5			13835·791
Greece			0·26	0·18	0·38	4·68	3·19	6·88	Yes	Region	1794·2165

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			0·26	0·18	0·38	0·22	0·15	0·32	Yes	Region	82·564
Ireland			0·26	0·18	0·38	3·1	2·11	4·56	Yes	Region	1188·9055
Israel			0·26	0·18	0·38	7·64	5·21	11·24	Yes	Region	2930·0895
Italy			0·26	0·17	0·40	24·17	15·67	36·76			9203·273
Luxembourg			0·26	0·18	0·38	0·32	0·22	0·47	Yes	Region	121·5805
Malta			0·26	0·18	0·38	0·21	0·15	0·31	Yes	Region	82·0285
Netherlands			0·27	0·17	0·44	9·01	5·79	14·52			3308·532
Norway			0·26	0·18	0·38	2·89	1·97	4·25	Yes	Region	1107·851
Portugal			0·25	0·16	0·40	4·27	2·63	6·75			1690·112
Spain			0·26	0·17	0·42	21·55	13·69	34·1			8198·1715
Sweden			0·27	0·17	0·42	5·97	3·84	9·4			2214·6035
Switzerland			0·26	0·18	0·38	4·07	2·77	5·99	Yes	Region	1560·1045
United Kingdom			0·26	0·16	0·41	37·08	23·31	57·48			14168·912
	Western Europe		0·26	0·18	0·38						
		High-income	0·23	0·15	0·34						
Bolivia			0·21	0·11	0·36	9·37	4·76	16·26	Yes	Super-region	4470·191
Ecuador			0·21	0·11	0·36	11·71	5·95	20·3	Yes	Super-region	5583·6205
Peru			0·21	0·11	0·36	22·31	11·34	38·69	Yes	Super-region	10639·093
	Andean Latin America		0·21	0·11	0·36				Yes	Super-region	
Antigua and Barbuda			0·21	0·11	0·36	0·04	0·02	0·08	Yes	Super-region	21·3345
Bahamas, The			0·21	0·11	0·36	0·21	0·11	0·36	Yes	Super-region	99·7965

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·21	0·11	0·36	0·12	0·06	0·21	Yes	Super-region	58·9655
Belize			0·21	0·11	0·36	0·29	0·15	0·5	Yes	Super-region	136·2625
Bermuda			0·21	0·11	0·36	0·02	0·01	0·04	Yes	Super-region	11·554
Cuba			0·21	0·11	0·36	4·49	2·28	7·79	Yes	Super-region	2141·7315
Dominica			0·21	0·11	0·36	0·04	0·02	0·06	Yes	Super-region	17·718
Dominican Republic			0·21	0·11	0·36	7·6	3·86	13·19	Yes	Super-region	3625·997
Grenada			0·21	0·11	0·36	0·07	0·04	0·13	Yes	Super-region	35·2985
Guyana			0·21	0·11	0·36	0·58	0·29	1	Yes	Super-region	274·961
Haiti			0·21	0·11	0·36	9·22	4·68	15·99	Yes	Super-region	4396·758
Jamaica			0·21	0·11	0·36	1·49	0·76	2·59	Yes	Super-region	712·155
Puerto Rico			0·21	0·11	0·36	1·16	0·59	2·01	Yes	Super-region	553·243
St. Lucia			0·21	0·11	0·36	0·08	0·04	0·15	Yes	Super-region	40·4595
St. Vincent and the Grenadines			0·21	0·11	0·36	0·06	0·03	0·1	Yes	Super-region	27·485
Suriname			0·21	0·11	0·36	0·41	0·21	0·71	Yes	Super-region	195·475
Trinidad and Tobago			0·21	0·11	0·36	0·74	0·38	1·28	Yes	Super-region	353·2365
Virgin Islands (U.S.)			0·21	0·11	0·36	0·05	0·02	0·08	Yes	Super-region	22·6065
	Caribbean		0·21	0·11	0·36				Yes	Super-region	
Colombia			0·21	0·11	0·36	28·38	14·42	49·22	Yes	Super-region	13536·469
Costa Rica			0·21	0·11	0·36	2·68	1·36	4·65	Yes	Super-region	1278·3895
El Salvador			0·21	0·11	0·36	4·13	2·1	7·15	Yes	Super-region	1967·4525

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·21	0·11	0·36	14·53	7·38	25·2	Yes	Super-region	6929·6475
Honduras			0·21	0·11	0·36	7·94	4·03	13·76	Yes	Super-region	3784·397
Mexico			0·21	0·11	0·36	79·99	40·64	138·71	Yes	Super-region	38144·238
Nicaragua			0·21	0·11	0·36	5·14	2·61	8·91	Yes	Super-region	2450·936
Panama			0·21	0·11	0·36	2·86	1·45	4·97	Yes	Super-region	1365·6255
Venezuela, RB			0·21	0·11	0·36	20·05	10·18	34·76	Yes	Super-region	9559·583
	Central Latin America		0·21	0·11	0·36				Yes	Super-region	
Brazil			0·17	0·08	0·32	89·55	45·22	168·89			53464·86
Paraguay			0·18	0·09	0·33	4·06	2·03	7·64	Yes	Region	2305·339
	Tropical Latin America		0·18	0·09	0·33						
		Latin America and Caribbean	0·21	0·11	0·36						
Afghanistan			0·32	0·20	0·50	64·14	41·48	101·46	Yes	Region	20297·886
Algeria			0·32	0·20	0·50	49·06	31·73	77·61	Yes	Region	15526·205
Bahrain			0·32	0·20	0·50	1·1	0·71	1·74	Yes	Region	347·7225
Egypt			0·32	0·20	0·51	134·5	85·83	216·14			41987·5
Iran			0·33	0·20	0·55	80·65	49·68	133·56			24425·467
Iraq			0·31	0·19	0·52	60·63	36·29	99·83			19351·613
Jordan			0·32	0·20	0·50	13·55	8·77	21·44	Yes	Region	4289·2735
Kuwait			0·32	0·20	0·50	3·29	2·13	5·21	Yes	Region	1042·7405
Lebanon			0·32	0·20	0·50	5·83	3·77	9·23	Yes	Region	1846·616

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			0·32	0·20	0·50	7·37	4·77	11·66	Yes	Region	2331·6735
Morocco			0·32	0·20	0·50	37·22	24·07	58·88	Yes	Region	11778·819
Oman			0·32	0·20	0·50	4·32	2·8	6·84	Yes	Region	1368·6555
Palestine			0·32	0·20	0·50	7·39	4·78	11·69	Yes	Region	2339·3655
Qatar			0·32	0·20	0·50	1·5	0·97	2·37	Yes	Region	474·9865
Saudi Arabia			0·32	0·20	0·54	35·75	21·93	59·33			11026·033
Sudan			0·32	0·20	0·50	68·16	44·08	107·82	Yes	Region	21570·344
Syria			0·32	0·20	0·50	27·42	17·74	43·38	Yes	Region	8679·183
Tunisia			0·32	0·20	0·50	11·29	7·3	17·86	Yes	Region	3573·8055
Turkey			0·31	0·19	0·51	73·75	45·57	120·76			23673·24
United Arab Emirates			0·32	0·20	0·50	5·05	3·27	7·99	Yes	Region	1599·154
Yemen, Rep.			0·32	0·20	0·50	48·5	31·37	76·72	Yes	Region	15348·016
	North Africa and Middle East		0·32	0·20	0·50						
		North Africa and Middle East	0·27	0·17	0·47						
Bangladesh			0·35	0·22	0·55	191·64	122·31	299·96	Yes	Region	54801·035
Bhutan			0·35	0·22	0·55	0·77	0·49	1·2	Yes	Region	219·9945
India			0·36	0·24	0·54	1584·48	1066·09	2363·6			438163·8
Nepal			0·36	0·21	0·61	38·86	23·06	65·55			10741·859
Pakistan			0·35	0·22	0·55	351·58	224·39	550·3	Yes	Region	100537·58
	South Asia		0·35	0·22	0·55						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	0·29	0·17	0·50						
China			0·15	0·09	0·24	454·41	280·99	734·22			300091·64
North Korea			0·16	0·09	0·26	9·31	5·53	15·68	Yes	Region	5940·115
Taiwan (Province of China)			0·15	0·09	0·25	5·4	3·13	9·11			3675·1525
	East Asia		0·16	0·09	0·26						
American Samoa			0·21	0·12	0·35	0·03	0·02	0·05	Yes	Super-region	14·671
Fiji			0·21	0·12	0·35	0·67	0·38	1·1	Yes	Super-region	316·0125
Guam			0·21	0·12	0·35	0·11	0·06	0·18	Yes	Super-region	53·1035
Kiribati			0·21	0·12	0·35	0·11	0·06	0·19	Yes	Super-region	53·4575
Marshall Islands			0·21	0·12	0·35	0·03	0·02	0·06	Yes	Super-region	16·2135
Micronesia, Fed. Sts.			0·21	0·12	0·35	0·4	0·23	0·65	Yes	Super-region	187·3075
Northern Mariana Islands			0·21	0·12	0·35	0·03	0·02	0·04	Yes	Super-region	12·558
Papua New Guinea			0·21	0·12	0·35	8·59	4·92	14·1	Yes	Super-region	4056·892
Samoa			0·21	0·12	0·35	0·2	0·12	0·33	Yes	Super-region	95·5775
Solomon Islands			0·21	0·12	0·35	0·68	0·39	1·12	Yes	Super-region	322·732
Tonga			0·21	0·12	0·35	0·09	0·05	0·15	Yes	Super-region	43·641
Vanuatu			0·21	0·12	0·35	0·31	0·18	0·51	Yes	Super-region	145·3105
	Oceania		0·21	0·12	0·35				Yes	Super-region	
Cambodia			0·25	0·12	0·59	14·61	6·97	33·93	Yes	Region	5756·472
Indonesia			0·25	0·12	0·59	211·13	100·74	490·36	Yes	Region	83187·529

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			0·25	0·12	0·59	6·95	3·32	16·15	Yes	Region	2739·0245
Malaysia			0·25	0·12	0·59	23·63	11·27	54·88	Yes	Region	9310·5265
Maldives			0·25	0·12	0·59	0·33	0·16	0·78	Yes	Region	131·649
Mauritius			0·25	0·12	0·59	0·69	0·33	1·6	Yes	Region	272·0095
Myanmar			0·25	0·12	0·59	40·93	19·53	95·05	Yes	Region	16125·124
Philippines			0·25	0·12	0·59	105·18	50·18	244·28	Yes	Region	41440·854
Seychelles			0·25	0·12	0·59	0·07	0·04	0·17	Yes	Region	28·9315
Sri Lanka			0·27	0·13	0·62	16·28	7·68	38·23			6119·722
Thailand			0·25	0·12	0·59	34·93	16·67	81·13	Yes	Region	13764·132
Timor-Leste			0·25	0·12	0·59	1·43	0·68	3·31	Yes	Region	562·007
Vietnam			0·25	0·12	0·59	66·45	31·71	154·34	Yes	Region	26183·123
	Southest Asia		0·25	0·12	0·59						
		Southeast Asia, East Asia, and Oceania	0·21	0·12	0·35						
Angola			0·22	0·13	0·37	39·62	23·14	65·25	Yes	Super-region	17832·976
Central African Republic			0·22	0·13	0·37	6·76	3·95	11·14	Yes	Super-region	3045·1885
Congo, Dem. Rep.			0·22	0·13	0·37	112·83	65·92	185·86	Yes	Super-region	50791·485
Congo, Rep.			0·22	0·13	0·37	6·19	3·62	10·2	Yes	Super-region	2786·308
Equatorial Guinea			0·22	0·13	0·37	1·6	0·94	2·64	Yes	Super-region	721·896
Gabon			0·22	0·13	0·37	2·19	1·28	3·6	Yes	Super-region	984·853

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·22	0·13	0·37				Yes	Super-region	
Burundi			0·21	0·11	0·38	14	7·6	25·53	Yes	Region	6655·184
Comoros			0·21	0·11	0·38	0·76	0·41	1·39	Yes	Region	363·462
Djibouti			0·21	0·11	0·38	0·86	0·47	1·57	Yes	Region	408·801
Eritrea			0·21	0·11	0·38	3·6	1·95	6·57	Yes	Region	1711·9745
Ethiopia			0·21	0·11	0·38	118·5	64·29	216·02	Yes	Region	56315·029
Kenya			0·21	0·11	0·38	50·61	27·45	92·25	Yes	Region	24049·734
Madagascar			0·21	0·11	0·38	27·97	15·17	50·99	Yes	Region	13291·74
Malawi			0·21	0·11	0·38	21·15	11·47	38·56	Yes	Region	10051·851
Mozambique			0·20	0·10	0·38	32·01	15·97	62·08			16167·656
Rwanda			0·21	0·11	0·38	12·97	7·03	23·63	Yes	Region	6161·532
Somalia			0·21	0·11	0·38	19·38	10·52	35·34	Yes	Region	9212·169
South Sudan			0·21	0·11	0·38	11·83	6·42	21·56	Yes	Region	5620·5125
Tanzania			0·22	0·12	0·42	70·73	37·45	133·63			32079·204
Uganda			0·21	0·11	0·38	50·7	27·5	92·42	Yes	Region	24092·461
Zambia			0·21	0·11	0·38	20·55	11·15	37·47	Yes	Region	9767·5045
	Eastern sub-Saharan Africa		0·21	0·11	0·38						
Botswana			0·22	0·13	0·37	2·22	1·3	3·66	Yes	Super-region	1000·1575
Lesotho			0·22	0·13	0·37	2·03	1·19	3·35	Yes	Super-region	915·6185
Namibia			0·22	0·13	0·37	2·36	1·38	3·88	Yes	Super-region	1060·4585
South Africa			0·22	0·13	0·37	44·34	25·91	73·04	Yes	Super-region	19961·409

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·22	0·13	0·37	1·1	0·64	1·81	Yes	Super-region	493·2915
Zimbabwe			0·22	0·13	0·37	16·93	9·89	27·89	Yes	Super-region	7622·261
	Southern sub-Saharan Africa		0·22	0·13	0·37				Yes	Super-region	
Benin			0·21	0·12	0·36	13·19	7·4	23	Yes	Region	6376·1645
Burkina Faso			0·21	0·12	0·36	23·26	13·05	40·56	Yes	Region	11243·912
Cameroon			0·21	0·11	0·39	28·04	15·16	52·17			13338·935
Cape Verde			0·21	0·12	0·36	0·39	0·22	0·68	Yes	Region	188·249
Chad			0·21	0·12	0·36	19·32	10·84	33·7	Yes	Region	9343·1435
Cote d'Ivoire			0·21	0·12	0·36	27·67	15·53	48·26	Yes	Region	13378·888
Gambia, The			0·21	0·12	0·36	2·75	1·54	4·8	Yes	Region	1330·6935
Ghana			0·20	0·11	0·38	29·02	15·42	53·94			14290·52
Guinea			0·21	0·12	0·36	13·57	7·62	23·67	Yes	Region	6562·419
Guinea-Bissau			0·21	0·12	0·36	2·02	1·13	3·52	Yes	Region	975·4305
Liberia			0·21	0·12	0·36	5·15	2·89	8·99	Yes	Region	2491·6085
Mali			0·21	0·12	0·39	25·07	13·71	46·1			11904·463
Mauritania			0·21	0·12	0·36	4·66	2·61	8·13	Yes	Region	2252·468
Niger			0·21	0·12	0·36	29·07	16·31	50·7	Yes	Region	14055·611
Nigeria			0·20	0·11	0·36	211·12	112·36	382·27			106611·13
Senegal			0·21	0·12	0·36	16·89	9·48	29·46	Yes	Region	8167·609
Sierra Leone			0·21	0·12	0·36	8·03	4·5	14	Yes	Region	3880·469
São Tomé and Principe			0·21	0·12	0·36	0·22	0·12	0·38	Yes	Region	105·079

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·21	0·12	0·36	8·35	4·68	14·56	Yes	Region	4034·911
	Western sub-Saharan Africa		0·21	0·12	0·36						
		Sub-Saharan Africa	0·22	0·13	0·37						
World			**0·24**	**0·16**	**0·37**	**5826·4**	**3779·74**	**8851·35**			**2392419·1**

Table S11. Lifetime self-reported prevalence of vitiligo for overall population and number of people with vitiligo (in thousands) with 95% credible confidence interval by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			0·65	0·35	1·42	18·25	9·67	39·64	Yes	Super-region	2790·9735
Azerbaijan			0·65	0·35	1·42	67·42	35·75	146·46	Yes	Super-region	10312·992
Georgia			0·65	0·35	1·42	24·57	13·03	53·37	Yes	Super-region	3757·98
Kazakhstan			0·65	0·35	1·42	125·5	66·54	272·61	Yes	Super-region	19196·4655
Kyrgyzstan			0·65	0·35	1·42	42·68	22·63	92·7	Yes	Super-region	6527·7435
Mongolia			0·65	0·35	1·42	21·89	11·6	47·54	Yes	Super-region	3347·7825
Tajikistan			0·65	0·35	1·42	63·74	33·8	138·46	Yes	Super-region	9750·064
Turkmenistan			0·65	0·35	1·42	41·46	21·98	90·06	Yes	Super-region	6341·855
Uzbekistan			0·65	0·35	1·42	222·81	118·14	484	Yes	Super-region	34081·449
	Central Asia		0·65	0·35	1·42				Yes	Super-region	
Albania			0·80	0·40	1·78	22·83	11·45	50·71	Yes	Region	2854·71
Bosnia and Herzegovina			0·80	0·40	1·78	26·16	13·12	58·11	Yes	Region	3270·943
Bulgaria			0·80	0·40	1·78	55·07	27·62	122·33	Yes	Region	6885·8675
Croatia			0·80	0·40	1·78	32·47	16·29	72·13	Yes	Region	4060·1355
Czech Republic			0·80	0·40	1·78	84·06	42·17	186·72	Yes	Region	10510·7505
Hungary			0·80	0·40	1·78	77·65	38·95	172·49	Yes	Region	9709·786
Macedonia, FYR			0·80	0·40	1·78	16·82	8·44	37·37	Yes	Region	2103·33
Montenegro			0·80	0·40	1·78	5·02	2·52	11·15	Yes	Region	627·8585
Poland			0·82	0·40	1·84	313·41	152·12	703·25			38307·7255

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			0·83	0·40	1·84	160·95	77·7	355·89			19328·56
Serbia			0·80	0·40	1·78	58·36	29·27	129·62	Yes	Region	7296·7685
Slovakia			0·80	0·40	1·78	43·57	21·85	96·78	Yes	Region	5447·622
Slovenia			0·80	0·40	1·78	16·95	8·5	37·65	Yes	Region	2119·4095
	Central Europe		0·80	0·40	1·78						
Belarus			0·65	0·35	1·42	62·62	33·2	136·02	Yes	Super-region	9578·1675
Estonia			0·65	0·35	1·42	8·69	4·61	18·87	Yes	Super-region	1328·701
Latvia			0·65	0·35	1·42	12·25	6·5	26·61	Yes	Super-region	1873·919
Lithuania			0·65	0·35	1·42	18·22	9·66	39·57	Yes	Super-region	2786·6505
Moldova			0·65	0·35	1·42	20·02	10·61	43·48	Yes	Super-region	3061·5065
Russian Federation			0·65	0·35	1·42	948·63	502·99	2060·64	Yes	Super-region	145102·755
Ukraine			0·65	0·35	1·42	284·59	150·9	618·2	Yes	Super-region	43531·422
	Eastern Europe		0·65	0·35	1·42				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	0·65	0·35	1·42						
Australia			0·54	0·26	1·13	139·52	67·95	291·72			25921·089
New Zealand			0·54	0·27	1·08	27·51	14	55·26	Yes	Region	5129·7275
	Australasia		0·54	0·27	1·08						
Brunei			0·46	0·27	0·78	2·05	1·21	3·47	Yes	Region	445·373
Japan			0·44	0·25	0·76	545·66	311·89	944·98			124612·5305
Singapore			0·45	0·25	0·81	26·62	14·86	48·11			5941·0605

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·47	0·27	0·82	244·56	140·05	425·87			51830·139
	High-income Asia Pacific		0·46	0·27	0·78						
Canada			0·44	0·26	0·73	166·38	97·7	277·4	Yes	Region	38155·012
Greenland			0·44	0·26	0·73	0·25	0·14	0·41	Yes	Region	56·243
United States			0·41	0·26	0·66	1388·4	868·34	2239·42			336997·624
	High-income North America		0·44	0·26	0·73						
Argentina			0·52	0·32	0·82	233·99	143·86	370·95	Yes	Super-region	45276·78
Chile			0·52	0·32	0·82	100·74	61·94	159·71	Yes	Super-region	19493·1845
Uruguay			0·52	0·32	0·82	17·71	10·89	28·07	Yes	Super-region	3426·2595
	High-income Southern Latin America		0·52	0·32	0·82				Yes	Super-region	
Andorra			0·59	0·37	0·94	0·47	0·3	0·75	Yes	Region	79·034
Austria			0·59	0·37	0·94	52·63	33·33	84·25	Yes	Region	8922·082
Belgium			0·59	0·37	0·94	68·49	43·38	109·65	Yes	Region	11611·4195
Cyprus			0·59	0·37	0·94	7·34	4·65	11·75	Yes	Region	1244·188
Denmark			0·58	0·35	0·97	33·83	20·27	56·92			5854·2405
Finland			0·63	0·37	1·11	34·86	20·61	61·18			5535·992
France			0·59	0·36	0·98	378·3	229·98	633·46			64531·444
Germany			0·58	0·36	0·95	485·34	296·42	795·02			83408·5545
Greece			0·59	0·37	0·94	61·61	39·02	98·64	Yes	Region	10445·365

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			0·59	0·37	0·94	2·18	1·38	3·5	Yes	Region	370·335
Ireland			0·59	0·37	0·94	29·41	18·63	47·09	Yes	Region	4986·526
Israel			0·59	0·37	0·94	52·5	33·25	84·05	Yes	Region	8900·059
Italy			0·59	0·36	0·98	351·77	212·96	578·8			59240·3295
Luxembourg			0·59	0·37	0·94	3·77	2·39	6·04	Yes	Region	639·321
Malta			0·59	0·37	0·94	3·11	1·97	4·97	Yes	Region	526·748
Netherlands			0·62	0·36	1·09	107·76	63·17	191·48			17501·6955
Norway			0·59	0·37	0·94	31·87	20·19	51·02	Yes	Region	5403·021
Portugal			0·57	0·33	0·98	58·8	34·35	100·66			10290·103
Spain			0·59	0·35	1·01	282·28	168·22	478·05			47486·935
Sweden			0·61	0·36	1·04	63·81	38·14	109·23			10467·097
Switzerland			0·59	0·37	0·94	51·26	32·47	82·08	Yes	Region	8691·4065
United Kingdom			0·59	0·36	0·99	398·05	242·5	667·74			67281·0395
	Western Europe		0·59	0·37	0·94						
		High-income	0·52	0·32	0·82						
Bolivia			0·47	0·23	0·89	57·27	27·63	106·99	Yes	Super-region	12079·472
Ecuador			0·47	0·23	0·89	84·38	40·71	157·64	Yes	Super-region	17797·737
Peru			0·47	0·23	0·89	159·85	77·13	298·62	Yes	Super-region	33715·4715
	Andean Latin America		0·47	0·23	0·89				Yes	Super-region	
Antigua and Barbuda			0·47	0·23	0·89	0·44	0·21	0·83	Yes	Super-region	93·2195
Bahamas, The			0·47	0·23	0·89	1·93	0·93	3·61	Yes	Super-region	407·9055

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·47	0·23	0·89	1·33	0·64	2·49	Yes	Super-region	281·1995
Belize			0·47	0·23	0·89	1·9	0·92	3·54	Yes	Super-region	400·031
Bermuda			0·47	0·23	0·89	0·3	0·15	0·57	Yes	Super-region	64·185
Cuba			0·47	0·23	0·89	53·37	25·75	99·7	Yes	Super-region	11256·3725
Dominica			0·47	0·23	0·89	0·34	0·17	0·64	Yes	Super-region	72·4125
Dominican Republic			0·47	0·23	0·89	52·71	25·43	98·47	Yes	Super-region	11117·8735
Grenada			0·47	0·23	0·89	0·59	0·29	1·1	Yes	Super-region	124·61
Guyana			0·47	0·23	0·89	3·81	1·84	7·13	Yes	Super-region	804·567
Haiti			0·47	0·23	0·89	54·27	26·19	101·39	Yes	Super-region	11447·569
Jamaica			0·47	0·23	0·89	13·41	6·47	25·05	Yes	Super-region	2827·6945
Puerto Rico			0·47	0·23	0·89	15·44	7·45	28·84	Yes	Super-region	3256·0275
St. Lucia			0·47	0·23	0·89	0·85	0·41	1·59	Yes	Super-region	179·6515
St. Vincent and the Grenadines			0·47	0·23	0·89	0·49	0·24	0·92	Yes	Super-region	104·332
Suriname			0·47	0·23	0·89	2·91	1·4	5·43	Yes	Super-region	612·9845
Trinidad and Tobago			0·47	0·23	0·89	7·23	3·49	13·51	Yes	Super-region	1525·663
Virgin Islands (U.S.)			0·47	0·23	0·89	0·47	0·23	0·89	Yes	Super-region	100·091
	Caribbean		0·47	0·23	0·89				Yes	Super-region	
Colombia			0·47	0·23	0·89	244·24	117·85	456·28	Yes	Super-region	51516·562
Costa Rica			0·47	0·23	0·89	24·43	11·79	45·65	Yes	Super-region	5153·957
El Salvador			0·47	0·23	0·89	29·94	14·44	55·92	Yes	Super-region	6314·1675

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·47	0·23	0·89	83·48	40·28	155·96	Yes	Super-region	17608·4835
Honduras			0·47	0·23	0·89	48·73	23·51	91·04	Yes	Super-region	10278·3455
Mexico			0·47	0·23	0·89	600·71	289·85	1122·23	Yes	Super-region	126705·138
Nicaragua			0·47	0·23	0·89	32·48	15·67	60·68	Yes	Super-region	6850·54
Panama			0·47	0·23	0·89	20·63	9·95	38·54	Yes	Super-region	4351·267
Venezuela, RB			0·47	0·23	0·89	133·7	64·51	249·77	Yes	Super-region	28199·8665
	Central Latin America		0·47	0·23	0·89				Yes	Super-region	
Brazil			0·38	0·18	0·78	811·68	382·01	1662·63			214326·223
Paraguay			0·40	0·19	0·82	26·69	12·41	54·96	Yes	Region	6703·799
	Tropical Latin America		0·40	0·19	0·82						
		Latin America and Caribbean	0·47	0·23	0·89						
Afghanistan			0·71	0·44	1·18	286·48	175·68	471·22	Yes	Region	40099·462
Algeria			0·71	0·44	1·18	315·61	193·55	519·15	Yes	Region	44177·9685
Bahrain			0·71	0·44	1·18	10·45	6·41	17·2	Yes	Region	1463·2655
Egypt			0·72	0·43	1·24	791·37	468·69	1358·26			109262·1775
Iran			0·75	0·44	1·31	656·34	385·42	1155·25			87923·4325
Iraq			0·71	0·41	1·23	308·38	179·42	534·16			43533·5925
Jordan			0·71	0·44	1·18	79·65	48·84	131·01	Yes	Region	11148·2775
Kuwait			0·71	0·44	1·18	30·36	18·62	49·94	Yes	Region	4250·114
Lebanon			0·71	0·44	1·18	39·95	24·5	65·72	Yes	Region	5592·631

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			0·71	0·44	1·18	48·12	29·51	79·15	Yes	Region	6735·277
Morocco			0·71	0·44	1·18	264·88	162·43	435·7	Yes	Region	37076·5845
Oman			0·71	0·44	1·18	32·29	19·8	53·12	Yes	Region	4520·471
Palestine			0·71	0·44	1·18	36·67	22·49	60·32	Yes	Region	5133·392
Qatar			0·71	0·44	1·18	19·21	11·78	31·59	Yes	Region	2688·235
Saudi Arabia			0·73	0·43	1·27	263·53	155·25	455·91			35950·396
Sudan			0·71	0·44	1·18	326·18	200·03	536·53	Yes	Region	45657·2015
Syria			0·71	0·44	1·18	152·34	93·42	250·59	Yes	Region	21324·367
Tunisia			0·71	0·44	1·18	87·61	53·72	144·11	Yes	Region	12262·946
Turkey			0·70	0·42	1·19	597·15	353·94	1011·96			84775·4035
United Arab Emirates			0·71	0·44	1·18	66·91	41·03	110·05	Yes	Region	9365·1445
Yemen, Rep.			0·71	0·44	1·18	235·63	144·49	387·58	Yes	Region	32981·6415
	North Africa and Middle East		0·71	0·44	1·18						
		North Africa and Middle East	0·62	0·35	1·09						
Bangladesh			0·79	0·47	1·35	1339	789·14	2284·84	Yes	Region	169356·251
Bhutan			0·79	0·47	1·35	6·15	3·62	10·49	Yes	Region	777·4865
India			0·82	0·50	1·34	11508·21	7102·02	18807·46			1407563·842
Nepal			0·82	0·46	1·48	245·68	137·76	445·97			30034·9895
Pakistan			0·79	0·47	1·35	1829·56	1078·25	3121·92	Yes	Region	231402·1165
	South Asia		0·79	0·47	1·35						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	0·65	0·36	1·24						
China			0·34	0·19	0·61	4881·65	2704·05	8760·78			1425893·465
North Korea			0·35	0·19	0·65	92·01	49·43	167·88	Yes	Region	25971·909
Taiwan (Province of China)			0·33	0·18	0·61	79·27	41·84	145·93			23859·912
	East Asia		0·35	0·19	0·65						
American Samoa			0·48	0·26	0·84	0·22	0·12	0·38	Yes	Super-region	45·035
Fiji			0·48	0·26	0·84	4·43	2·44	7·77	Yes	Super-region	924·6095
Guam			0·48	0·26	0·84	0·82	0·45	1·43	Yes	Super-region	170·534
Kiribati			0·48	0·26	0·84	0·62	0·34	1·08	Yes	Super-region	128·874
Marshall Islands			0·48	0·26	0·84	0·2	0·11	0·35	Yes	Super-region	42·05
Micronesia, Fed. Sts.			0·48	0·26	0·84	2·56	1·41	4·49	Yes	Super-region	534·606
Northern Mariana Islands			0·48	0·26	0·84	0·24	0·13	0·42	Yes	Super-region	49·4815
Papua New Guinea			0·48	0·26	0·84	47·66	26·23	83·56	Yes	Super-region	9949·437
Samoa			0·48	0·26	0·84	1·05	0·58	1·84	Yes	Super-region	218·764
Solomon Islands			0·48	0·26	0·84	3·39	1·87	5·94	Yes	Super-region	707·851
Tonga			0·48	0·26	0·84	0·51	0·28	0·89	Yes	Super-region	106·017
Vanuatu			0·48	0·26	0·84	1·53	0·84	2·68	Yes	Super-region	319·1365
	Oceania		0·48	0·26	0·84				Yes	Super-region	
Cambodia			0·57	0·26	1·36	95·19	43·56	225·73	Yes	Region	16589·0235
Indonesia			0·57	0·26	1·36	1570·89	718·77	3725·09	Yes	Region	273753·191

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			0·57	0·26	1·36	42·61	19·5	101·04	Yes	Region	7425·0575
Malaysia			0·57	0·26	1·36	192·66	88·15	456·86	Yes	Region	33573·8735
Maldives			0·57	0·26	1·36	2·99	1·37	7·1	Yes	Region	521·4575
Mauritius			0·57	0·26	1·36	7·45	3·41	17·67	Yes	Region	1298·9145
Myanmar			0·57	0·26	1·36	308·71	141·25	732·06	Yes	Region	53798·0845
Philippines			0·57	0·26	1·36	653·48	299·01	1549·62	Yes	Region	113880·328
Seychelles			0·57	0·26	1·36	0·61	0·28	1·45	Yes	Region	106·4705
Sri Lanka			0·60	0·27	1·45	130·92	58·39	315·43			21773·4405
Thailand			0·57	0·26	1·36	410·87	188	974·31	Yes	Region	71601·103
Timor-Leste			0·57	0·26	1·36	7·58	3·47	17·97	Yes	Region	1320·942
Vietnam			0·57	0·26	1·36	559·3	255·91	1326·29	Yes	Region	97468·0285
	Southest Asia		0·57	0·26	1·36						
		Southeast Asia, East Asia, and Oceania	0·48	0·26	0·84						
Angola			0·50	0·27	0·89	173·3	93·55	307·9	Yes	Super-region	34503·7735
Central African Republic			0·50	0·27	0·89	27·41	14·8	48·7	Yes	Super-region	5457·1545
Congo, Dem. Rep.			0·50	0·27	0·89	481·65	259·99	855·73	Yes	Super-region	95894·1185
Congo, Rep.			0·50	0·27	0·89	29·31	15·82	52·08	Yes	Super-region	5835·806
Equatorial Guinea			0·50	0·27	0·89	8·21	4·43	14·59	Yes	Super-region	1634·4655
Gabon			0·50	0·27	0·89	11·76	6·35	20·89	Yes	Super-region	2341·179

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·50	0·27	0·89				Yes	Super-region	
Burundi			0·48	0·24	0·90	59·71	30·36	113·25	Yes	Region	12551·213
Comoros			0·48	0·24	0·90	3·91	1·99	7·41	Yes	Region	821·6255
Djibouti			0·48	0·24	0·90	5·26	2·67	9·98	Yes	Region	1105·5575
Eritrea			0·48	0·24	0·90	17·22	8·76	32·67	Yes	Region	3620·312
Ethiopia			0·48	0·24	0·90	572·25	290·94	1085·36	Yes	Region	120283·026
Kenya			0·48	0·24	0·90	252·17	128·21	478·29	Yes	Region	53005·614
Madagascar			0·48	0·24	0·90	137·57	69·94	260·92	Yes	Region	28915·6525
Malawi			0·48	0·24	0·90	94·63	48·11	179·47	Yes	Region	19889·742
Mozambique			0·45	0·22	0·90	143·58	69·45	288·14			32077·072
Rwanda			0·48	0·24	0·90	64·04	32·56	121·47	Yes	Region	13461·8875
Somalia			0·48	0·24	0·90	81·19	41·28	153·99	Yes	Region	17065·581
South Sudan			0·48	0·24	0·90	51·13	26	96·99	Yes	Region	10748·2725
Tanzania			0·50	0·25	1·00	317·01	157·35	633·4			63588·334
Uganda			0·48	0·24	0·90	218·15	110·91	413·75	Yes	Region	45853·778
Zambia			0·48	0·24	0·90	92·64	47·1	175·71	Yes	Region	19473·125
	Eastern sub-Saharan Africa		0·48	0·24	0·90						
Botswana			0·50	0·27	0·89	13	7·02	23·1	Yes	Super-region	2588·423
Lesotho			0·50	0·27	0·89	11·46	6·19	20·36	Yes	Super-region	2281·4545
Namibia			0·50	0·27	0·89	12·71	6·86	22·58	Yes	Super-region	2530·1505
South Africa			0·50	0·27	0·89	298·31	161·02	530	Yes	Super-region	59392·255

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·50	0·27	0·89	5·99	3·23	10·64	Yes	Super-region	1192·271
Zimbabwe			0·50	0·27	0·89	80·33	43·36	142·72	Yes	Super-region	15993·524
	Southern sub-Saharan Africa		0·50	0·27	0·89				Yes	Super-region	
Benin			0·47	0·24	0·90	60·78	31·75	116·32	Yes	Region	12996·895
Burkina Faso			0·47	0·24	0·90	103·35	53·99	197·8	Yes	Region	22100·6835
Cameroon			0·48	0·24	0·96	129·27	64·88	261·65			27198·628
Cape Verde			0·47	0·24	0·90	2·75	1·44	5·26	Yes	Region	587·925
Chad			0·47	0·24	0·90	80·34	41·97	153·76	Yes	Region	17179·74
Cote d'Ivoire			0·47	0·24	0·90	128·49	67·12	245·93	Yes	Region	27478·249
Gambia, The			0·47	0·24	0·90	12·34	6·45	23·63	Yes	Region	2639·9155
Ghana			0·46	0·23	0·93	150·72	75·55	305·07			32833·0315
Guinea			0·47	0·24	0·90	63·28	33·06	121·11	Yes	Region	13531·906
Guinea-Bissau			0·47	0·24	0·90	9·64	5·03	18·44	Yes	Region	2060·721
Liberia			0·47	0·24	0·90	24·29	12·69	46·48	Yes	Region	5193·4155
Mali			0·48	0·24	0·96	104·29	52·77	209·69			21904·983
Mauritania			0·47	0·24	0·90	21·58	11·27	41·3	Yes	Region	4614·974
Niger			0·47	0·24	0·90	118·09	61·69	226·02	Yes	Region	25252·722
Nigeria			0·45	0·22	0·90	955·48	466·26	1926·35			213401·3225
Senegal			0·47	0·24	0·90	78·92	41·23	151·05	Yes	Region	16876·72
Sierra Leone			0·47	0·24	0·90	39·38	20·57	75·37	Yes	Region	8420·641
São Tomé and Principe			0·47	0·24	0·90	1·04	0·55	2	Yes	Region	223·1075

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·47	0·24	0·90	40·43	21·12	77·37	Yes	Region	8644·829
	Western sub-Saharan Africa		0·47	0·24	0·90						
		Sub-Saharan Africa	0·50	0·27	0·89						
World			**0·55**	**0·33**	**0·92**	**43550·16**	**26179·77**	**72979·54**			**7909295·152**

Table S12. Lifetime self-reported prevalence of vitiligo for adults and number of adults with vitiligo (in thousands) with 95% credible confidence interval by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			1·22	0·66	2·70	25·95	13·94	57·25	Yes	Super-region	2121·798
Azerbaijan			1·22	0·66	2·70	90·71	48·74	200·12	Yes	Super-region	7417·088
Georgia			1·22	0·66	2·70	34·71	18·65	76·57	Yes	Super-region	2837·887
Kazakhstan			1·22	0·66	2·70	155·31	83·44	342·63	Yes	Super-region	12698·936
Kyrgyzstan			1·22	0·66	2·70	48·35	25·98	106·67	Yes	Super-region	3953·605
Mongolia			1·22	0·66	2·70	26·02	13·98	57·41	Yes	Super-region	2127·772
Tajikistan			1·22	0·66	2·70	69·18	37·17	152·62	Yes	Super-region	5656·627
Turkmenistan			1·22	0·66	2·70	49·65	26·67	109·53	Yes	Super-region	4059·3815
Uzbekistan			1·22	0·66	2·70	272·39	146·35	600·94	Yes	Super-region	22272·623
	Central Asia		1·22	0·66	2·70				Yes	Super-region	
Albania			1·50	0·75	3·40	34·12	17·14	77·43	Yes	Region	2280·3225
Bosnia and Herzegovina			1·50	0·75	3·40	40·14	20·16	91·1	Yes	Region	2682·8995
Bulgaria			1·50	0·75	3·40	85·72	43·06	194·55	Yes	Region	5729·8965
Croatia			1·50	0·75	3·40	50·4	25·32	114·38	Yes	Region	3368·753
Czech Republic			1·50	0·75	3·40	127·58	64·09	289·55	Yes	Region	8527·5865
Hungary			1·50	0·75	3·40	119·73	60·15	271·74	Yes	Region	8003·276
Macedonia, FYR			1·50	0·75	3·40	25·36	12·74	57·57	Yes	Region	1695·408
Montenegro			1·50	0·75	3·40	7·35	3·69	16·69	Yes	Region	491·441
Poland			1·53	0·74	3·45	479·44	231·63	1079·68			31326·0285

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			1·56	0·76	3·48	243·12	119·14	543·37			15607·023
Serbia			1·50	0·75	3·40	90·42	45·42	205·21	Yes	Region	6043·7235
Slovakia			1·50	0·75	3·40	66·15	33·23	150·12	Yes	Region	4421·3775
Slovenia			1·50	0·75	3·40	26·02	13·07	59·06	Yes	Region	1739·3885
	Central Europe		1·50	0·75	3·40						
Belarus			1·22	0·66	2·70	93·89	50·44	207·13	Yes	Super-region	7676·7365
Estonia			1·22	0·66	2·70	13·07	7·02	28·84	Yes	Super-region	1068·9885
Latvia			1·22	0·66	2·70	18·66	10·02	41·16	Yes	Super-region	1525·5745
Lithuania			1·22	0·66	2·70	27·98	15·03	61·73	Yes	Super-region	2287·8675
Moldova			1·22	0·66	2·70	28·77	15·46	63·48	Yes	Super-region	2352·6915
Russian Federation			1·22	0·66	2·70	1405·52	755·13	3100·79	Yes	Super-region	114924·9705
Ukraine			1·22	0·66	2·70	435·79	234·13	961·42	Yes	Super-region	35633·301
	Eastern Europe		1·22	0·66	2·70				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	1·22	0·66	2·70						
Australia			1·01	0·52	2·03	203·93	104·34	411·68			20254·151
New Zealand			1·00	0·53	1·97	39·83	21·18	78·13	Yes	Region	3970·489
	Australasia		1·00	0·53	1·97						
Brunei			0·86	0·52	1·37	2·8	1·68	4·47	Yes	Region	325·9675
Japan			0·82	0·48	1·34	873·61	516·74	1426·87			106650·0435
Singapore			0·84	0·49	1·43	42·58	24·76	72·79			5080·6815

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·88	0·52	1·49	391·14	230·87	660·35			44313·0555
	High-income Asia Pacific		0·86	0·52	1·37						
Canada			0·82	0·49	1·33	252·39	151·11	413·03	Yes	Region	30940·394
Greenland			0·82	0·49	1·33	0·35	0·21	0·57	Yes	Region	42·3585
United States			0·77	0·49	1·21	2021·27	1281·07	3164·88			262262·7025
	High-income North America		0·82	0·49	1·33						
Argentina			0·97	0·61	1·48	315·24	199·23	482·84	Yes	Super-region	32607·9345
Chile			0·97	0·61	1·48	146·75	92·75	224·77	Yes	Super-region	15179·711
Uruguay			0·97	0·61	1·48	25·29	15·98	38·73	Yes	Super-region	2615·569
	High-income Southern Latin America		0·97	0·61	1·48				Yes	Super-region	
Andorra			1·10	0·76	1·61	0·73	0·5	1·07	Yes	Region	66·2575
Austria			1·10	0·76	1·61	81·43	55·96	118·81	Yes	Region	7379·798
Belgium			1·10	0·76	1·61	102·42	70·39	149·44	Yes	Region	9282·645
Cyprus			1·10	0·76	1·61	11·12	7·64	16·23	Yes	Region	1007·896
Denmark			1·08	0·69	1·68	50·83	32·52	79·08			4702·388
Finland			1·18	0·76	1·95	53·01	34·11	87·56			4499·6195
France			1·10	0·72	1·68	558·89	366·49	857·34			50963·731
Germany			1·09	0·72	1·65	757·32	498·87	1147·85			69572·764
Greece			1·10	0·76	1·61	95·46	65·6	139·27	Yes	Region	8651·1485

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			1·10	0·76	1·61	3·18	2·18	4·63	Yes	Region	287·771
Ireland			1·10	0·76	1·61	41·9	28·8	61·14	Yes	Region	3797·6205
Israel			1·10	0·76	1·61	65·87	45·27	96·11	Yes	Region	5969·9695
Italy			1·11	0·73	1·69	555·81	367·65	848·03			50037·0565
Luxembourg			1·10	0·76	1·61	5·71	3·93	8·34	Yes	Region	517·7405
Malta			1·10	0·76	1·61	4·91	3·37	7·16	Yes	Region	444·7195
Netherlands			1·15	0·74	1·90	163·48	104·87	269·26			14193·1635
Norway			1·10	0·76	1·61	47·39	32·57	69·15	Yes	Region	4295·17
Portugal			1·07	0·67	1·68	91·93	57·8	144·09			8599·991
Spain			1·11	0·72	1·75	436·89	281·29	685·59			39288·7635
Sweden			1·14	0·74	1·84	94·11	60·7	151·99			8252·4935
Switzerland			1·10	0·76	1·61	78·69	54·08	114·81	Yes	Region	7131·302
United Kingdom			1·11	0·72	1·70	587·81	382·98	903·45			53112·1275
	Western Europe		1·10	0·76	1·61						
		High-income	0·97	0·61	1·48						
Bolivia			0·89	0·43	1·66	67·49	32·59	126·31	Yes	Super-region	7609·281
Ecuador			0·89	0·43	1·66	108·33	52·32	202·75	Yes	Super-region	12214·1165
Peru			0·89	0·43	1·66	204·66	98·84	383·05	Yes	Super-region	23076·3785
	Andean Latin America		0·89	0·43	1·66				Yes	Super-region	
Antigua and Barbuda			0·89	0·43	1·66	0·64	0·31	1·19	Yes	Super-region	71·885
Bahamas, The			0·89	0·43	1·66	2·73	1·32	5·11	Yes	Super-region	308·109

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·89	0·43	1·66	1·97	0·95	3·69	Yes	Super-region	222·234
Belize			0·89	0·43	1·66	2·34	1·13	4·38	Yes	Super-region	263·7685
Bermuda			0·89	0·43	1·66	0·47	0·23	0·87	Yes	Super-region	52·631
Cuba			0·89	0·43	1·66	80·84	39·04	151·3	Yes	Super-region	9114·641
Dominica			0·89	0·43	1·66	0·49	0·23	0·91	Yes	Super-region	54·6945
Dominican Republic			0·89	0·43	1·66	66·44	32·09	124·36	Yes	Super-region	7491·8765
Grenada			0·89	0·43	1·66	0·79	0·38	1·48	Yes	Super-region	89·3115
Guyana			0·89	0·43	1·66	4·7	2·27	8·79	Yes	Super-region	529·606
Haiti			0·89	0·43	1·66	62·53	30·2	117·04	Yes	Super-region	7050·811
Jamaica			0·89	0·43	1·66	18·76	9·06	35·12	Yes	Super-region	2115·5395
Puerto Rico			0·89	0·43	1·66	23·97	11·58	44·86	Yes	Super-region	2702·7845
St. Lucia			0·89	0·43	1·66	1·23	0·6	2·31	Yes	Super-region	139·192
St. Vincent and the Grenadines			0·89	0·43	1·66	0·68	0·33	1·28	Yes	Super-region	76·847
Suriname			0·89	0·43	1·66	3·7	1·79	6·93	Yes	Super-region	417·5095
Trinidad and Tobago			0·89	0·43	1·66	10·4	5·02	19·46	Yes	Super-region	1172·4265
Virgin Islands (U.S.)			0·89	0·43	1·66	0·69	0·33	1·29	Yes	Super-region	77·4845
	Caribbean		0·89	0·43	1·66				Yes	Super-region	
Colombia			0·89	0·43	1·66	336·84	162·67	630·45	Yes	Super-region	37980·0935
Costa Rica			0·89	0·43	1·66	34·37	16·6	64·33	Yes	Super-region	3875·5675
El Salvador			0·89	0·43	1·66	38·55	18·62	72·15	Yes	Super-region	4346·715

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·89	0·43	1·66	94·71	45·74	177·26	Yes	Super-region	10678·836
Honduras			0·89	0·43	1·66	57·59	27·81	107·8	Yes	Super-region	6493·9485
Mexico			0·89	0·43	1·66	785·44	379·32	1470·06	Yes	Super-region	88560·9005
Nicaragua			0·89	0·43	1·66	39·02	18·84	73·03	Yes	Super-region	4399·604
Panama			0·89	0·43	1·66	26·48	12·79	49·56	Yes	Super-region	2985·6415
Venezuela, RB			0·89	0·43	1·66	165·32	79·84	309·42	Yes	Super-region	18640·2835
	Central Latin America		0·89	0·43	1·66				Yes	Super-region	
Brazil			0·71	0·34	1·45	1139·62	538·96	2329·81			160861·363
Paraguay			0·74	0·35	1·52	32·76	15·2	66·78	Yes	Region	4398·46
	Tropical Latin America		0·74	0·35	1·52						
		Latin America and Caribbean	0·89	0·43	1·66						
Afghanistan			1·34	0·78	2·30	264·64	155·38	455·82	Yes	Region	19801·576
Algeria			1·34	0·78	2·30	382·91	224·83	659·54	Yes	Region	28651·7635
Bahrain			1·34	0·78	2·30	14·91	8·75	25·68	Yes	Region	1115·543
Egypt			1·35	0·77	2·42	911·5	518·05	1628·38			67274·6775
Iran			1·40	0·78	2·52	886·72	498·12	1598·15			63497·966
Iraq			1·33	0·74	2·39	320·44	179·48	578·47			24181·98
Jordan			1·34	0·78	2·30	91·67	53·82	157·89	Yes	Region	6859·004
Kuwait			1·34	0·78	2·30	42·86	25·17	73·83	Yes	Region	3207·3735
Lebanon			1·34	0·78	2·30	50·06	29·39	86·23	Yes	Region	3746·015

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			1·34	0·78	2·30	58·85	34·55	101·37	Yes	Region	4403·6035
Morocco			1·34	0·78	2·30	338·09	198·51	582·34	Yes	Region	25297·7655
Oman			1·34	0·78	2·30	42·12	24·73	72·55	Yes	Region	3151·8155
Palestine			1·34	0·78	2·30	37·34	21·92	64·32	Yes	Region	2794·0265
Qatar			1·34	0·78	2·30	29·58	17·37	50·95	Yes	Region	2213·2485
Saudi Arabia			1·37	0·78	2·49	341·78	193·98	619·45			24924·363
Sudan			1·34	0·78	2·30	321·91	189·01	554·46	Yes	Region	24086·858
Syria			1·34	0·78	2·30	169	99·23	291·08	Yes	Region	12645·184
Tunisia			1·34	0·78	2·30	116·13	68·18	200·02	Yes	Region	8689·1405
Turkey			1·32	0·74	2·37	805·13	454·21	1446·18			61102·1635
United Arab Emirates			1·34	0·78	2·30	103·79	60·94	178·77	Yes	Region	7765·9905
Yemen, Rep.			1·34	0·78	2·30	235·66	138·37	405·91	Yes	Region	17633·626
	North Africa and Middle East		1·34	0·78	2·30						
		North Africa and Middle East	1·16	0·66	2·13						
Bangladesh			1·48	0·87	2·54	1694·31	992·38	2911·27	Yes	Region	114555·2165
Bhutan			1·48	0·87	2·54	8·25	4·83	14·17	Yes	Region	557·492
India			1·53	0·92	2·55	14826·62	8910·31	24732·14			969400·0455
Nepal			1·53	0·85	2·83	295·22	164·2	546·63			19293·131
Pakistan			1·48	0·87	2·54	1935·53	1133·67	3325·75	Yes	Region	130864·537
	South Asia		1·48	0·87	2·54						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	1·22	0·67	2·36						
China			0·64	0·36	1·12	7210·09	4086·86	12612·89			1125801·825
North Korea			0·66	0·36	1·21	132·75	72·75	241·48	Yes	Region	20031·794
Taiwan (Province of China)			0·62	0·33	1·12	125·44	66·98	227·05			20184·7595
	East Asia		0·66	0·36	1·21						
American Samoa			0·90	0·50	1·57	0·27	0·15	0·48	Yes	Super-region	30·364
Fiji			0·90	0·50	1·57	5·45	3·06	9·58	Yes	Super-region	608·597
Guam			0·90	0·50	1·57	1·05	0·59	1·85	Yes	Super-region	117·4305
Kiribati			0·90	0·50	1·57	0·68	0·38	1·19	Yes	Super-region	75·4165
Marshall Islands			0·90	0·50	1·57	0·23	0·13	0·41	Yes	Super-region	25·8365
Micronesia, Fed. Sts.			0·90	0·50	1·57	3·11	1·75	5·47	Yes	Super-region	347·2985
Northern Mariana Islands			0·90	0·50	1·57	0·33	0·19	0·58	Yes	Super-region	36·9235
Papua New Guinea			0·90	0·50	1·57	52·8	29·62	92·78	Yes	Super-region	5892·545
Samoa			0·90	0·50	1·57	1·1	0·62	1·94	Yes	Super-region	123·1865
Solomon Islands			0·90	0·50	1·57	3·45	1·94	6·06	Yes	Super-region	385·119
Tonga			0·90	0·50	1·57	0·56	0·31	0·98	Yes	Super-region	62·376
Vanuatu			0·90	0·50	1·57	1·56	0·87	2·74	Yes	Super-region	173·826
	Oceania		0·90	0·50	1·57				Yes	Super-region	
Cambodia			1·07	0·50	2·53	116·28	54·07	274·27	Yes	Region	10832·5515
Indonesia			1·07	0·50	2·53	2045·64	951·12	4824·95	Yes	Region	190565·6625

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			1·07	0·50	2·53	50·3	23·39	118·65	Yes	Region	4686·033
Malaysia			1·07	0·50	2·53	260·46	121·1	614·33	Yes	Region	24263·347
Maldives			1·07	0·50	2·53	4·18	1·95	9·87	Yes	Region	389·8085
Mauritius			1·07	0·50	2·53	11·02	5·13	26	Yes	Region	1026·905
Myanmar			1·07	0·50	2·53	404·4	188·03	953·85	Yes	Region	37672·9605
Philippines			1·07	0·50	2·53	777·61	361·55	1834·1	Yes	Region	72439·474
Seychelles			1·07	0·50	2·53	0·83	0·39	1·96	Yes	Region	77·539
Sri Lanka			1·12	0·51	2·73	176·08	80·54	427·79			15653·7185
Thailand			1·07	0·50	2·53	620·86	288·67	1464·38	Yes	Region	57836·9715
Timor-Leste			1·07	0·50	2·53	8·15	3·79	19·22	Yes	Region	758·935
Vietnam			1·07	0·50	2·53	765·21	355·79	1804·87	Yes	Region	71284·906
	Southest Asia		1·07	0·50	2·53						
		Southeast Asia, East Asia, and Oceania	0·90	0·50	1·57						
Angola			0·94	0·50	1·69	156·64	84·07	282·24	Yes	Super-region	16670·7975
Central African Republic			0·94	0·50	1·69	22·66	12·16	40·83	Yes	Super-region	2411·966
Congo, Dem. Rep.			0·94	0·50	1·69	423·78	227·45	763·59	Yes	Super-region	45102·634
Congo, Rep.			0·94	0·50	1·69	28·65	15·38	51·63	Yes	Super-region	3049·498
Equatorial Guinea			0·94	0·50	1·69	8·57	4·6	15·45	Yes	Super-region	912·5695
Gabon			0·94	0·50	1·69	12·74	6·84	22·96	Yes	Super-region	1356·326

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·94	0·50	1·69				Yes	Super-region	
Burundi			0·89	0·45	1·72	52·47	26·63	101·6	Yes	Region	5896·029
Comoros			0·89	0·45	1·72	4·08	2·07	7·9	Yes	Region	458·1635
Djibouti			0·89	0·45	1·72	6·2	3·15	12·01	Yes	Region	696·7565
Eritrea			0·89	0·45	1·72	16·98	8·62	32·88	Yes	Region	1908·3375
Ethiopia			0·89	0·45	1·72	569·3	288·97	1102·3	Yes	Region	63967·9975
Kenya			0·89	0·45	1·72	257·7	130·8	498·97	Yes	Region	28955·8805
Madagascar			0·89	0·45	1·72	139·05	70·58	269·23	Yes	Region	15623·913
Malawi			0·89	0·45	1·72	87·55	44·44	169·53	Yes	Region	9837·8915
Mozambique			0·84	0·41	1·68	133·22	64·46	267·78			15909·4165
Rwanda			0·89	0·45	1·72	64·97	32·98	125·8	Yes	Region	7300·3555
Somalia			0·89	0·45	1·72	69·89	35·48	135·33	Yes	Region	7853·412
South Sudan			0·89	0·45	1·72	45·64	23·16	88·36	Yes	Region	5127·76
Tanzania			0·93	0·46	1·92	293·85	145·05	604·09			31509·1305
Uganda			0·89	0·45	1·72	193·67	98·3	374·99	Yes	Region	21761·3175
Zambia			0·89	0·45	1·72	86·38	43·84	167·25	Yes	Region	9705·6205
	Eastern sub-Saharan Africa		0·89	0·45	1·72						
Botswana			0·94	0·50	1·69	14·92	8·01	26·89	Yes	Super-region	1588·2655
Lesotho			0·94	0·50	1·69	12·83	6·89	23·12	Yes	Super-region	1365·836
Namibia			0·94	0·50	1·69	13·81	7·41	24·88	Yes	Super-region	1469·692
South Africa			0·94	0·50	1·69	370·49	198·85	667·56	Yes	Super-region	39430·846

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·94	0·50	1·69	6·57	3·52	11·83	Yes	Super-region	698·9795
Zimbabwe			0·94	0·50	1·69	78·66	42·22	141·73	Yes	Super-region	8371·263
	Southern sub-Saharan Africa		0·94	0·50	1·69				Yes	Super-region	
Benin			0·87	0·45	1·69	57·92	29·86	111·74	Yes	Region	6620·7305
Burkina Faso			0·87	0·45	1·69	94·97	48·96	183·23	Yes	Region	10856·772
Cameroon			0·89	0·44	1·85	123·23	61·48	256·35			13859·6935
Cape Verde			0·87	0·45	1·69	3·5	1·8	6·75	Yes	Region	399·676
Chad			0·87	0·45	1·69	68·55	35·34	132·26	Yes	Region	7836·5965
Cote d'Ivoire			0·87	0·45	1·69	123·34	63·58	237·96	Yes	Region	14099·3615
Gambia, The			0·87	0·45	1·69	11·45	5·9	22·1	Yes	Region	1309·222
Ghana			0·86	0·42	1·77	159·23	78·59	327·49			18542·5115
Guinea			0·87	0·45	1·69	60·97	31·43	117·62	Yes	Region	6969·487
Guinea-Bissau			0·87	0·45	1·69	9·49	4·89	18·32	Yes	Region	1085·2905
Liberia			0·87	0·45	1·69	23·63	12·18	45·6	Yes	Region	2701·807
Mali			0·89	0·44	1·82	89·07	43·88	182·07			10000·52
Mauritania			0·87	0·45	1·69	20·67	10·65	39·87	Yes	Region	2362·506
Niger			0·87	0·45	1·69	97·95	50·5	188·97	Yes	Region	11197·111
Nigeria			0·84	0·40	1·69	894·45	426·78	1808·28			106790·1895
Senegal			0·87	0·45	1·69	76·18	39·28	146·98	Yes	Region	8709·111
Sierra Leone			0·87	0·45	1·69	39·72	20·47	76·62	Yes	Region	4540·172
São Tomé and Principe			0·87	0·45	1·69	1·03	0·53	1·99	Yes	Region	118·0285

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·87	0·45	1·69	40·33	20·79	77·8	Yes	Region	4609·918
	Western sub-Saharan Africa		0·87	0·45	1·69						
		Sub-Saharan Africa	0·94	0·50	1·69						
World			**1·03**	**0·62**	**1·69**	**56825·59**	**34233·6**	**93455·05**			**5516876·082**

Table S13. Lifetime self-reported prevalence of vitiligo for children and number of children with vitiligo (in thousands) with 95% credible confidence interval by country, region, and super region

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Armenia			0·44	0·23	0·96	2·96	1·54	6·43	Yes	Super-region	669·1755
Azerbaijan			0·44	0·23	0·96	12·81	6·67	27·81	Yes	Super-region	2895·904
Georgia			0·44	0·23	0·96	4·07	2·12	8·84	Yes	Super-region	920·093
Kazakhstan			0·44	0·23	0·96	28·75	14·98	62·39	Yes	Super-region	6497·5295
Kyrgyzstan			0·44	0·23	0·96	11·39	5·93	24·72	Yes	Super-region	2574·1385
Mongolia			0·44	0·23	0·96	5·4	2·81	11·72	Yes	Super-region	1220·0105
Tajikistan			0·44	0·23	0·96	18·11	9·43	39·31	Yes	Super-region	4093·437
Turkmenistan			0·44	0·23	0·96	10·1	5·26	21·92	Yes	Super-region	2282·4735
Uzbekistan			0·44	0·23	0·96	52·25	27·22	113·39	Yes	Super-region	11808·826
	Central Asia		0·44	0·23	0·96				Yes	Super-region	
Albania			0·54	0·26	1·22	3·11	1·48	7·04	Yes	Region	574·3875
Bosnia and Herzegovina			0·54	0·26	1·22	3·18	1·52	7·2	Yes	Region	588·0435
Bulgaria			0·54	0·26	1·22	6·26	2·99	14·16	Yes	Region	1155·971
Croatia			0·54	0·26	1·22	3·74	1·79	8·47	Yes	Region	691·3825
Czech Republic			0·54	0·26	1·22	10·73	5·12	24·29	Yes	Region	1983·164
Hungary			0·54	0·26	1·22	9·24	4·41	20·9	Yes	Region	1706·51
Macedonia, FYR			0·54	0·26	1·22	2·21	1·05	5	Yes	Region	407·922
Montenegro			0·54	0·26	1·22	0·74	0·35	1·67	Yes	Region	136·4175
Poland			0·55	0·25	1·28	38·66	17·72	89·03			6981·697

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Romania			0·56	0·26	1·27	20·97	9·75	47·11			3721·537
Serbia			0·54	0·26	1·22	6·78	3·24	15·35	Yes	Region	1253·045
Slovakia			0·54	0·26	1·22	5·55	2·65	12·57	Yes	Region	1026·2445
Slovenia			0·54	0·26	1·22	2·06	0·98	4·65	Yes	Region	380·021
	Central Europe		0·54	0·26	1·22						
Belarus			0·44	0·23	0·96	8·41	4·38	18·26	Yes	Super-region	1901·431
Estonia			0·44	0·23	0·96	1·15	0·6	2·49	Yes	Super-region	259·7125
Latvia			0·44	0·23	0·96	1·54	0·8	3·34	Yes	Super-region	348·3445
Lithuania			0·44	0·23	0·96	2·21	1·15	4·79	Yes	Super-region	498·783
Moldova			0·44	0·23	0·96	3·14	1·63	6·81	Yes	Super-region	708·815
Russian Federation			0·44	0·23	0·96	133·51	69·56	289·78	Yes	Super-region	30177·785
Ukraine			0·44	0·23	0·96	34·94	18·2	75·84	Yes	Super-region	7898·121
	Eastern Europe		0·44	0·23	0·96				Yes	Super-region	
		Central Europe, Eastern Europe, and Central Asia	0·44	0·23	0·96						
Australia			0·36	0·17	0·78	20·64	9·68	44·35			5666·938
New Zealand			0·36	0·18	0·75	4·21	2·05	8·74	Yes	Region	1159·2385
	Australasia		0·36	0·18	0·75						
Brunei			0·31	0·18	0·54	0·37	0·21	0·64	Yes	Region	119·4055
Japan			0·30	0·16	0·53	53·23	29·57	95·63			17962·487
Singapore			0·30	0·16	0·56	2·61	1·41	4·85			860·379

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
South Korea			0·32	0·18	0·57	24	13·24	42·98			7517·0835
	High-income Asia Pacific		0·31	0·18	0·54						
Canada			0·30	0·17	0·51	21·29	11·99	37·1	Yes	Region	7214·618
Greenland			0·30	0·17	0·51	0·04	0·02	0·07	Yes	Region	13·8845
United States			0·28	0·17	0·48	208·37	123·5	355·82			74734·922
	High-income North America		0·30	0·17	0·51						
Argentina			0·35	0·21	0·58	44·31	26·4	73·03	Yes	Super-region	12668·846
Chile			0·35	0·21	0·58	15·09	8·99	24·86	Yes	Super-region	4313·4735
Uruguay			0·35	0·21	0·58	2·84	1·69	4·67	Yes	Super-region	810·6905
	High-income Southern Latin America		0·35	0·21	0·58				Yes	Super-region	
Andorra			0·40	0·24	0·65	0·05	0·03	0·08	Yes	Region	12·7765
Austria			0·40	0·24	0·65	6·16	3·71	10·1	Yes	Region	1542·284
Belgium			0·40	0·24	0·65	9·3	5·6	15·25	Yes	Region	2328·7745
Cyprus			0·40	0·24	0·65	0·94	0·57	1·55	Yes	Region	236·292
Denmark			0·39	0·22	0·68	4·5	2·56	7·79			1151·8525
Finland			0·43	0·24	0·78	4·42	2·47	8·07			1036·3725
France			0·40	0·23	0·68	53·83	30·77	92·5			13567·713
Germany			0·39	0·23	0·67	54·48	32·25	92·92			13835·791
Greece			0·40	0·24	0·65	7·16	4·32	11·75	Yes	Region	1794·2165

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Iceland			0·40	0·24	0·65	0·33	0·2	0·54	Yes	Region	82·564
Ireland			0·40	0·24	0·65	4·75	2·86	7·79	Yes	Region	1188·9055
Israel			0·40	0·24	0·65	11·7	7·05	19·19	Yes	Region	2930·0895
Italy			0·40	0·23	0·68	36·98	21·57	62·2			9203·273
Luxembourg			0·40	0·24	0·65	0·49	0·29	0·8	Yes	Region	121·5805
Malta			0·40	0·24	0·65	0·33	0·2	0·54	Yes	Region	82·0285
Netherlands			0·42	0·23	0·75	13·79	7·76	24·95			3308·532
Norway			0·40	0·24	0·65	4·42	2·66	7·26	Yes	Region	1107·851
Portugal			0·39	0·21	0·67	6·54	3·61	11·32			1690·112
Spain			0·40	0·23	0·70	32·98	18·72	57·62			8198·1715
Sweden			0·41	0·24	0·73	9·14	5·25	16·13			2214·6035
Switzerland			0·40	0·24	0·65	6·23	3·75	10·22	Yes	Region	1560·1045
United Kingdom			0·40	0·23	0·68	56·73	32·5	97			14168·912
	Western Europe		0·40	0·24	0·65						
		High-income	0·35	0·21	0·58						
Bolivia			0·32	0·15	0·62	14·34	6·69	27·92	Yes	Super-region	4470·191
Ecuador			0·32	0·15	0·62	17·91	8·36	34·88	Yes	Super-region	5583·6205
Peru			0·32	0·15	0·62	34·13	15·92	66·46	Yes	Super-region	10639·093
	Andean Latin America		0·32	0·15	0·62				Yes	Super-region	
Antigua and Barbuda			0·32	0·15	0·62	0·07	0·03	0·13	Yes	Super-region	21·3345
Bahamas, The			0·32	0·15	0·62	0·32	0·15	0·62	Yes	Super-region	99·7965

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Barbados			0·32	0·15	0·62	0·19	0·09	0·37	Yes	Super-region	58·9655
Belize			0·32	0·15	0·62	0·44	0·2	0·85	Yes	Super-region	136·2625
Bermuda			0·32	0·15	0·62	0·04	0·02	0·07	Yes	Super-region	11·554
Cuba			0·32	0·15	0·62	6·87	3·2	13·38	Yes	Super-region	2141·7315
Dominica			0·32	0·15	0·62	0·06	0·03	0·11	Yes	Super-region	17·718
Dominican Republic			0·32	0·15	0·62	11·63	5·43	22·65	Yes	Super-region	3625·997
Grenada			0·32	0·15	0·62	0·11	0·05	0·22	Yes	Super-region	35·2985
Guyana			0·32	0·15	0·62	0·88	0·41	1·72	Yes	Super-region	274·961
Haiti			0·32	0·15	0·62	14·11	6·58	27·47	Yes	Super-region	4396·758
Jamaica			0·32	0·15	0·62	2·28	1·07	4·45	Yes	Super-region	712·155
Puerto Rico			0·32	0·15	0·62	1·78	0·83	3·46	Yes	Super-region	553·243
St. Lucia			0·32	0·15	0·62	0·13	0·06	0·25	Yes	Super-region	40·4595
St. Vincent and the Grenadines			0·32	0·15	0·62	0·09	0·04	0·17	Yes	Super-region	27·485
Suriname			0·32	0·15	0·62	0·63	0·29	1·22	Yes	Super-region	195·475
Trinidad and Tobago			0·32	0·15	0·62	1·13	0·53	2·21	Yes	Super-region	353·2365
Virgin Islands (U.S.)			0·32	0·15	0·62	0·07	0·03	0·14	Yes	Super-region	22·6065
	Caribbean		0·32	0·15	0·62				Yes	Super-region	
Colombia			0·32	0·15	0·62	43·43	20·26	84·56	Yes	Super-region	13536·469
Costa Rica			0·32	0·15	0·62	4·1	1·91	7·99	Yes	Super-region	1278·3895
El Salvador			0·32	0·15	0·62	6·31	2·94	12·29	Yes	Super-region	1967·4525

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Guatemala			0·32	0·15	0·62	22·23	10·37	43·29	Yes	Super-region	6929·6475
Honduras			0·32	0·15	0·62	12·14	5·66	23·64	Yes	Super-region	3784·397
Mexico			0·32	0·15	0·62	122·38	57·08	238·28	Yes	Super-region	38144·238
Nicaragua			0·32	0·15	0·62	7·86	3·67	15·31	Yes	Super-region	2450·936
Panama			0·32	0·15	0·62	4·38	2·04	8·53	Yes	Super-region	1365·6255
Venezuela, RB			0·32	0·15	0·62	30·67	14·31	59·72	Yes	Super-region	9559·583
	Central Latin America		0·32	0·15	0·62				Yes	Super-region	
Brazil			0·26	0·12	0·54	137·02	62·95	287·59			53464·86
Paraguay			0·27	0·12	0·57	6·21	2·84	13·25	Yes	Region	2305·339
	Tropical Latin America		0·27	0·12	0·57						
		Latin America and Caribbean	0·32	0·15	0·62						
Afghanistan			0·48	0·29	0·81	98·13	58·86	165·2	Yes	Region	20297·886
Algeria			0·48	0·29	0·81	75·06	45·02	126·37	Yes	Region	15526·205
Bahrain			0·48	0·29	0·81	1·68	1·01	2·83	Yes	Region	347·7225
Egypt			0·49	0·28	0·85	205·8	119·39	355·9			41987·5
Iran			0·51	0·29	0·90	123·39	70·68	219·25			24425·467
Iraq			0·48	0·27	0·85	92·77	51·96	165·17			19351·613
Jordan			0·48	0·29	0·81	20·74	12·44	34·91	Yes	Region	4289·2735
Kuwait			0·48	0·29	0·81	5·04	3·02	8·49	Yes	Region	1042·7405
Lebanon			0·48	0·29	0·81	8·93	5·35	15·03	Yes	Region	1846·616

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Lybia			0·48	0·29	0·81	11·27	6·76	18·98	Yes	Region	2331·6735
Morocco			0·48	0·29	0·81	56·95	34·15	95·87	Yes	Region	11778·819
Oman			0·48	0·29	0·81	6·62	3·97	11·14	Yes	Region	1368·6555
Palestine			0·48	0·29	0·81	11·31	6·78	19·04	Yes	Region	2339·3655
Qatar			0·48	0·29	0·81	2·3	1·38	3·87	Yes	Region	474·9865
Saudi Arabia			0·50	0·29	0·88	54·7	31·71	96·85			11026·033
Sudan			0·48	0·29	0·81	104·29	62·54	175·56	Yes	Region	21570·344
Syria			0·48	0·29	0·81	41·96	25·17	70·64	Yes	Region	8679·183
Tunisia			0·48	0·29	0·81	17·28	10·36	29·09	Yes	Region	3573·8055
Turkey			0·48	0·28	0·84	112·85	65·31	197·99			23673·24
United Arab Emirates			0·48	0·29	0·81	7·73	4·64	13·02	Yes	Region	1599·154
Yemen, Rep.			0·48	0·29	0·81	74·2	44·5	124·92	Yes	Region	15348·016
	North Africa and Middle East		0·48	0·29	0·81						
		North Africa and Middle East	0·42	0·23	0·76						
Bangladesh			0·54	0·31	0·91	293·22	170·49	501·08	Yes	Region	54801·035
Bhutan			0·54	0·31	0·91	1·18	0·68	2·01	Yes	Region	219·9945
India			0·55	0·34	0·90	2424·35	1479·54	3964·89			438163·8
Nepal			0·55	0·30	1·00	59·46	32·55	107·5			10741·859
Pakistan			0·54	0·31	0·91	537·93	312·78	919·27	Yes	Region	100537·58
	South Asia		0·54	0·31	0·91						

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
		South Asia	0·44	0·24	0·84						
China			0·23	0·12	0·43	695·27	368·17	1278·42			300091·64
North Korea			0·24	0·12	0·46	14·24	7·32	27·12	Yes	Region	5940·115
Taiwan (Province of China)			0·22	0·12	0·43	8·26	4·25	15·69			3675·1525
	East Asia		0·24	0·12	0·46						
American Samoa			0·32	0·17	0·60	0·05	0·02	0·09	Yes	Super-region	14·671
Fiji			0·32	0·17	0·60	1·02	0·53	1·89	Yes	Super-region	316·0125
Guam			0·32	0·17	0·60	0·17	0·09	0·32	Yes	Super-region	53·1035
Kiribati			0·32	0·17	0·60	0·17	0·09	0·32	Yes	Super-region	53·4575
Marshall Islands			0·32	0·17	0·60	0·05	0·03	0·1	Yes	Super-region	16·2135
Micronesia, Fed. Sts.			0·32	0·17	0·60	0·61	0·32	1·12	Yes	Super-region	187·3075
Northern Mariana Islands			0·32	0·17	0·60	0·04	0·02	0·08	Yes	Super-region	12·558
Papua New Guinea			0·32	0·17	0·60	13·15	6·86	24·32	Yes	Super-region	4056·892
Samoa			0·32	0·17	0·60	0·31	0·16	0·57	Yes	Super-region	95·5775
Solomon Islands			0·32	0·17	0·60	1·05	0·55	1·93	Yes	Super-region	322·732
Tonga			0·32	0·17	0·60	0·14	0·07	0·26	Yes	Super-region	43·641
Vanuatu			0·32	0·17	0·60	0·47	0·25	0·87	Yes	Super-region	145·3105
	Oceania		0·32	0·17	0·60				Yes	Super-region	
Cambodia			0·39	0·17	0·94	22·35	9·82	54·2	Yes	Region	5756·472
Indonesia			0·39	0·17	0·94	323·05	141·89	783·19	Yes	Region	83187·529

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Laos			0·39	0·17	0·94	10·64	4·67	25·79	Yes	Region	2739·0245
Malaysia			0·39	0·17	0·94	36·16	15·88	87·66	Yes	Region	9310·5265
Maldives			0·39	0·17	0·94	0·51	0·22	1·24	Yes	Region	131·649
Mauritius			0·39	0·17	0·94	1·06	0·46	2·56	Yes	Region	272·0095
Myanmar			0·39	0·17	0·94	62·62	27·5	151·81	Yes	Region	16125·124
Philippines			0·39	0·17	0·94	160·93	70·68	390·16	Yes	Region	41440·854
Seychelles			0·39	0·17	0·94	0·11	0·05	0·27	Yes	Region	28·9315
Sri Lanka			0·41	0·17	1·00	24·9	10·68	61·26			6119·722
Thailand			0·39	0·17	0·94	53·45	23·48	129·59	Yes	Region	13764·132
Timor-Leste			0·39	0·17	0·94	2·18	0·96	5·29	Yes	Region	562·007
Vietnam			0·39	0·17	0·94	101·68	44·66	246·51	Yes	Region	26183·123
	Southest Asia		0·39	0·17	0·94						
		Southeast Asia, East Asia, and Oceania	0·32	0·17	0·60						
Angola			0·34	0·18	0·63	60·61	31·81	112·84	Yes	Super-region	17832·976
Central African Republic			0·34	0·18	0·63	10·35	5·43	19·27	Yes	Super-region	3045·1885
Congo, Dem. Rep.			0·34	0·18	0·63	172·64	90·59	321·38	Yes	Super-region	50791·485
Congo, Rep.			0·34	0·18	0·63	9·47	4·97	17·63	Yes	Super-region	2786·308
Equatorial Guinea			0·34	0·18	0·63	2·45	1·29	4·57	Yes	Super-region	721·896
Gabon			0·34	0·18	0·63	3·35	1·76	6·23	Yes	Super-region	984·853

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
	Central sub-Saharan Africa		0·34	0·18	0·63				Yes	Super-region	
Burundi			0·32	0·16	0·63	21·43	10·88	41·92	Yes	Region	6655·184
Comoros			0·32	0·16	0·63	1·17	0·59	2·29	Yes	Region	363·462
Djibouti			0·32	0·16	0·63	1·32	0·67	2·58	Yes	Region	408·801
Eritrea			0·32	0·16	0·63	5·51	2·8	10·78	Yes	Region	1711·9745
Ethiopia			0·32	0·16	0·63	181·31	92·04	354·74	Yes	Region	56315·029
Kenya			0·32	0·16	0·63	77·43	39·31	151·5	Yes	Region	24049·734
Madagascar			0·32	0·16	0·63	42·79	21·72	83·73	Yes	Region	13291·74
Malawi			0·32	0·16	0·63	32·36	16·43	63·32	Yes	Region	10051·851
Mozambique			0·30	0·14	0·62	48·97	23·39	100·97			16167·656
Rwanda			0·32	0·16	0·63	19·84	10·07	38·81	Yes	Region	6161·532
Somalia			0·32	0·16	0·63	29·66	15·06	58·03	Yes	Region	9212·169
South Sudan			0·32	0·16	0·63	18·1	9·19	35·41	Yes	Region	5620·5125
Tanzania			0·34	0·17	0·70	108·23	53·63	224·97			32079·204
Uganda			0·32	0·16	0·63	77·57	39·38	151·76	Yes	Region	24092·461
Zambia			0·32	0·16	0·63	31·45	15·96	61·53	Yes	Region	9767·5045
	Eastern sub-Saharan Africa		0·32	0·16	0·63						
Botswana			0·34	0·18	0·63	3·4	1·78	6·33	Yes	Super-region	1000·1575
Lesotho			0·34	0·18	0·63	3·11	1·63	5·79	Yes	Super-region	915·6185
Namibia			0·34	0·18	0·63	3·6	1·89	6·71	Yes	Super-region	1060·4585
South Africa			0·34	0·18	0·63	67·85	35·6	126·31	Yes	Super-region	19961·409

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Swaziland			0·34	0·18	0·63	1·68	0·88	3·12	Yes	Super-region	493·2915
Zimbabwe			0·34	0·18	0·63	25·91	13·6	48·23	Yes	Super-region	7622·261
	Southern sub-Saharan Africa		0·34	0·18	0·63				Yes	Super-region	
Benin			0·32	0·16	0·61	20·18	10·35	38·91	Yes	Region	6376·1645
Burkina Faso			0·32	0·16	0·61	35·58	18·26	68·61	Yes	Region	11243·912
Cameroon			0·32	0·16	0·66	42·9	21·19	88·61			13338·935
Cape Verde			0·32	0·16	0·61	0·6	0·31	1·15	Yes	Region	188·249
Chad			0·32	0·16	0·61	29·57	15·17	57·01	Yes	Region	9343·1435
Cote d'Ivoire			0·32	0·16	0·61	42·34	21·73	81·63	Yes	Region	13378·888
Gambia, The			0·32	0·16	0·61	4·21	2·16	8·12	Yes	Region	1330·6935
Ghana			0·31	0·15	0·64	44·39	21·91	90·82			14290·52
Guinea			0·32	0·16	0·61	20·77	10·66	40·04	Yes	Region	6562·419
Guinea-Bissau			0·32	0·16	0·61	3·09	1·58	5·95	Yes	Region	975·4305
Liberia			0·32	0·16	0·61	7·88	4·05	15·2	Yes	Region	2491·6085
Mali			0·32	0·16	0·64	38·36	19·05	76·45			11904·463
Mauritania			0·32	0·16	0·61	7·13	3·66	13·74	Yes	Region	2252·468
Niger			0·32	0·16	0·61	44·48	22·82	85·76	Yes	Region	14055·611
Nigeria			0·30	0·15	0·61	323·03	158·51	655·04			106611·13
Senegal			0·32	0·16	0·61	25·85	13·26	49·84	Yes	Region	8167·609
Sierra Leone			0·32	0·16	0·61	12·28	6·3	23·68	Yes	Region	3880·469
São Tomé and Principe			0·32	0·16	0·61	0·33	0·17	0·64	Yes	Region	105·079

Country	Region	Super-region	Prevalence (%)	95% Lower credible interval	95% Upper credible interval	Number of people with vitiligo (in thousands)	95% Lower credible interval	95% Upper credible interval	Missing data	Estimate borrowed from	UN population 2021 (in thousands)
Togo			0·32	0·16	0·61	12·77	6·55	24·62	Yes	Region	4034·911
	Western sub-Saharan Africa		0·32	0·16	0·61						
		Sub-Saharan Africa	0·34	0·18	0·63						
World			**0·37**	**0·22**	**0·63**	**8914·73**	**5234·78**	**15167·75**			**2392419·1**

Table S14: **List of studies providing incidence rates by specific age group**

	Diagnostic method	Number with vitiligo	Incidence rate per 100 000 person-years (95% CI)
Children			
Mastacouris et al (2023), United States			
Study period: 2015–19			
0–9 years	Physician	162	20·2 (17·2–23·5)*†
10–17 years		131	21·9 (18·3–26·0)*†
Adults			
Lee et al (2020), South Korea			
Study period: 2009–2012			
20–39 years	Physician	4,521	15·5 (15·1–16·0)
40–64 years		14,477	25·2 (24·8–25·6)
>65 years		3,813	27·1 (26·3–28·0)
Lee et al (2021), South Korea			
Study period: 2005–2008			
<65 years	Physician	22,109	20·2 (19·9–20·5)
≥65 years		7,087	26·8 (26·2–27·4)
Mastacouris et al (2023), United States			
Study period: 2015–19			
18–29 years		167	19·3 (16·4–22·6)*†
30–39 years		195	24·8 (21·4–28·7)*†
40–49 years		218	24·7 (21·4–28·2)*†
50–59 years		272	24·9 (22·0–28·1)*†
60–69 years		256	25·3 (22·2–28·6)*†
≥70 years		204	20·9 (18·1–24·0)*†

All ages			
Kang et al (2023), South Korea			
Study period: 2003			
<20 years	Physician	1,423	10·7 (10·1–11·2)*
20–29 years		716	9·0 (8·4–9·7)*
30–39 years		742	9·0 (8·3–9·6)*
40–49 years		756	10·9 (10·1–11·7)*
50–59 years		621	14·4 (13·3–15·6)*
>60 years		748	15·0 (13·9–16·1)*
Study period: 2004			
<20 years		1,903	14·3 (13·6–14·9)*
20–29 years		872	11·0 (10·3–11·7)*
30–39 years		949	11·5 (10·7–12·2)*
40–49 years		1,063	15·3 (14·4–16·3)*
50–59 years		889	20·6 (19·3–22·0)*
>60 years		1,089	21·8 (20·6–23·2)*
Study period: 2005			
<20 years		2,153	17·8 (17·1–18·6)*
20–29 years		1,067	14·6 (13·7–15·5)*
30–39 years		1,183	14·4 (13·6–15·3)*
40–49 years		1,323	16·5 (15·6–17·4)*
50–59 years		1,215	23·7 (22·4–25·0)*
>60 years		1,337	21·4 (20·3–22·6)*
Study period: 2006			
<20 years		2,308	19·1 (18·3–19·9)*
20–29 years		1,150	15·7 (14·8–16·6)*

30–39 years		1,107	13·5 (12·7–14·3)*
40–49 years		1,354	16·9 (16·0–17·8)*
50–59 years		1,224	23·8 (22·5–25·2)*
>60 years		1,477	23·6 (22·4–24·9)*
Study period: 2007			
<20 years		2,464	20·4 (19·6–21·2)*
20–29 years		1,177	16·1 (15·2–17·0)*
30–39 years		1,227	15·0 (14·1–15·8)*
40–49 years		1,395	17·4 (16·5–18·3)*
50–59 years		1,333	26·0 (24·6–27·4)*
>60 years		1,701	27·2 (25·9–28·5)*
Study period: 2008			
<20 years		2,689	22·3 (21·4–23·1)*
20–29 years		1,186	16·2 (15·3–17·1)*
30–39 years		1,337	16·3 (15·4–17·2)*
40–49 years		1,493	18·6 (17·7–19·6)*
50–59 years		1,478	28·8 (27·3–30·3)*
>60 years		1,778	28·4 (27·1–29·8)*
Study period: 2009			
<20 years		2,731	22·6 (21·8–23·5)*
20–29 years		1,183	16·1 (15·2–17·1)*
30–39 years		1,238	15·1 (14·3–16·0)*
40–49 years		1,496	18·6 (17·7–19·6)*
50–59 years		1,544	30·1 (28·6–31·6)*
>60 years		1,832	29·3 (28·0–30·7)*
Study period: 2010			

<20 years		2,943	26·2 (25·3–27·2)*
20–29 years		1,047	15·9 (14·9–16·9)*
30–39 years		1,258	16·1 (15·3–17·1)*
40–49 years		1,522	18·6 (17·6–19·5)*
50–59 years		1,650	25·1 (23·9–26·4)*
>60 years		2,000	26·3 (25·2–27·5)*
Study period: 2011			
<20		2,848	25·4 (24·5–26·3)*
20–29		1,068	16·2 (15·2–17·2)*
30–39		1,268	16·3 (15·4–17·2)*
40–49		1,484	18·1 (17·2–19·0)*
50–59		1,806	27·5 (26·3–28·8)*
>60		2,000	26·3 (25·2–27·5)*
Study period: 2012			
<20		2,825	25·2 (24·3–26·1)*
20–29		1,068	16·2 (15·2–17·2)*
30–39		1,219	15·6 (14·8–16·5)*
40–49		1,423	17·3 (16·5–18·3)*
50–59		1,875	28·6 (27·3–29·9)*
>60		2,206	29·0 (27·8–30·2)*
Study period: 2013			
<20		2,764	24·6 (23·7–25·6)*
20–29		1,057	16·0 (15·1–17·0)*
30–39		1,284	16·5 (15·6–17·4)*
40–49		1,448	17·7 (16·8–18·6)*
50–59		1,973	30·1 (28·7–31·4)*

>60		2,384	31·4 (30·1–32·6)*
Study period: 2014			
<20		3,169	28·2 (27·3–29·2)*
20–29		1,063	16·1 (15·2–17·1)*
30–39		1,301	16·7 (15·8–17·6)*
40–49		1,481	18·1 (17·1–19·0)*
50–59		1,973	30·1 (28·7–31·4)*
>60		2,554	33·6 (32·3–34·9)*
Study period: 2015			
<20		2,984	29·6 (28·6–30·7)*
20–29		975	15·2 (14·3–16·2)*
30–39		1,137	15·4 (14·5–16·3)*
40–49		1,410	16·6 (15·8–17·5)*
50–59		1,960	24·5 (23·4–25·6)*
>60		2,426	26·0 (25·0–27·1)*
Study period: 2016			
<20		3,259	33·2 (32·0–34·3)*
20–29		1,055	16·3 (15·3–17·3)*
30–39		1,236	17·0 (16·1–18·0)*
40–49		1,726	20·5 (19·6–21·5)*
50–59		2,240	27·6 (26·5–28·8)*
>60		3,084	31·5 (30·4–32·7)*
Study period: 2017			
<20		3,185	33·4 (32·3–34·6)*
20–29		1,002	15·4 (14·4–16·4)*
30–39		1,260	17·7 (16·7–18·7)*

40–49		1,629	19·6 (18·6–20·6)*
50–59		2,364	28·9 (27·8–30·1)*
>60		3,431	33·4 (32·3–34·5)*
Study period: 2018			
<20		3,128	33·9 (32·8–35·2)*
20–29		943	14·4 (13·5–15·4)*
30–39		1,129	16·1 (15·2–17·1)*
40–49		1,496	18·4 (17·5–19·3)*
50–59		2,232	27·0 (25·8–28·1)*
>60		3,260	30·2 (29·2–31·3)*
Study period: 2019			
<20		3,050	34·2 (33·0–35·5)*
20–29		1,029	15·7 (14·8–16·7)*
30–39		1,215	17·8 (16·8–18·8)*
40–49		1,527	19·1 (18·1–20·0)*
50–59		2,163	25·9 (24·8–27·0)*
>60		3,817	33·6 (32·6–34·7)*

The diagnostic method is provided in the first row of data for each study

**Values reported from the study.*
†Age or sex adjusted in the original source.